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ABSTRACT 
      α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) and α-
aminomuconate-ε-semialdehyde dehydrogenase (AMSDH) are two neighboring enzymes in the 
L-tryptophan and 2-nitrobenzoic acid degradation pathways. The substrates of the two enzymes, 
α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) and α-aminomuconate-ε-semialdehyde 
(2-AMS), are unstable and spontaneously decay to quinolinic acid and picolinic acid, 
respectively.   
      ACMSD utilizes a divalent zinc metal as cofactor and is a member of the amidohydrolase 
superfamily. In this dissertation work, we have identified an important histidine residue in the 
active site that plays dual roles in tuning metal selectivity and activating a metal bound water 
ligand using mutagenesis, resonance Raman, EPR, crystallography, and ICP metal analysis 
techniques. The crystal structures of ACMSD from Pseudomonas fluorescens (PfACMSD) have 
been solved as homodimers in our laboratory while human ACMSD (hACMSD) was annotated 
as a monomer by another group. To resolve this structural difference, we used two conserved 
active site arginine residues as probes to study the oligomeriztion state of ACMSD and 
demonstrated that these two arginine residues are involved in substrate binding and that both Pf- 
and h- ACMSD are catalytically active only in the dimeric state. Subsequently, we solved the 
crystal structure of hACMSD and found it to be a homodimer in both catalytically active and 
inhibitor-bound forms.  
      AMSDH is an NAD+ dependent enzyme and belongs to the aldehyde dehydrogenase 
superfamily. Due to the high instability of its substrate, AMSDH has not been studied at the 
molecular level prior to our work. We have cloned and expressed PfAMSDH in E. coli. The 
purified protein has high activity towards both 2-AMS and 2-hydroxymuconate semialdehyde (2-
HMS), a stable substrate analog. We have successfully crystallized AMSDH with/without NAD+ 
and solved the crystal structure at up to 1.95 Å resolution. Substrate bound ternary complex 
structures were obtained by soaking the NAD+ containing crystals with 2-AMS or 2-HMS. 
Notably, two covalently bound catalytic intermediates were captured and characterized using a 
combination of crystallography, stopped-flow, single crystal spectroscopy, and mass 
spectrometry. The first catalytic working model of AMSDH has been proposed based on our 
success in structural and spectroscopic characterization of the enzyme in five catalytically 
relevant states in this dissertation work. 
 
INDEX WORDS: α-Amino β-carboxymuconate ε-semialdehyde decarboxylase, α-
Aminomuconate ε-semialdehyde dehydrogenase, Quinolinic acid, Amidohydrolase superfamily, 
Crystallography, Oligomeriztion, Reaction intermediate. 
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CHAPTER 1     INTRODUCTION  
Part of chapter 1 has been published in our two review papers: Amidohydrolase Superfamily. 
Aimin Liu, and Lu Huo. (2014) Els. John Wiley & Sons, Ltd: Chichester. DOI: 
10.1002/9780470015902.a0020546.pub2. Decarboxylation mechanisms in biological system. 
Tingfeng Li, Lu Huo, Christopher Pulley, and Aimin Liu. (2012) Bioorg. Chem., 43, 2-14. 
1.1 The Kynurenine Pathway 
As the major route for L-tryptophan (TRP) catabolism, which takes place in the liver, kidney, 
and brain of mammals, the kynurenine pathway (KP) has been found to be highly related with 
numerous disease states, and thus has gained significant attention from the scientific field. 
Studies in the past few decades have shown that the KP is a powerful regulator of 
neurodegenerative disorders: Alzheimer’s disease, Huntington’s disease, anxiety, depression, and 
epilepsy (1-7). This is because several neurologically active compounds including kynurenic 
acid, 2-hydroxykynurenine, and quinolinic acid (QUIN) are metabolites generated by the KP. 
QUIN is an agonist of N-methyl-D-aspartate receptors and could cause overexcitement of 
neurons and cell death in the central nervous system (2,5,8,9). The precursor of QUIN is α-
amino-β-carboxymuconate-ε-semialdehyde (ACMS), which is an unstable metabolic 
intermediate and spontaneously decays to QUIN with a t1/2 of 33 min at 20 °C, pH 7.0 (10). The 
formation of QUIN in vivo is controlled by the enzyme ACMS decarboxylase (ACMSD) because 
the decarboxylation reaction it catalyzes competes with the decay of ACMS. The product of 
ACMSD is α-aminomuconate-ε-semialdehyde (2-AMS), which is even more unstable than 
ACMS and decays to picolinic acid (PIC) with a t1/2 of 9 s at pH 7.4, 37 °C. The biological role 
of PIC remains controversial. Several studies have shown various physiological effects when 
using millimolar concentrations of PIC; however endogenous concentrations have been 
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measured to be in the sub-micromolar range. The formation of PIC is controlled by the 
downstream enzyme 2-AMS dehydrogenase (AMSDH) which oxidizes the unstable aldehyde to 
a stable acid, 2-aminomuconic acid (Scheme 1.1). This dissertation focuses on structural and 
mechanistic studies of two consecutive enzymes of the KP, ACMSD and AMSDH.  
1.2 The 2-Nitrobenzoic Acid Degradation Pathway 
The toxic organic compound 2-nitrobenzoic acid (2-NBA) is biodegradated by a bacterial 
strain KU-7, identified as Pseudomonas fluorescens (11), which can utilize 2-NBA as the sole 
source of carbon, nitrogen, and energy (11). The initial two steps catalyze the transformation of 
2-NBA to 3-HAA, at which point the 2-NBA degradation pathway “borrows” part of the 
kynurenine pathway as shown in Scheme 1.1. These two pathways share three enzymes, non-
heme Fe2+ dependent 3-hydroxyanthranilinic acid 3,4-dioxygenase (HAO), ACMSD, and 
AMSDH, and also the mechanism to regulate nonenzymatic production of QA and PA. This 
discovery suggests that the genes for these three enzymes of the kynurenine pathway are 
evolutionarily conserved genome segments which are important for at least two independent 
catabolic pathways. Before our work, human ACMSD can only be expressed as insoluble 
inclusion body in E. coli, and human AMSDH had not been identified. ACMSD and AMSDH 
Scheme 1.1 The L-tryptophan and 2-NBA degradation pathways share an enzyme trio system. 
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from the 2-NBA pathway had been used as model enzymes for structural and mechanistic studies 
before our recent progresses on the human analog enzymes.  
1.3 ACMSD is a Member of the Amidohydrolase Superfamily 
ACMSD was initially thought to be a cofactor-free enzyme (12,13). A comprehensive in 
vitro study on ACMSD from Pseudomonas fluorescens (PfACMSD) demonstrated that this 
enzyme is actually critically dependent on transition metal ions (14). Further sequence analysis 
and mutagenesis studies suggest that ACMSD belongs to the amidohydrolase superfamily (15), 
which is a structure-based cluster of metalloenzymes that contain a sturdy and versatile 
triosephosphate isomerase (TIM)-like (β/α)8-barrel fold embracing the catalytic active site. Later 
on, the crystal structure of PfACMSD was solved with a zinc metal center and a TIM-barrel 
overall fold, supporting that ACMSD is a new member of the amidohydrolase superfamily.   
1.3.1  The concept of amidohydrolase superfamily 
      Up to date, the amidohydrolase superfamily has grown into one of the largest families of 
enzymes, with tens of thousands of members catalyzing a wide range of hydrolytic and 
nonhydrolytic metabolic reactions which are important in amino acid and nucleotide metabolism 
as well as biodegradation of agricultural and industrial compounds. Previously, presence of a 
mono- or di-nuclear d-block metal cofactor in the active site was thought to be one of the main 
characters for the members in this superfamily. Recently, new members that contain trinuclear 
metal cofactor or no cofactor were also discovered. It has become evident that activating a well-
ordered water molecule by an active site residue for nucleophilic attack on the organic substrate 
is a common mechanistic feature for all members of the superfamily.  
      Amidohydrolase superfamily is one of the largest enzyme families. The concept of the 
‘amidohydrolase superfamily’ was introduced by Holm and Sander. The sbtriking similarities of 
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the three-dimensional structures of adenosine deaminase (ADA), phosphotriesterase (PTE) and 
urease (URE) inspired the unification of a broad set of d-block metal-dependent hydrolase 
enzymes into a unique enzyme superfamily (16). The amidohydrolase superfamily is more than 
just a group of hydrolase enzymes. It is a functionally diverse enzyme group. Members of this 
enzyme superfamily catalyze the cleavage of not only C–N but also C–C, C–O, C–Cl, C–S and 
O–P bonds of organic compounds. Most of the characterized members of the amidohydrolase 
superfamily are important enzymes for histidine, tryptophan and lignin derived compounds 
metabolism, de novo biosynthesis of purine and pyrimidine nucleotides, and biodegradation of 
agricultural and industrial materials including rubber chemicals, herbicides, leather, paper and 
others. Some members of this enzyme superfamily are medically relevant. For instance, ADA 
catalyzes ammonia elimination from the heterocyclic nitrogenous base of the substrate. The 
deficiency of this enzyme is linked to a common form of severe combined immunodeficiency 
(SCID). Since the superfamily is not function-designated, an enzyme with amidohydrolase in its 
name is not necessarily a member of the amidohydrolase superfamily. For instance, penicillin 
amidohydrolase (also known as penicillin acylase, EC 3.5.1.11) contains neither a catalytic metal 
ion nor a TIM-barrel domain; thus, it is not a member of the amidohydrolase superfamily.  
      The amidohydrolase superfamily contains more than five related subfamilies in the Pfam 
database annotation (17). The Amidohydrolase_1 subset (accession number: PF01979) contains 
a large group of 18,418 protein sequences (http://pfam.janelia.org). Its members catalyze the 
hydrolysis of a wide range of substrates bearing amide, ester, halogen or other functional groups 
at carbon and phosphorus centers. This family includes well-characterized enzymes such as 
ADA, PTE, URE, cytosine deaminase (CDA), D-amino acid deacetylase (AAD), dihydroorotase 
(DHO), N-acetylglucosamine-6-phosphate deacetylase (AGD) and renal dipeptidase (RDP). 
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Among them, DHO and URE also belong to MEROPS peptidase family M38 (β-aspartyl 
dipeptidase, clan MJ), where they are classified as nonpeptidase homologues. 
      The Amidohydrolase_2 subset (accession number: PF04909) contains 6,287 aligned protein 
sequences. These proteins are related to the metal-dependent hydrolases but they appear to be 
either structurally or functionally divergent from the Amidohydrolase_1 group. Members of this 
branch are known to catalyze nonhydrolytic reactions including decarboxylation and hydration 
(18). The prototypic member of the Amidohydrolase_2 is ACMSD (EC 4.1.1.45), which 
converts ACMS to 2-AMS in a nonhydrolytic C-C bond cleavage process (14). Despite the 
similar tertiary structures, it is not clear if members of the Amidohydrolase_2 subset have arisen 
from a single evolutionary origin with those in the Amidohydrolase_1 because of their very low 
overall sequence similarities. 
      The Amidohydrolase_3 subset (accession number: PF07969) consists of 5,270 protein 
sequences, most of which are hypothetical proteins. Some, including D-aminoacylase, 
formyltransferase/hydrolase complex Fhc subunit A, are amidohydrolase-like enzymes. This 
branch of the amidohydrolase superfamily contains the most diverse set of sequences, including 
a high proportion of outlier sequences that have only low levels of sequence identity to their 
closest superfamily relatives. 
      The Amindohydolase_4 subset (accession number: PF13147) consists of 10,639 protein 
sequences. The representative member of this subset includes allantoinase, D-hydantoinase 
(DYH), dihydropyrimidinase (DHPase), imidazolonepropionase (IPase), and a latent form of 
dihydroorotase. 
      The Amidohydrolase_5 subset (accession number: PF13594) is a relative small group of 
enzymes with 3,712 sequences to date. Isoaspartyl dipeptidase is its representative member. 
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More than thirty additional new subsets of amidohydrolases are being added, most of which are 
based on the functional distinctions. These include Creatininase (accession number: PF02633, 
1,362 sequences), which is a group of urease-related amidohydrolases hydrolysing creatinine to 
creatine, FGase (accession number: PF05013, 1,531 sequences) which consists of a group of N-
formylglutamate amidohydrolases, and TatD_DNase (accession number: PF01026, 8,430 
sequences) which is a rapidly growing subgroup of DNAse. 
1.3.2  Structural features of members in the amidohydrolase superfamily 
      Most members of the amidohydrolase superfamily consist of a central (β/α)8 barrel in which 
eight parallel β strands flanked on the outer face by eight α helices (Figure 1.1). Members 
contain a trinuclear metal center instead possesses a distorted (β/α)7 barrel fold. This gives rise to 
a prominent architectural feature: a sturdy pocket with an internal cavity adjacent to the active 
site. The pocket has a propeller-like shape made by the seven or eight β strands with a depth of 
around 15-18 Å and a diameter of about 14-16 Å that forms a compact thermo-stable core. The 
Figure 1.1. Metal cofactor and the TIM-like parallel barrel core in ADA (PDB entry 1A4M). The 
metal ion is depicted as CPK sphere, metal ligands are shown in sticks and the propeller structural 
fold is highlighted in blue colour in the representation. Substrate nalogue 6-hydroxy-1,6-dihydro 
purine nucleoside is represented in scaled ball and stick. 
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(β/α)8-barrel fold is a common structural platform found in about 10% of all proteins with known 
three-dimensional structures and in about 33 superfamilies in the SCOP database 
(http://scop.mrc-lmb.cam.ac.uk/scop). It is also known as the TIM-barrel fold because it was first 
defined from the three-dimensional structure of TIM. Containing a d-block metal cofactor with 
one or two metal ions conjunction with the TIM-barrel used to be another structural character for 
the amidohydrolase superfamily. Recently, several new members have been identified either 
with a trinuclear metal center or cofactor free. However, four active site residues, three histidine 
and one aspartate/glutamate, serve as metal ligands in the metal containing amidohydrolase 
superfamily proteins are still conserved in the metal independent members with new catalytic 
roles. Figure 1.2 shows examples of the TIM-barrel along with active site that contains no-, 
mono-, di- or tri- nuclear metal cofactors. There are currently 25 functionally annotated unique 
members of the amidohydrolase superfamily for which high-resolution X-ray crystal structures 
are available (Table 1.1). 
 
 
 
Figure 1.2. The crystal structures of TIM-barrel along with different metal center. (A) 
BmulJ_04915 (PDB entry 4DNM, cofactor free), (B) ADA (PDB entry 1A4M, mononuclear 
metal cofactor), (C) PTE (PDB entry 1HZY, dinuclear metal cofactor) and (D) HPP (PDB entry 
4GC3, trinuclear metal cofactor). Metal ions are shown as yellow spheres. Metal ligandresidues 
are shown in sticks and the propeller structural fold is highlighted in purple. 
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Table 1.1. Functionally annotated and structurally characterized members of the amidohydrolase 
superfamily 
Enzyme Abbreviation E.C. number PDB code
α-Amino-β-carboxymuconate-ε-
semialdehyde decarboxylase ACMSD 4.1.1.45 2HBV 
Adenosine deaminase ADA 3.5.4.4 1A4M 
Adenine deaminase ADase 3.5.4.2 2ICS 
N-acetylglucosamine-6-phosphate 
deacetylase AGD 3.5.1.25 1O12 
Allantoate amidohydrolase ATase 3.5.2.5 1Z2L 
Adenosine 5′-monophosphate 
deaminase AMPD 3.5.4.6 2A3L 
Cytosine deaminase CDA 3.5.4.1 1K6W 
D-Aminoacylase DAA 3.5.1.81 1M7J 
Dihydroorotase DHO 3.5.2.3 1J79 
Dihydropyrimidinase (L-
hydantoinase)a DHPase 3.5.2.2 1GKR 
Guanine deaminase GAH 3.5.4.3 1WKQ 
D-Hydantoinase HYD 3.5.2.2 1NFG 
Isoaspartyl dipeptidase IAD 3.4.19.5 1ONW 
Imidazolonepropionase IPase 3.5.2.7 2BB0 
Phosphotriesterase PTE 3.1.8.1 1HZY 
Renal dipeptidase RDP 3.4.13.11 1ITQ 
γ-Resorcylate decarboxylase RSD 4.1.1.44 2DVT 
Urease URE 3.5.1.5 2UBP 
5-Methylthioadenosine/S-
adenosylhomocysteine deaminase MTAD 3.5.4.28 1J6P 
4-Oxalomesaconate hydratase OMAH 4.2.1.83 2GWG 
2-Pyrone-4,6-dicarboxylic acid 
hydrolase PHD 3.1.1.57 4D8L 
N-Acyl-D-glutamate 
deacylase AGD 3.5.1.82 3GIP 
N-Isopropylammelide isopropyl 
amidohydrolase IIA 3.5.99.4 2QT3 
Enamidase ENA 3.5.2.18 2UVN 
Isoorotate decarboxylase IDCase 4.1.1.66 4HK7 
L-Histidinol phosphate phosphatase HPP 3.1.3.15 4GC3 
Atrazine chlorohydrolase ATZA 3.8.1.8 3LS9 
a Although DHPase and HYD have the same E.C. number, they are different enzymes and have different substrate 
specificities. DHPase enzymes (including L-hydantoinase) catalyze the reversible hydrolytic ring opening of six- or 
five-membered cyclic diamides such as dihydropyrimidines and 5′-monosubstituted hydantoins to the corresponding 
3-ureido acids and carbamoyl amino acids, respectively. HYD is an industrial enzyme that is widely used in the 
production of D-amino acids which are precursors for synthesis of antibiotics, peptides and pesticides. 
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      Biochemical studies on the amidohydrolase superfamily have revealed that the metal cofactor 
is catalytically essential for the majority members (19). The metal cofactor is located at the 
opening of the barrel near the C-terminal ends of several β strands, coordinated by several 
histidine, aspartic acid and in some occasions cysteine residues of the β strands and βα loops. 
The metal-containing site is referred to as the catalytic face of the barrel, in contrast to the 
stabilizing face of the opposite end of the barrel (20). To accommodate the metal center and 
substrates, the catalytic face often has a wider width than the stabilizing face, consequently 
making the other side of the barrel appear more compressed. Thus, the barrel sometimes looks 
like a conoid. 
      The most common metal in this enzyme superfamily is a zinc ion or a dinuclear Zn2 pair. 
However, transition metals, such as divalent iron, nickel and manganese ions, are also observed 
in amidohydrolase enzymes. Cobalt ion can often be substituted for zinc in vitro, producing a 
comparable or even higher level of enzyme activity (14). Non d-block metal ions, such as Mg2+ 
and Ca2+, are usually unable to perform the biochemical functions at the enzyme active site, 
suggesting that the role of the d-block metal cofactor is beyond simply providing a cationic 
charge for substrate binding. 
      The metal cofactor is tethered to the protein through a few protein residues. There are several 
types of active site structural architecture known in this enzyme superfamily, and the origin of 
the metal ligands is a valuable tool to divide the enzyme superfamily into seven subgroups (19). 
A mononuclear cofactor requires four or five ligands, while a dinuclear cofactor demands five or 
six protein ligands. One notable structural feature is that at least one water molecule or water-
derived hydroxide is coordinated to the metal ion(s) in the enzyme structures. The solvent-
derived ligand generally remains bound to the metal in the enzyme–substrate complex, but it is 
10 
replaced by substrate on some occasions such as 2,6-dihydroxybenzoate (γ resorcylate) 
decarboxylase (RSD) (21). 
      For a mononuclear metal cofactor of this enzyme superfamily, the fifth β strand invariably 
provides a histidine ligand for the metal coordination. The sixth β strand contributes a histidine 
residue either as a metal ligand or a nonligand but an important catalytic component at the 
enzyme active site. These two histidine residues are the signature amino acids conserved across 
the mononuclear and dinuclear metal cofactor containing amidohydrolase superfamily members. 
It is common for the first and/or eighth β strands to add more protein ligands for metal 
coordination. An aspartic acid residue from the eighth β strand in many amidohydrolase enzymes 
plays a dual role, i.e. acid/base catalyst and metal ligand. 
      The two divalent metals are separated by ׽3.6 Å in the dinuclear metal cofactor. The more 
buried metal cation is coordinated to two histidine residues from the end of β strand 1 and an 
aspartate from β strand 8. The more solvent-exposed metal ion is ligated to protein through two 
imidazole side chains of histidine from β strands 5 and 6 (19). The two divalent metal ions are 
bridged by a hydroxide in addition to a carbamate functional group originating from the 
posttranslational modification of a lysine residue from β strand 4 in the presence of bicarbonate. 
In some cases, an unmodified glutamic acid from β strand 4 or a cysteine from β strand 2 is 
employed as a bridge instead of the modified lysine. Until now, the characterized dinuclear 
amidohydrolase enzymes have a homogeneous metal preference. However, some mixed metal 
cofactors may exist. Enamidase, for instance, is a bifunctional enzyme belonging to the 
amidohydrolase family that mediates hydrolysis of 1,4,5,6-tetrahydro-6-oxonicotinate to 
ammonia and (S)-2-formylglutarate; it reportedly contains a Fe-Zn cofactor (22). 
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      A subfamily under the amidohydrolase superfamily, polymerase and histidinol phosphatase, 
catalyzes the reaction of phosphoester hydrolysis. Members in this subfamily have a trinuclear 
metal center buried in a distorted (β/α)7 barrel. The β-strand 3 is much longer than other strands 
composed the barrel and overlays with the β-strand 3 and 4 of the (β/α)8 structures. All the metal 
ligands for the mono- and di- nuclear metal center are conserved and coordinate the α and β 
metals. In addition, the third metal is coordinated by an aspartate or histidine from the end of β-
strand 1 and two histidine residues from the end of β-strand 2 and 8.    
      The identification of several metal independent members further expanded the structural 
diversity of the amidohydroloase superfamily. The overall structure of metal independent 
members still adopts a (β/α)8 TIM-barrel fold and the four conserved residues, three histidine 
(two from the end of β-strand 1 and one from β-strand 6) and one aspartate (from the end of β-
strand 8) ligand residues in the mononuclear metal center, are still present in the active site. 
These conserved residues are now proposed to conduct new catalytic roles since they no longer 
serve as metal ligand. Other than the histidine residues from the sixth β strands, which are 
conserved throughout the entire family, the remaining metal ligands exhibit some variations. For 
example, an HxH metal-binding motif is commonly seen in strand 1 of the β-barrel, but HxD and 
ExH have been observed from the ACMSD protein subfamily of Amidohydrolase_2 (18). The 
histidine from the fifth β-strand is absent in the cofactor free members. Moreover, the metal-
binding motif from strand 1 does not always serve as metal ligands. For instance, in the 
structures of AGD, the HxH motif is present in the active site but it is not ligated directly to the 
divalent metal.  
      The overall sequence conservation among the amidohydrolase superfamily is rather low, 
indicating that the TIM-like barrel fold is not dictated by details of sequences but rather by 
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overall distribution of polar or charged and nonpolar or noncharged residues. Also, it is not 
unusual that enzymes in this superfamily contain noncatalytic domains in addition to the 
catalytic domain. Thus, conventional sequence alignments occasionally fail to reveal the general 
characteristics of a potential new member of the amidohydrolase superfamily. When either the 
metal-binding motif or the TIM-like barrel is not obvious, an advanced sequence alignment may 
be required. If this is the case, a secondary structure pattern can be calculated by the PSIPRED 
protein structure prediction server at http://bioinf.cs.ucl.ac.uk/psipred (23). Then a ‘secondary 
structure-based’ sequence alignment with those members with known three-dimensional 
structures may reveal clusters of similar residues at topologically equivalent positions. An 
example using this strategy was described in a recent study of ACMSD, which successfully 
predicted that this is a new member of the amidohydrolase superfamily. A site-directed 
mutagenesis analysis was followed and the results revealed important information concerning the 
enzyme such as metal ligand identities and active site residues as well as their possible roles in 
the catalytic process (15). 
      However, one should be cautious in drawing conclusions solely based upon a sequence 
study. Sequence, and even structural, similarities do not always translate into functional 
similarities. One extreme example in the functionally diverse amidohydrolase superfamily is the 
difference between melamine deaminase and atrazine chlorohydrolase. These two enzymes share 
98% sequence identity, but catalyze completely different reactions (24). 
1.3.3 Catalytic mechanism of members in the amidohydrolase superfamily 
      The best-characterized members of the amidohydrolase superfamily share a common 
catalytic mechanism. Scheme 1.2 illustrates the proposed hydrolytic mechanism for the 
mononuclear Zn-dependent enzyme ACMSD. The common feature of the mechanism is that a 
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reaction catalyzed by the enzyme of this superfamily. From a chemical perspective, the enzyme 
OMAH of the ACMSD protein family catalyzes a mechanistically insightful reaction; it adds a 
water molecule to the substrate, as if it were the half-reaction in a decarboxylation mechanism 
proposed for ACMSD (Scheme 1.2). Although there is no characterized member of the 
Amidohydrolase_3 subfamily at the present stage, it is almost certain that some structural 
variations and new functionalities will soon be described for members of this branch. 
      An arginine residue, Arg239 in ACMSD, is conserved across the characterized members 
catalyze the decarboxylation reaction and proved to be catalytically essential. Arg239 has been 
shown to play important role in substrate binding in solution for ACMSD. Crystal structure of 
IDCase in complex with a substrate analogue further demonstrated that this arginine specifically 
binds to the leaving carboxyl group. Unlike other active site residues, Arg239 is intruded from a 
neighbouring subunit, indicating this subfamily of enzymes needs to function as dimers.  This is 
also verified by the gel filtration studies done for OMAH and RDC. 
      The dinuclear enzymes proceed similarly, with a second divalent metal ion providing 
additional activation power towards the substrate. DHO is one of the best characterized dinuclear 
amidohydrolase enzymes. It is believed that the original keto oxygen of the substrate interacts 
with the more solvent exposure metal ion in DHO, while the more buried metal ion activates the 
nucleophilic attack during catalysis. A proposed mechanism of DHO catalyzed reaction is shown 
in Scheme 1.3.  
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not require a divalent metal (30). Later on, BmulJ_04915 and GLI are found as the second and 
third examples (31). Although this group of enzymes does not contain a metal cofactor, the 
original metal binding residues, including three histidine and one aspartate, are still conserved in 
the active site with new catalytic functions. For LigI and BmuIJ_04915, the three histidine 
residues are proposed to bind and polarize the substrate. The Aspartate residue is proposed to 
activate a water molecule for nucleophilic attack (Scheme 1.5). 
      The amidohydrolase superfamily has attracted substantial attention as a large structure-based 
cluster of enzymes with thousands of members and divergent catalytic functions. In the past few 
years there have been huge advances in the studies of the amidohydrolase superfamily. Large 
volumes of sequence are now becoming functionally annotated, and many members that exhibit 
distinct biological significances are now structurally defined. It is becoming clear that the metal-
cofactor elaborated by the sturdy and versatile TIM-like β barrel is enormously powerful. The 
substrate specificity appears to be mostly dictated by the loops, insertions and conformational 
restrictions of the catalytic face of the TIM-like β barrel. This insight has come from site-directed 
mutagenesis, kinetics, structural and spectroscopic studies of many members of the superfamily. 
Major advances have been made, but a structure-based functional annotation is still 
challenging. Many principals and strategies related to the design of loops, insertions, subunit 
interactions and the catalytic impact of protein dynamics remain to be elucidated. Nonetheless, 
the rapid expansion of knowledge concerning the metal-dependent TIM-barrel enzymes is 
making the amidohydrolase superfamily a well characterized large enzyme group that may 
enable a reliable evolutionary analysis for the origin of the divergent members. The 
amidohydrolase superfamily as a whole is emerging as a popular and valuable asset in the 
enzymology field for studying structure–function relationships and evolution. 
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1.4  ACMSD is a Transition Metal Dependent Decarboxylase 
Decarboxylation is one of the most common processes in nature and one of the most 
fundamentally important reactions in biological systems. Essentially all of the carbon dioxide 
evolved in fermentation and respiration is generated by the decarboxylation of organic acids 
(32). Decarboxylases are known for their roles in a wide variety of catabolic and anabolic 
pathways including decarboxylation of α- and β-keto acids, amino acid conversions, and 
carbohydrate synthesis (33). Within the IUPAC classification scheme, these are currently divided 
into at least 90 different classes. Substantial effort has been applied to the study of the 60 origin 
and the mechanisms of production of metabolic carbon dioxide, and considerable knowledge has 
been accumulated regarding the decarboxylation mechanisms in biological systems. Enzymatic 
decarboxylation usually utilizes either an organic cofactor such as pyridoxal 50-phosphate and 
biotin, or an inorganic cofactor, such as an iron or zinc complex, in the catalytic reaction. 
ACMSD is one of the decarboxylases whose activity is dependent of inorganic metals. Metal 
ions are employed as cofactors in many decarboxylases, some of which do not function as 
catalytic centers. For instance, the Zn2+ ion in the biotin-dependent decarboxylases helps to 
properly orient the substrate while the Mg2+ ion in the ThDP-dependent decarboxylases assists in 
binding the thiamine cofactor. In NAD(P)+-dependent decarboxylases, such as malic enzymes, a 
divalent metal ion (Mn2+ or Mg2+) plays an important role in both catalysis and structure stability. 
In some cases, metal cofactors play critical catalytic roles. 
1.4.1 Mechanism of ferrous-dependent oxidative decarboxylases 
      α-Ketoglutarate (αKG)- and nonheme ferrous-dependent dioxygenases are classic ferrous-
dependent decarboxylases (34,35). The αKG-dependent dioxygenase reaction proceeds in two 
half reactions. The first half of the reaction is a ferrous and O2-dependent oxidative 
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decarboxylation reaction of αKG. The cleavage of the O-O bond results in one oxygen atom 
inserting into αKG while the other oxygen remaining at the Fe center (Scheme 1.6). The αKG- 
and Fe-dependent enzymes are widespread and versatile, catalyzing an exceptionally wide range 
of energetically demanding biosynthetic and degradative reactions such as the stereo-selective 
desaturation of inactivated C-C single bonds, ring expansion, oxidative ring closure, and 
hydroxylation processes (35), which are important in the biosynthesis of collagen (36), 
antibiotics biosynthesis (37,38), cellular response of hypoxia (39), repair of 
alkylatedDNA(40,41), regulation of gene expression by demethylation of histones (42), and 
many other biological processes. 
 
Scheme 1.6. A proposed mechanism for ferrous-dependent oxidative decarboxylation of αKG. 
 
      The catalytic mechanism of αKG-dependent dioxygenases has been extensively studied. This 
family of enzymes all require an iron(II) center, which is relatively weakly coordinated by three 
amino acid side chains, typically in a 2-his-1-carboxylate facial triad (43). The mechanism for 
this group of decarboxylases proceeds via a Fe(IV)=O intermediate (Scheme 1.6), which was 
first proposed three decades ago and recently confirmed by Bollinger and Krebs using EPR and 
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Mössbauer spectroscopy (44-49) and by Hausinger using continuous-flow resonance Raman 
spectroscopy (50,51). In this model, the binding of the enzyme to αKG, theprimary substrate, and 
the binding of molecular oxygen follows an ordered binding mechanism (49,52). The iron center 
of the resting enzyme is coordinated with two histidines and one carboxylate (Asp or Glu) 
residues together with three water molecules. The addition of the co-substrate, αKG, will replace 
the two water ligands with its 1-carboxyl and 2-keto groups. The primary substrate will then 
enter and expel the third water molecule, which leads to an empty coordination site ready for a 
dioxygen molecule to come in and bind to the iron center (49,53). Addition of dioxygen to the 
substrate/co-substrate/iron-bound enzyme complex leads to the oxidation and decarboxylation of 
αKG to produce succinate and form a substrate-hydroxylating Fe(IV)=O species through two 
non-accumulating complex species in which the Fe(IV)=O intermediate has been trapped and 
characterized (44,48,50,54-56). Although the details of the decarboxylating mechanism remain 
elusive, it has been demonstrated that decarboxylation of αKG occurs prior to or concomitantly 
with the formation of this substrate-hydroxylating Fe(IV)=O intermediate (55). Carbon dioxide 
may remain bound to the metal center in its hydrated or nonhydrated form as observed in the 
self-hydroxylation reaction study in taurine/aKG dioxygenase (57) and the crystallographic study 
in deacetoxycephalosporin C synthase (58). In the next step, the highly reactive Fe(IV)=O 
intermediate abstracts a hydrogen atom from the primary substrate and generates a radical 
species on the substrate. It also causes a reduction of the metal center. The radical abstracts the 
hydroxyl group from the iron center, resulting in the hydroxylation of the substrate (47,48). The 
rate-determining step in the catalytic cycle is the release of products (55). For some enzymes in 
this family, the Fe(IV)=O intermediate is believed to perform an electrophilic attack on the 
aromatic ring of the primary substrate rather than hydrogen abstraction (47,59,60).  
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1.4.2  Mechanism of manganese-dependent decarboxylases 
      Enzymes that require Mn2+ and O2, but not any organic cofactors, to decarboxylate substrates 
include oxalate decarboxylase (EC 4.1.1.2) and the closely related oxalate oxidase (EC 1.2.3.4). 
Moreover, 4-oxalocrotonate decarboxylase (EC 4.1.1.77) forms a complex with vinylpyruvate 
hydratase and utilizes either Mn2+ or Mg2+ as a cofactor to convert 2-oxo-3-hexenedioate to 2-
oxo-4-hydroxypentanoate (61,62). Oxalate decarboxylase catalyzes the conversion of oxalate to 
formate and carbon dioxide. Oxalate decarboxylase utilizes both Mn2+ and dioxygen as its 
cofactors, but the reaction does not involve a net redox change (63). Oxalate oxidase also 
requires Mn2+ and dioxygen for its catalytic activity. Furthermore, it degrades oxalate to produce 
carbon dioxide. However, the reaction uses dioxygen as a substrate involves a net redox reaction 
(64,65). Both oxalate decarboxylase and oxalate oxidase catalyzing reactions utilize free radicals 
to cleave a relatively stable carbon–carbon bond. Current proposed mechanisms for oxalate 
degradation by oxalate decarboxylase and oxalate oxidase suggest several essentially identical 
steps up to formation of the Mn-bound formyl radical (64,66). In fact, it has been demonstrated 
that oxalate decarboxylase can be converted to an efficient oxalate oxidase by mutating amino 
acids on a flexible active site lid (67). Scheme 1.7 illustrates a proposed mechanism for oxalate 
decar boxylase based on a number of hypotheses (64-69).  
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Scheme 1.7. Proposed mechanism for oxalate decarboxylase. 
 
      In 2007, the two metal centers in oxalate decarboxylase were individually characterized 
using high field, multifrequency EPR spectroscopy (70). The carbon dioxide anion radical shown 
in step five in Scheme 1.7 was trapped in oxalate decarboxylase by Angerhofer and co-workers 
in 2011 using an EPR spin trapping technique.  Through mutagenesis, the authors were able to 
disrupt a hydrogen bond responsible for closing the flexible loop across the substrate binding 
channel. This led to a buildup of a carbon dioxide anion radical. A closed conformation is 
required for decarboxylation, which ensures that the harmful anion radical intermediate remains 
bound at the active site during catalysis (71). At the resting state of the enzyme, Mn2+ 
coordinates to three conserved histidine residues, a conserved glutamate or aspartate residue, and 
two water molecules (65,69). When malate comes into the active site, it binds to the metal ion 
monodentately and replaces one of the water molecule ligands. Then dioxygen binds to Mn2+ and 
replaces the other water molecule. One electron transferred from the metal to the binding 
dioxygen results in a Mn3+-superoxo species, which functions as an electron sink to facilitate the 
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decarboxylation reaction. An electron is drawn from the bound substrate to the metal to generate 
a radical on the bound oxalate. Cleavage of the C-C bond of this radical intermediate releases 
CO2 and gives a manganese ion-bound formyl radical anion intermediate. At this point the 
mechanisms of oxalate oxidase and oxalate decarboxylase purportedly divert. In the hypothetical 
mechanism of oxalate decarboxylase, protonation occurs at the carbanionic carbon of the formyl 
radical intermediate, which is followed by an electron transfer from the manganese ion to the 
formyl radical forming a product bound Mn3+-superoxo species. Product dissociation from the 
active site completes the reaction cycle and regenerates the enzyme.  
1.4.3 Mechanism of magnesium-dependent decarboxylases 
      Divalent metal ions can catalyze a decarboxylation reaction at the β-carbon of α-keto 
carboxylic acid, while decarboxylases can increase the rate of the reaction dramatically. One of 
the most extensively studied cases is the decarboxylation of oxaloacetate. The reaction catalyzed 
by oxaloacetate decarboxylase is dependent on divalent metal ions. This enzyme is active with 
either Mn2+ or Mg2+. Besides the divalent ion, the decarboxylation catalyzed by this enzyme from 
some organisms also requires biotin, while NAD(P)+ is essential for the enzyme from other 
species. A proposed mechanism for oxaloacetate decarboxylase from Pseudomonas putida, 
which requires only divalent metal cations, is shown in Scheme 1.8 upper (72). The 
decarboxylation catalyzed by 4-oxalocrotonate decarboxylase is believed to proceed in a 
mechanism similar to that of oxaloacetate decarboxylase (61). The metal divalent cation is 
thought to form a complex with the α-keto acid moiety and one of the oxygen atoms from 
thecarboxyl group of the substrate, functioning as an electron sink to stabilize the enolate 
intermediate (73,74). The enzyme serves to provide substrate specificity and to lower the energy 
of the ground state to a much more favorable value. Protonation at the Cb position yields the 
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product pyruvate. The proton incorporated in the product can be in a retained or inverted 
stereochemical configuration compared to the leaving carboxyl group of the substrate. A recent 
study reported that the decarboxylation catalyzed by 3-keto-L-gulonate 6-phosphate 
decarboxylase is also Mg2+ ion-dependent. The reaction mechanism of this enzyme has been 
extensively studied (75-79). These studies have provided a hypothetical mechanism shown in 
Scheme 1.8 lower). In the proposed mechanism, the departure of CO2 is facilitated by forming an 
enediolate intermediate stabilized by the Mg2+ ion. However, the required Mg2+ ion does not 
ligate to the oxygen of the carboxyl group. Instead it coordinates to the oxygen of the keto-group 
at the C3 position and the oxygen of the hydroxyl-group at the C4 position of the substrate, 
forming a cis-1,2-enediolate intermediate. Protonation of C1 of the intermediate is completed 
through a proton relay system involving two alternative water molecules in the active site and the 
side chains of a conserved histidine or a conserved arginine as the ultimate proton sources. 
Protonation can lead to either R or S configurations depending on which of the two conserved 
residues is used as the ultimate source of the proton. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.8. Hypothetical mechanisms for magnesium-dependent decarboxylases. 
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1.4.4 Transient metal-dependent, O2-independent decarboxylases 
      ACMSD was initially thought to be a cofactor-free enzyme (12,13). It has recently been 
found to be a metalloenzyme belonging to the amidohydralase superfamily (14,15). This enzyme 
is an illustrative example of the ACMSD protein family (also known as the Amidohydrolase_2 
subfamily) (18,80), whose members are decarboxylases or hydrotases rather than hydrolases or 
deaminases. Members of the ACMSD protein family catalyze a CAC bond cleavage reaction 
instead of hydrolytic reaction (80,81). Understanding the mechanism of ACMSD will shed light 
on the mechanisms of the continually emerging members of the ACMSD protein family. 
However, it is unknown whether ACMSD adopts the mechanism from the amidohydrolase_1 
subfamily or follows a model evolved by other decarboxylases (82). Scheme 1.9 is a mechanistic 
model adopted from the well-characterized amidohydrolase_1 subfamily. In the first step, the 
substrate binds to the enzyme with its C2 carboxylate close but not to themetal center at a rate of 
2.4 * 106 s-1M-1 (10). An active site histidine, His228 as numbered in the Pseudomonas 
fluorescens enzyme (80), assists in the deprotonation of a water ligand to form hydroxide, which 
then nucleophilically attacks the double bond between C2 and C3 of the substrate, resulting in a 
hydrated tetrahedral intermediate. The subsequent collapse of the tetrahedral intermediate is 
assisted by the concerted deprotonation of His228 and the rebinding of the hydroxyl group to 
themetal ion. The carboxylate attached to the C3 position becomes the leaving group. The 
decarboxylation step is a rapid reaction (>500 s-1) but the release of the product aminomuconate-
e-semialdehyde is slow (9 s-1) (10).  
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Scheme 1.9. A working hypothesis for mechanism of the ACMSD reaction. 
 
The amidohydrolase-derived mechanism shown in Scheme 1.9 predicts that the metal-bound 
hydroxide is the catalytic driving force of the decarboxylation reaction. The pKa value of the 
water ligand is lowered from 15.7 of the unbound state to about 9.6 because of its coordination to 
zinc (83). This value can be further reduced to nearly the physiological pH with the assistance of 
an active site base catalyst, presumably His228 in PfACMSD, and therefore generates a 
hydroxide anion, which performs a nucleophilic attack on the C2 and C3 double bond of the 
substrate. As expected, mutation at His228 significantly reduces the enzyme activity and removal 
of the metal bound water molecule completely deprives the enzyme activity. This hydroxide 
attack mechanism is believed to be present in the enzyme 4-oxalomesaconate hydratase, which 
was identified as a part of this family in a recent bioinformatics study (80). This enzyme 
catalyzes the addition of a hydroxide ion and a proton across a C=C bond of its substrate. The 
added hydroxide is preserved in the product so that the proposed hydroxide attack for the 
ACMSD enzyme family is visualized in this specific member, as if it were an interruption of an 
ACMS decarboxylation reaction. The metal-bound hydroxide attack of the substrate is also 
proposed to occur in another zinc-dependent structurally characterized decarboxylase member of 
the ACMSD family, c-resorcylate decarboxylase (21). Therefore, the metal-bound hydroxide 
assisted C-C/C=C cleavage is likely to be a common mechanism for the ACMSD subfamily of 
the amidohydrolase superfamily. 
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1.5 AMSDH is a Member of the Aldehyde Dehydrogenase Superfamily 
AMSDH is an NAD+ dependent aldehyde dehydrogenase that oxidizes the aldehyde group of 
2-AMS to its corresponding acid, competing with the spontaneous decay of 2-AMS to picolinic 
acid (Scheme 1.1). Sequence alignment indicates that AMSDH is a member of the 
hydroxymuconate semialdehyde dehydrogenase subfamily under the aldehyde dehydrogenase 
(ALDH) superfamily. AMSDH has not been studied at the molecular level, and no structure was 
available before our work. 
1.5.1 Aldehyde dehydrogenase superfamily 
      Due to the innate chemical reactivity of aldehyde molecules, many of them are toxic even at 
low concentrations. Aldehydes are generated from both endogenous (formed during metabolism 
of alcohols, amino acids, biogenic amines, vitamins, steroids, and lipids) and exogenous (formed 
from the metabolism of a number of drugs and environmental agents) precursors. Members of 
the ALDH superfamily catalyze the detoxification of endogenous and exogenous aldehydes and 
are widely spread in both prokaryotic and eukaryotic organisms.  
      The first aldehyde dehydrogenase was identified and purified from beef liver in 1949 (84). 
The first primary structure of an ALDH was obtained from human liver in 1984 (85). Since then, 
43,773 ALDH sequences (listed as aldedh in the Pfam database) are identified and 607 structures 
have been solved. Although ALDH are found in 5325 species with very diverse substrate 
preferences, they all utilize NAD(P)+ as a cofactor to provide oxidation power during catalysis 
and their overall tertiary structure is highly conserved.  The primary sequence, however, has 
relatively low conservation. Based on a primary sequence alignment of 145 ALDH proteins, only 
four residues are strictly conserved across the superfamily, including two glycines, one 
phenylalanine, and one glutamate (86). The catalytic thiol, a cysteine residue, is also conserved 
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in all sequences except one. In cephalopod omega-crystallins, the otherwise conserved cysteine 
is replaced by an arginine, and it has been reported to lack ALDH activity (87). 
      To date, nineteen human ALDH genes have been identified according to their divergent 
evolution based on the ALDH nomenclature system established in 1998. Human ALDH genes 
are closely related to human health and many diseases caused by defects in aldehyde metabolism 
are caused by mutations in the genes which encode the respective enzymes. For example, 
ALDH1a1 helps maintain the corneal transparency (88). A single nucleotide polymorphism in 
encoded ALDH1b1 was found to be related with alcohol induced hypersensitivity symptoms 
including asthma and flushing (89). Inactivation of ALDH2 will cause both heart disease (90) 
and alcohol sensitivity problems (91). It has been shown that a much higher percentage of Asian 
exhibit acute alcohol intoxication compared to Europeans. The underlying reason is a mutation 
of a glutamate residue to lysine in the ALDH2 gene which leads to inactivation of the expressed 
enzyme (92). Mutations in the ALDH7a1 gene were found to be related to pyridoxine-dependent 
seizures in children. This is because the mutation abolishes the activity of antiquitin and leads to 
the accumulation of δ 1-piperideine-6-carboxylate-α-aminoadipic semialdehyde (93). Recent 
studies also indicate that increased activity of ALDH1a1 could serve as a hallmark of cancer 
stem cells (94). 
1.5.2 Structural features of members in the ALDH superfamily 
      The first X-ray crystal structure of an ALDH was solved in 1997 as a homo-dimer (95). 
Quaternary structures of most ALDH solved later are either homodimers or homotetramers, 
which consists of a dimer of dimers. All members of the ALDH superfamily have very similar 
three-dimensional structures, even those with low sequence identities. These similarities arise 
from several conserved glycine and proline residues which are responsible for constructing the 
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Rossmann folds with six β-strands and four α-helices. The majority of ALDH enzymes have a 
strong preference for either NAD+ or NADP+. Studies have shown that residues close to the 
adenosine ribose are responsible for co-substrate selectivity in NAD(P)+ dependent 
dehydrogenases. Presence of an acidic residue near the adenosine 2’-position is a major 
characteristic for NAD+ binding proteins because the anion side chain can interact with both 2’- 
and 3’-hydroxyl group of the NAD+ adenosine ribose. Also, the carboxyl group of the acidic 
residue could prevent NADP+ from binding by repelling its 2’-phosphate (98-101). On the other 
hand, placing a positively charged lysine or arginine at the same position will tune the co-
substrate selectivity towards NADP+ (102-104). 
      Multiple hydrogen bonds and salt bridges are involved in stabilizing the co-substrate. 
However, the nicotinamide head of NAD(P) remains flexible and stays in different 
conformations dependent upon the oxidation state (105,106). In the oxidized state, NAD(P)+ lies 
in the Rossmann fold in an extended conformation, allowing the hydride to transfer from the 
substrate to reduce the co-substrate during the first half of the reaction. Reduced NAD(P)H 
adopts a bent conformation, in which the nicotinamide head moves back towards protein surface 
and leaves space for the second half of the reaction, acyl-enzyme hydrolysis, to take place.   
The catalytic domain has a topologically related βαβ-type polypeptide fold. The catalytic driving 
force, a cysteine residue, sits in the active site in close proximity to the NAD(P)+ nicotinamide 
group and is connected to the protein surface by a channel, presumed to be the substrate binding 
channel. As an active-site catalytic thiol, this cysteine is easier to be oxidized than regular 
cysteine residues. Hence, purified ALDH enzymes easily lose their catalytic activity if they are 
not protected by reducing agents. It was suggested that the cysteine residue can be protected by 
forming a covalent bond with the NAD(P)+ co-substrate (107,108). In some ALDH enzymes, a 
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After the glutamate residue rotates into an active position, it will work as a general base to 
deprotonate an ordered water molecule. The activated water will then attack the thioester carbon 
(previously the aldehydic carbon), leading to the formation of the second tetrahedral intermediate 
(Scheme 1.10, intermediate 3). This glutamate is another strictly conserved residue in the ALDH 
superfamily and its function as a general base has been well studied in the past decades 
(108,117,119,120). Finally, collapse of the second tetrahedral intermediate and scission of the C-
S bond leads to product release.  
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CHAPTER 2    EVIDENCE FOR A DUAL ROLE OF AN ACTIVE SITE HISTIDINE IN 
α-AMINO-β-CARBOXYMUCONATE-ε-SEMIALDEHYDE DECARBOXYLASE 
The section of chapter 2 is our published work on ACMSD: Evidence for a Dual Role of an 
Active Site Histidine in α-Amino-β-Carboxymuconate-ε-Semialdehyde Decarboxylase. Lu Huo, 
Andrew J. Fielding, Yan Chen, Tingfeng Li, Hiroaki Iwaki, Jonathan P. Hosler, Lirong Chen, 
Yoshie Hasegawa, Lawrence Que, Jr., and Aimin Liu. (2012) Biochemistry, 51(29), 5811-5821. 
This work is supported in part by grants from NSF Grant MCB-0843537 (AL), NIH grants GM 
038767 (LQ) and GM 056824 (JPH), the Japanese strategic projects to support the formation of 
research bases at private universities: matching fund subsidy from MEXT, 2008-2012 and the 
University of Minnesota Chemical Biology Initiative in conjunction with the NIH-supported 
Chemistry Biology Interface Training Grant GM 08700 (AJF).  
2.1 Abstract 
The previously reported crystal structures of α-amino-β-carboxymuconate-ε-semialdehyde 
decarboxylase (ACMSD) show a five-coordinate Zn(II)(His)3(Asp)(OH2) active site. The water 
ligand is H-bonded to a conserved His228 residue adjacent to the metal center in ACMSD from 
Pseudomonas fluorescences (PfACMSD). Site directed mutagenesis of His228 to tyrosine and 
glycine in the present study results in complete or significant loss of activity. Metal analysis 
shows that H228Y and H228G contain iron rather than zinc, indicating that this residue plays a 
role in metal selectivity of the protein. As-isolated H228Y displays a blue color, which is not 
seen in wild-type ACMSD. Quinone staining and resonance Raman analyses indicate that the 
blue color originates from Fe(III)-tyrosinate ligand-to-metal-charge-transfer (LMCT). Co(II)-
substituted H228Y ACMSD is brown in color and exhibits an EPR spectrum showing a high-
spin Co(II) center with a well-resolved 59Co (I = 7/2) eight-line hyperfine splitting pattern. The 
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X-ray crystal structures of the as-isolated Fe-H228Y (2.8 Å), Co- (2.4 Å) and Zn-substituted 
H228Y (2.0 Å resolution) support the spectroscopic assignment of metal ligation of the Tyr228 
residue. The crystal structure of Zn-H228G (2.6 Å) was also solved. These four structures show 
that the water ligand present in WT Zn-ACMSD is either missing (Fe-H228Y, Co-H228Y, and 
Zn-H228G) or disrupted (Zn-H228Y) in response to His228 mutation. Together, these results 
highlight the importance of His228 for PfACMSD’s metal specificity as well as maintaining a 
water molecule as ligand of the metal center. His228 is thus proposed to play a role in activating 
the metal-bound water ligand for subsequent nucleophilic attack on the substrate. 
2.2  Introduction 
Histidine, an essential amino acid, is found at the active site of a myriad of enzymes. The 
imidazole side chain of histidine can serve as a coordinating ligand in metalloproteins and in 
many cases is a catalytically important component in the active sites of enzymes. The pKa of the 
imidazolium ion (~ 7) permits significant concentrations of both acidic and basic forms near 
neutral pH, making it a commonly found general acid-base catalyst in enzymes (121). The 
participation of histidine in catalysis has also been illustrated in the well-studied mechanisms 
proposed for members of the amidohydrolase superfamily (19,81). The best-characterized 
members of the amidohydrolase superfamily share a common catalytic mechanism by which a 
metal-bound water is proposed to be activated by an active site base to yield a metal-hydroxo 
species. Subsequently, the hydroxide attacks the substrate bearing the amide or other functional 
groups at the carbon or phosphorus center to form a tetrahedral carbon or pentacoordinate 
phosphorus intermediate on the substrate (19,81). The collapse of the substrate-based 
intermediate leads to the hydrolytic products. 
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The enzyme α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) 
catalyzes the decarboxylation of its substrate ACMS to form 2-aminomuconate semialdehyde 
product (AMS). It is the first enzyme known to perform an O2-independent nonoxidative 
decarboxylation with d-block divalent metal cofactors such as zinc, cobalt, or iron (14). ACMSD 
is proposed to be a prototypical member of a new protein subfamily in the amidohydrolase 
superfamily representing a novel nonhydrolytic C-C bond breaking activity (15,18). Scheme 2.1 
outlines a working mechanism of ACMSD action.  
ACMSD plays an important role in two distinct metabolic pathways, the mammalian 
kynurenine pathway for tryptophan degradation (122) and the bacterial 2-nitrobenzoic acid 
pathway for biodegradation of nitroaromatic compounds (12,123,124). In both pathways, 
ACMSD controls the final fate of the metabolites by competing with a slow spontaneous reaction 
that produces the excitotoxin quinolinic acid (QA) and directs the metabolic flux away from QA 
to energy production (125), QA is an endogenous selective agonist of N-methyl-D-aspartate 
receptors (2). It modulates neurotransmission and mediates immune tolerance. Reduced activity 
of ACMSD can lead to abnormal QA concentration in body fluids, which has been linked to 
numerous diseases, including diabetes (125), neuropsychiatric diseases (126), neurodegenerative 
disorders such as Alzheimer’s and Huntington’s diseases (127,128), stroke, and epilepsy (2,129). 
Therefore, the results of mechanistic study on ACMSD have significant medical implications. 
Although ACMSD was discovered more than 55 years ago (130), little was known about the 
catalytic mechanism until our recent collaborative studies of Pseudomonas fluorescences 
ACMSD (PfACMSD) (14) unmasked its metal cofactor and determined its three dimensional 
structure (80). The as-isolated enzyme contains a zinc ion (80) and it works equally well when 
substituted with a cobalt(II) ion (14,15). The decarboxylation is rapid (> 500 s-1); the product 
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release from the active site is the rate-limiting step (10). Recently, the crystal structure of human 
ACMSD was reported with a bound inhibitor 1,3-dihydroxyacetonephosphate (131). The human 
ACMSD and PfACMSD present a nearly identical overall structure consisting of an (α/β)8-barrel 
core and a five-coordinate protein-bound zinc ion (80,131). The metal ion is bound to the 
enzyme by three histidines (His9, His11, and His177), one aspartic acid residue (Asp294), and 
one water ligand. A nearby histidine from β-strand 6, i.e. His228 in PfACMSD residue 
numbering, is located in the secondary sphere and is part of a hydrogen-bonded system that 
appears to facilitate deprotonation of the water ligated to the catalytic zinc (Figure 2.1). A 
comprehensive biochemical, spectroscopic and structural study presented in this work suggests 
that His228 is a major determinant of metal preference in PfACMSD and that it plays an 
important role in maintaining the hydrolytic water ligand necessary for the decarboxylase 
chemistry in this enzyme. 
 
2.3 Experimental Procedures 
Site-Directed Mutagenesis. The plasmid containing His-tagged ACMSD from Pseudomonas 
fluorescens was used as a template for construction of all of the mutants (15). The forward 
Figure 2.1. The active site histidine (His228 or hHis224) is in H-bond distance with the metal-
bound water ligand (Wat) in crystal structures of ACMSD. (A) as-isolated Zn-PfACMSD (PDB: 
2HBV), (B) Co(II)-substituted PfACMSD (2HBX), and (C) an inhibitor-bound structure of 
hACMSD (2WM1).  
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primers used in the site-directed mutagenesis are 5’-
CAAGATCTGTTTCGGGggTGGTGGGGGAAGTTTCG-3’ for H228G and 5’-
CAAGATCTGTTTCGGGtATGGTGGGGGAAGTTTCG-3’ for H228Y. ACMSD mutants were 
constructed by the PCR overlap extension mutagenesis technique (132). The insertion of each 
construct was verified by DNA sequencing to ensure that base alterations were introduced 
correctly as expected and with no undesired changes. After sequencing, the positive clone was 
used for overexpression of these mutants in E. coli BL21(DE3). 
Bacterial Growth and Protein Preparation. The expression and purification of WT 
PfACMSD and its mutants were the same as described previously (15). Apo H228G was 
prepared by EDTA treatment; Zn(II) and Co(II) containing H228G proteins were prepared by 
metal reconstitution reaction as previously described (14). Because iron cannot be removed from 
as-isolated H228Y by high concentration EDTA, Zn(II)- and Co(II)-H228Y proteins were 
obtained by substituting 0.1 mM CoCl2 or ZnCl2 to M9 medium prior to the addition of IPTG for 
induction during cell culture. The protein was purified in the presence of 0.1 mM CoCl2 or ZnCl2 
during affinity chromatographic step by using Co(II)- and Zn(II)-charged IMAC columns, 
respectively. 
Metal Analysis. The metal content of the as-isolated ACMSD from LB was determined by 
inductively coupled plasma optical emission spectroscopy (ICP-OES) using a Spectro Genesis 
spectrometer (Spectro Analytical Instruments). Assays were performed in triplicate for the 
mutants the same day as the assay samples of the wild-type (WT) enzyme. Standard curves were 
prepared using a transition element standard mixture (CCS-6) from Inorganic Ventures. Error 
(standard deviation) within three measurements of each sample was less than 1%, while error 
between different ACMSD preparations was within 4%. Metal content is reported per ACMSD 
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monomer. Protein concentration was measured using Coomassie Plus protein assay reagent 
(Pierce) according to the manufacturer's instruction. Molar concentration of PfACMSD 
monomer was determined by using 39 kDa as the molecular weight (14).  
Circular Dichroism Spectroscopy. The CD spectra (190 - 250 nm) of ACMSD and mutant 
proteins were acquired on a JASCO J-810 spectropolarimeter (JASCO, Easton, MD, USA) at 
ambient temperature. In each measurement, a protein sample (10 μM) was placed in a 1-mm path 
length quartz cell in 0.05 M potassium phosphate, pH 7.5. All spectra were the average of ten 
scans with a scan rate of 50 nm min−1.  
Preparation of ACMS and Enzyme Activity Assay. ACMS was generated from 3-hydroxy-
anthranilic acid using 3-hydroxyanthranilate 3,4-dioxygenase containing no free transient metal 
ion as reported previously (15). Specific activities of ACMSD proteins were measured in 
triplicate at room temperature on an Agilent 8453 diode-array spectrophotometer by monitoring 
the absorbance of ACMS at 360 nm as described previously (15).  
Electronic Spectroscopy. UV-Vis absorption spectra were obtained in 25 mM HEPES-NaOH 
buffer, pH 7.0, and 5% glycerol at room temperature on a Cary 50 spectrophotometer. Reduced 
Fe(II)-H228Y for UV-Vis and resonance Raman experiments was prepared by adding 13 μL 30 
mM sodium dithionite or L-ascorbate (~ 2 equivalents per Fe) to 150 μL 1.4 mM Fe(III)-H228Y 
in an 1-mm path length cuvette. 
Quinone-based NBT Staining. Purified proteins were first electrophoresized on a 12% SDS–
PAGE gel and then transferred onto a nitrocellulose membrane using the Mini Trans-Blot Cell 
Assembly (Bio-Rad). The transblotting was conducted in the transfer buffer (25 mM Tris-HCl, 
192 mM glycine, and 20% methanol) at 100 V for 1 h. The proteins were temporarily visualized 
by 0.1% ponceau S in 5% acetic acid (133). After the temporary stains were removed by washing 
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with water, the protein-containing nitrocellulose membrane was immersed in a solution of 0.24 
mM NBT and 2 M potassium glycinate, pH 10, in the dark for 45 min to visualize the quinone-
containing protein band (134). This method was designed to identify quinonoid compounds, such 
as DOPA, and is a convenient assay for quinone-containing proteins (135). Purified methylamine 
dehydrogenase (MADH) from Paracoccus denitricans (a generous gift from Dr. Victor L. 
Davidson), a protein consisting of two large α-subunits and two small β-subunits with a 
tryptophan tryptophyquinone prosthetic group in each of its small subunit (136), was used as 
both of a positive and a negative control in Ponceau S staining and NBT staining experiments. 
Electronic Paramagnetic Resonance (EPR) Spectroscopy. HEPES buffer (25 mM, pH 7.0) 
containing 10% glycerol was used in the EPR sample preparations. X-band EPR spectra were 
obtained in perpendicular mode on a Bruker (Billerica, MA) EMX spectrometer at 100-kHz 
modulation frequency using a 4119HS high-sensitivity resonator. Low temperature was 
maintained with an ITC503S temperature controller, an ESR910 liquid helium cryostat, and a 
LLT650/13 liquid helium transfer tube (Oxford Instruments, Concord, MA). Measurements were 
conducted by keeping the frequency of the electromagnetic radiation constant while the magnetic 
field was swept. 
Raman Spectroscopy. Resonance Raman spectra were collected on an Acton AM-506 
spectrophotometer (1200 groove rating) using Kaiser Optical Systems holographic supernotch 
filters and a Princeton Instruments liquid N2-cooled CCD detector (LN-1100PB) with 4 cm-1 
spectral resolution. HEPES buffer (25 mM, pH 7.0) containing 5% glycerol was used in the 
sample preparations. Spectra were collected at 100 mW laser power using a Spectra Physics 
1060-KR-V krypton ion laser (568.2 and 647.1 nm) or a 2030-15 argon ion laser (488.0 and 
514.5 nm). Raman frequencies were referenced to indene standard with an accuracy of ± 1 cm-1. 
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Raman spectra were collected at 4 °C by 90° scattering from a flat bottomed NMR tube with 30-
60 minutes to collect each window of spectra. The full spectra were collected in two overlapping 
windows; the florescent background was subtracted before normalizing spectra at nonresonance 
enhanced protein phenylalanine ring vibration at 1004 cm-1 and splicing normalized spectra 
together. Baseline corrections (polynomial fits) were applied using Gram/32 Spectral Notebook 
(ThermoGalactic). Excitation profiles were constructed by comparing peak intensities of 
resonance enhanced bands of normalized spectra to nonresonance enhanced vibration at 1004 
cm-1. Difference resonance Raman spectra of Fe(III)-H228Y were obtained by subtracting the 
spectrum of WT Zn-ACMSD both normalized at 1004 cm-1 vibration followed by a base line 
correction. 
X-ray Data Collection and Crystallographic Refinement. Co(II)-H228Y, Zn(II)-H228Y and 
Zn(II)-H228G ACMSD were crystallized following the condition previously established for WT 
ACMSD by hanging drop vapor diffusion in VDX plates (Hampton Research). Single crystals 
suitable for X-ray data collection were obtained from drops assembled with 1 μL protein solution 
layered with 1 μL reservoir solution containing 0.1 M Tris-Hcl (pH 8.75), 0.2 M MgCl2, and 
15% PEG 5000. Reservoir solution for Fe(III)-H228Y was modified and contained 0.1 M Tris 
(pH 7.0), 0.2 M MgCl2, and 17% PEG 5000. Crystals were frozen in liquid nitrogen after being 
dipped into the cryoprotectant solution that contained 30% of glycerol or ethylene glycol in the 
mother liquid. X-ray diffraction data were collected at SER-CAT beamline 22-ID or 22-BM of 
the Advanced Photon Source (APS), Argonne National Laboratory, Argonne, IL. Data were 
collected at 100 K using a beam size matching the dimensions of the largest crystal face. The 
data were processed with HKL-2000 (137). Structure solutions were obtained by molecular 
replacement using MolRep (138) from the CCP4i program suite (139) with the entire WT Co(II)-
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ACMSD structure (PDB entry 2HBX) for Co(II)/Fe(III)-H228Y ACMSD and WT Zn(II)-
ACMSD structure (PDB entry 2HBV) for Zn(II)-H228Y/Zn(II)-H228G ACMSD as the search 
models. Refinement was carried out using REFMAC (140) in the CCP4i program suite (139) for 
Fe(III)- and Co(II)-H228Y and PHENIX software for Zn(II)-H228Y and Zn(II)-H228G, and 
model-building was carried out in COOT (141). Restrained refinement was carried out using no 
distance restraints between the metal center and its ligands. Residue Tyr228 and Gly228 were 
well-ordered and added to the model based on the 2Fo-Fc and Fo-Fc electron density maps. 
Refinement was assessed as complete when the Fo-Fc electron density contained only noise. 
2.4 Results 
Biochemical properties of the His228 mutants—To probe its role in the enzyme mechanism, 
His228 was mutated to tyrosine, which also has a ring structure and is capable of hydrogen 
bonding, and glycine, which effectively deletes the side chain and thus eliminates hydrogen 
bonding. Both variants were expressed as soluble proteins. Surprisingly, the H228Y mutant 
purified from cells grown in LB medium exhibits a blue chromophore while wild-type (WT) Zn-
ACMSD is colorless (Figure 2.2). Metal analysis of the blue H228Y-ACMSD by ICP-OES 
spectroscopy showed the enzyme contained 0.51 ± 0.013% Fe, 0.08 ± 0.003 Zn and 0.001 ± 
0.0004 Cu ions per polypeptide chain, whereas the wild-type enzyme prepared under the same 
experimental conditions contained only zinc (80). Likewise, the as-isolated H228G mutant 
contained mainly Fe ion (0.32 ± 0.001 per polypeptide chain) and trace amount of zinc. A sharp 
ferric EPR signal is seen at g = 4.27 from the two as-isolated His228 mutants (not shown). These 
results suggest His228 is an important determinant of metal selectivity in this enzyme. 
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The as-isolated H228G and H228Y were catalytically inactive regardless of whether the Fe 
ion is in the ferrous or ferric oxidation state. Zinc- and cobalt-substituted variants were also 
tested. H228Y was inactive in both Zn(II) and Co(II) forms, as was Zn(II)-H228G. These results 
suggest that His228 is essential for the enzyme catalytic activity. 
The blue color in H228Y is not due to formation of a metal-bound dihydroxyphenylalanine—
Two possibilities were considered for the origin of the blue chromophore of the as-isolated Fe-
containing H228Y. The first option is an oxygenated Tyr may be produced by post-translational 
modification resulting from oxygen activation by the redox active iron. Examples can be found 
for a number of non-heme iron enzymes (135,142,143). However, this option is not supported by 
A quinone-based staining assay (135) using reversible ponceau S staining of a nitrocellulose 
membrane (See Supporting information Figure S2.1). Alternatively, it could be due to the 
coordination of Tyr228 to the active site metal, as tyrosinate-metal interactions have been 
Figure 2.2. UV-Vis spectra of Fe-H228Y. The as-isolated Fe(III)-H228Y protein(dark blue 
trace), its reduced form (black) and the different spectrum (red) showing two absorption at 
370 nm and 595 nm. Photographs of the as-isolated Fe(III)-H228Y (right) and reduced Fe(II)-
H228Y (left) are shown in the inset. 
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observed in many other enzymes, such as purple acid phosphatases (144). phospholipase D 
(145), and catalases (146).  
Resonance Raman characterization suggests an Fe(III)-tyrosinate chromophore in as-
isolated Fe-H228Y—The blue Fe-H228Y mutant exhibits two UV-Vis absorption bands at 370 
and 595 nm, with respective extinction coefficients of 3000 and 1300 M-1 cm-1 (Figure 2.2). 
While the 370 nm feature is a common spectral characteristic of the Fe(III)-bound nonheme Fe 
proteins, the blue chromophore at 595 nm is within the range of the Fe(III)-tyrosinate LMCT 
band with an absorption maximum that is typically between 410 – 600 nm (1000 – 2500 M-1cm-1 
per phenolate ligand) (147). In contrast, an iron(III)-catecholate LMCT chromophore typically 
exhibits two lower energy bands between 400 – 580 nm and 550 – 900 nm (2000 – 2500 M-1cm-
1), these are not present in Figure 2.2. The blue chromophore vanished upon the addition of 
sodium dithionite or L-ascorbate to the protein, suggesting that reduction of the Fe(III) metal 
center to Fe(II) is linked with the loss of the intense ligand-to-metal charge-transfer (LMCT) 
transition. 
Figure 2.3A shows resonance Raman spectra of the as-isolated blue Fe-H228Y acquired with 
568.2 nm laser excitation using 90° scattering geometry compared to the spectra of reduced Fe-
H228Y, WT Zn-ACMSD and the buffer (25 mM HEPES pH 7.0 with 5% glycerol by volume) 
collected under the same conditions. Vibrations associated with the buffer solution and protein 
were subtracted by taking the difference spectra of the as-isolated blue Fe-H228Y and WT Zn-
ACMSD after normalizing both spectra by scaling to non-resonance-enhanced protein 
phenylalanine ring vibration at 1004 cm-1 (Figure 2.3B). The difference spectrum shows 
resonance-enhanced vibrations at 573, 792, 873, 1164, 1290, 1503, and 1604 cm-1. The 
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excitation profile of the 1164, 1290, 1503, and 1604 cm-1 features shown in Figure 2.3C 
illustrates maximum enhancement of these vibrations near the absorption maximum of the blue 
chromophore at 595 nm, while the 573, 792, and 873 cm-1 vibrations are more enhanced at 647.1 
nm. The spectrum of the reduced form of the colorless Fe(II)-H228Y does not exhibit any 
resonance-enhanced vibrations but closely resembles the WT Zn-ACMSD (Figure 2.3A). 
Figure 2.3. Resonance Raman spectra of H228Y-ACMSD. (A) Resonance Raman spectrum with
568.2 nm laser excitation of (a) as-isolated blue Fe(III)-H228Y, (b) native Zn-ACMSD, (c)
Fe(II)-H228Y ACMSD, and (d) Fe(III)-H228Y ACMSD. (B) Difference resonance Raman
spectra of Fe(III)-H228. (C) Excitation profiles for resonance enhanced bands. 
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      The resonance enhanced vibrations of Fe(III)-H228Y at 573, 1164, 1290, 1503, and 1604  
cm-1 are collectively regarded as the Raman signature for a Fe(III)-tyrosinate chromophore 
(Table 2.1) (147-159). These vibrations are distinct from those expected for a Fe(III)-catecholate 
chromophore, which has characteristic vibrations observed at 1270, 1320, 1425, and 1475 cm-1 
(Table 2.1) (160-164). By analogy to previous work on nonheme Fe proteins the 573 cm-1 can be 
assigned to the Fe-(O)Tyr vibration, while the higher frequency vibrations are associated with 
aromatic ring modes. The 792 and 873 cm-1 vibrations may originate from a Fermi doublet 
formed by the mixing of the fundamental υ1 symmetric ring-breathing vibrational mode and first 
overtone υ16a non-planar ring vibration (165-168). Solid L-tyrosine exhibits a Fermi doublet with 
peaks at 803 and 845 cm-1 as well as the υ16a fundamental at 419 cm-1 (166). The two peaks 
observed for the blue Fe-H228Y have a much larger splitting of 81 cm-1. An even larger splitting 
has been observed for porcine uteroferrin (803 and 873 cm-1), while the υ16a fundamental was not 
detected (165,168). The large splitting of tyrosine Fermi doublet was rationalized as a result of 
strong covalence of the Fe(III)-tyrosinate metal ligand bond based on the fact that it was 
resonance enhanced and that its center of gravity (~ 838 cm-1) is similar to that of L-tyrosine (~ 
824 cm-1) (165). Upon 647.1 nm laser excitation of the blue Fe-H288Y, a weak peak is observed 
at 418 cm-1 that may be assigned to the fundamental υ16a vibration. 
Table 2.1. Resonance Raman vibrations and LMCT bands of nonheme iron protein and model 
complexes with Fe(III)-phenolate and Fe(III)-catecholate chromophores. 
Complexa λmax (nm) (ε, M-1cm-1) Resonance Raman Vibrations (cm
-1) Reference 
Fe(III)-phenolate complexes  
H228Y-Fe(III)-
ACMSD 
370(3000), 
595(1255) 573 792 873 1164 1290 1503 1604 this work 
Fe(II)-HPPD + O2 595(2600) 583 751 881 1171 1290 1502 1600 (148,169) 
Porcine uteroferrin 545(1000) 575 803 873 1173 1293 1504 1607 (165,168) 
[Fe(salhis)2]ClO4 530(4100) 1159 1337 1476 1625 (153) 
  1132 1310 1452 1605  
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Fe(III)-
serotransferrin 470(2500) 759 828 1174 1288 1508 1613 (156,159) 
Fe(III)-lactoferrin 465(2070) 1170 1272 1500 1604 (157,158) 
Fe(III)-
ovotransferrin 465(2000) 759 860 1173 1264 1501 1603 (151) 
Catechol 1,2-
dioxygenase 
450(3000–
4000) 757 872 1175 1289 1506 1604 (153,154) 
Protocatechuate 
3,4-dioxygenase 
435(3000), 
525 592 756 826 1172 1254 1506 1604 (149,152) 
  854 1180 1266  
[Fe(salen)(OC6H-
4-CH3)] 
410 568 1168 1272 1501 1603 (147,155) 
Fe(III)-catecholate complexes  
Fe(III)TyrH-
dopamine 
415(1700), 
695(2000) 528 592 631 1275 1320 1425 1475 (163) 
Blue PMI 420(1500), 680(2100) 591 631 1266 1330 1428 1482 (161) 
Fe(III)-MndD-
DOPA 675(750) 530 569 646 666 1273 1318 1423 1464 (170) 
  586  
Fe(II)TauD-αKG 
+O2 
550(700) 544 580 623 644 1261 1314 1425 1475 (162,171) 
aAbbreviations used in this table: ACMSD, α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase from 
Pseudomonas fluorescens; salhis, N-[2-(4-imidazolyl)ethyl]salicylaldimine; salen, N,N'-ethylenebis 
(salicy1idenamine) dianion; MndD, homoprotocatechuase 2,3-dioxygenase from Arthrobacter globiformis; DOPA, 
dihydroxyphenylalanine; PMI, phosphomannose isomerase from Candida albicans expressed in Escherichia coli; 
TauD taurine/α-ketoglutarate dioxygenase from Escherichia coli; HPPD, (4-hydroxyphenyl) pyruvate dioxygenase 
from Pseudomonas fluorescens; α-KG, α-ketoglutarate. 
      Fe(III)-tyrosinate LMCT bands in the visible region typically range from 410–600 nm where 
the energy of the LMCT transition can be correlated with the Lewis acidity and the Fe(III/II) 
redox potential of the iron center and can give additional information about the nature of the 
other coordinating ligands (147). The low energy of the Fe(III)-tyrosinate LMCT band of Fe-
H228Y at 595 nm and the observation that Fe-H228Y is easily reduced by mild reducing agents 
are consistent with a Lewis acidic metal center with weak field ligands (148). Post-translationally 
modified blue (4-hydroxyphenyl) pyruvate dioxygenase (HPPD) has a similarly low-energy Fe-
tyrosinate LMCT band at 595 nm (148,169). From its crystal structure (172), unmodified HPPD 
has an iron center coordinated by two histidines and one glutamate, but no tyrosinate ligand. 
However it does have several phenylalanine amino acid residues in the second sphere, one of 
which has been proposed to be self-hydroxylated to form the tyrosinate ligand in blue-HPPD 
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(164,172). Based on the similar energies of their LMCT bands, blue Fe(III)-H228Y and the self-
hydroxylated HPPD are likely to have comparable ligand environments with two or three 
histidine residues and a carboxylate group from either an aspartate or glutamate. Along with the 
fact that H228Y no longer picks up Zn(II), the Fe(III) is likely to be coordinated by His9, His11, 
His177, Asp294 and Tyr228 residues in the ACMSD active site. 
      Spectroscopic characterization of Co(II)-substituted H228Y— Co(II)-H228Y was obtained 
by adding supplemental CoCl2 to the M9 minimum growth medium and purification buffer (see 
experimental procedures). ICP-OES spectroscopic analysis confirmed that H228Y isolated with 
supplemented cobalt contains 0.98 ± 0.02 cobalt and 0.05 ± 0.03 iron per protein monomer. The 
cobalt-substituted H228Y displays a brown chromophore that is darker than the color of the WT 
Co(II)-substituted ACMSD (Figure 2.4, top), The brown chromophore originates from forbidden 
metal d-d transitions, the intensities of which can be correlated to the metal coordination number. 
Decreasing the coordination number increases the intensity of the d-d bands due to greater p-d 
orbital mixing. Typically, six-coordinate high-spin Co(II) complexes have extinction coefficients 
of less than 50 M-1cm-1 above 500 nm, while five- and four-coordinate complexes have values 
between 50 – 250 M-1 cm-1 and greater than 300 M-1cm-1, respectively (173-175). The visible 
spectrum of the brown Co(II)-substituted H228Y is similar to that of WT Co(II)-ACMSD above 
500 nm (Figure 2.4, top), consistent with a 5-coordinate Co(II) center (176). However, the 
spectrum below 500 nm is distinct from that of the wild-type protein (Figure 2.4, top). The 
absorption peaks at 355 (680 ± 20 cm-1M-1) and 420 nm (430 ± 10 cm-1M-1) in WT ACMSD are 
respectively red shifted to 380 (590 ± 30 cm-1M-1) and 458 (490 ± 20 cm-1M-1) in the Co(II)-
substituted H228Y. These differences indicate that the Co(II) center in the H228Y mutant is in a 
weaker ligand field environment than in WT Co(II)-substituted ACMSD. This observation is 
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consistent with the substitution of a water ligand by a stronger π-donating ligand in Co(II)-
substituted H228Y due to Tyr228 ligation to the metal as suggested by resonance Raman study 
for Fe-H228Y in as-isolated H228Y protein. 
 
      Electron paramagnetic resonance (EPR) spectroscopy was employed to characterize the 
electronic structure of the metal center in Co(II)-substituted H228Y. The EPR spectrum of Co-
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Figure 2.4. UV-Vis and EPR spectra of Co(II)-H228Y-ACMSD. Top panel: UV-Vis spectra of 
Co(II)-H228Y ACMSD (black) and Co(II)-substituted WT ACMSD (red). Photographs of the 
as-isolated Co-WT (left) and Co-H228Y (right) are shown in the inset. Bottom panel: EPR 
spectra of Co(II)-H228Y ACMSD obtained at 3G modulation, 0.25 mW microwave power, and 
10K. The asterisk indicates a g=4.27 signal from a small amount of Fe ion present in the sample 
due to a change in the metals preference of H228Y. 
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      X-ray crystal structure—While the spectroscopic data strongly suggest a tyrosinate ligation 
to Fe in the as-isolated H228Y protein, it remains unclear that if Tyr228 is a metal ligand in 
Co(II)-substituted H228Y. The zinc-containing mutants do not have chromophore or EPR 
features. In order to observe directly what changes at the enzyme active site arise from the point 
mutation and metal substitution, we obtained single crystals from the as-isolated Fe(III)-H228Y, 
Co(II)-substituted H228Y, Zn(II)-substituted H228Y, and Zn(II)-reconstituted H228G proteins. 
The X-ray crystal structures of Fe(III)-H228Y (2.8 Å, PDB entry: 4ERG), Co(II)-H228Y (2.4 Å 
resolution, PDB entry: 4ERA), and Zn(II)-H228G (2.6 Å, PDB entry: 4EPK) were solved in the 
P42212 space group, while Zn(II)-H228Y (2.0 Å, PDB entry: 4ERI) was determined in the C2 
space group. Data collection and refinement statistics are presented in Table 2.2. Figure 2.5 
shows the superimposition of the four structures we determined against the previously reported 
WT Zn(II)-ACMSD and Co(II)-substituted ACMSD data. As previously seen in the wild-type 
enzyme, the mutants of PfACMSD exhibits a homodimeric quaternary structure. The substitution 
of His228 with either Tyr or Gly has little impact on the folding of the overall TIM-barrel 
scaffold, regardless of the metal identity. The circular dichroism spectra of these variants were 
nearly identical to that of the WT enzyme (not shown), consistent with the structural data. In 
Figure 2.5, structural variations relative to WT ACMSD are highlighted in different colors. 
These structural differences are mainly observed in the previously defined mobile insertion 
domain, which is more flexible compared with other parts of the structure (80). Limited 
structural differences in a few loop regions are observed due to changes of metal ligation in the 
metal-substituted mutants. Therefore, we conclude that no significant change in secondary 
structure was introduced due to the mutation and metal substitution. The organization of amino 
acids residues surrounding the metal center is very similar in all four structures with one 
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exception of one of the metal ligands, Asp294, which tilts towards the imidazole ring of His9 to 
various degrees (Figure 2.6).  
 
Table 2.2. X-ray crystallography data collection and refinement statistics 
Data collection Fe-H228Y Co-H228Y Zn-H228Y Zn-H228G 
Detector type MAR300 CCD MAR225 CCD MAR300 CCD MAR300 CCD 
Source APS, Sector 22-ID APS, Sector 22-BM APS, Sector 22-ID APS, Sector 22-ID 
Space group P42212 P42212 C2 P42212 
Unit cell lengths (Å) 
a=b=90.43, 
c=167.53 
 
a=b=90.03, 
c=167.31 
 
a=153.84, b=48.56, 
c=110.20 
a=b=91.50, 
c=170.12 
Unit cell angles (˚) α=β=γ=90º α=β=γ=90º α=γ=90º, β=126.89º α=β=γ=90º 
Figure 2.6. The active site structures of ACMSD containing different metals. (A) As-isolated 
Fe(III)-H228Y, (B) Co(II)-substituted H228Y, (C) Zn(II)-H228Y, and (D) Zn(II)-substituted 
H228G. The 2Fo − Fc electron densities are taken from chain A and contoured at 1.5σ. The larger 
spheres represent metal ions. The smaller gray sphere in panel C represents a water molecule, 
which is weakly bound to the zinc ion (2.44 Å) as compared to the zinc−water ligand distance of 
2.04 Å in the wild-type enzyme (PDB entry 2HBV). Such a water ligand is missing from the metal 
center in all other H228G and H228Y structures. 
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Wavelength (Å) 1.00 1.00 1.00 1.00 
Temperature (K) 100 100 100 100 
Resolution (Å) a 2.80 (2.85) 2.40 (2.44) 2.00 (2.03) 2.60 (2.64) 
Completeness (%)a 99.8 (99.8) 99.2 (94.1) 92.7 (54.7) 98.4 (68.7) 
Rmerge (%)a, b 10.1 (69.7) 10.1 (61.0) 6.1 (22.8) 7.7 (65.6) 
I/σI a 60.8 (2.5) 40.5 (2.9) 51.1 (6.0) 63.1 (1.9) 
Multiplicity a 24.2 (9.8) 13.9 (9.6) 6.3 (3.4) 18.6 (7.2) 
Refinement
Resolution (Å) 2.8 2.4 2.0 2.6 
No. reflections; 
working/test 17041/915 26155/1382 41014/2073 22859/1173 
Rwork (%)c 19.9 21.5 20.5 20.8 
Rfree (%)d 27.3 29.5 25.6 28.1 
Protein atoms 5194 5194 5194 5153 
Ligand atoms 2 2 3 3 
Solvent sites 9 88 209 32 
Ramachandran statisticse 
Preferred 93.48 92.73 94.52 91.78 
Allowed (%) 5.61 5.61 4.72 7.61 
Root mean square deviation 
Bond lengths (Å) 0.011 0.011 0.008 0.009 
Bond angles (˚) 1.299 1.464 1.098 1.204 
PDB access code 4ERG 4ERA 4ERI 4EPK 
a Values in parentheses are for the highest resolution shell. 
b Rmerge = Σi |Ihkl,i - ‹Ihkl›|/Σhkl Σi Ihkl,i, where I is the observed intensity and ‹Ihkl› is the average intensity of multiple 
measurements. 
c Rwork = Σ||Fo|-|Fc||/Σ|Fo|, where |Fo| is the observed structure factor amplitude, and |Fc| is the calculated structure 
factor amplitude. 
d Rfree is the R factor based on 5% of the data excluded from refinement. 
e Based on values attained from refinement validation options in COOT. 
Inspection of the metal center shows that Tyr228 is a metal ligand in all three H228Y mutant 
proteins (Figure 2.6), with Tyr-to-metal bond lengths of 2.13, 2.12, and 2.41 Å in chain A, and 
2.26, 2.16, 2.44 Å in chain B in the Co-, Fe-, and Zn-H228Y structures, respectively. It would 
appear that the interaction between the Zn ion and the Tyr228 residue weaker than corresponding 
interactions with Fe and Co. Nonetheless, the angles of the Tyr228 plane, phenolic oxygen and 
the metal, including zinc, are well within the range of typical metal-ligand angular orientations 
(110 – 140°) reported in biological systems (130.2°, 137.3°, and 128.7° in chain A, and 129.7°, 
132.5°, and 122.6° in chain B in the Co-, Fe-, and Zn-H228Y structures, respectively) (178). 
Hence, the prediction of Tyr228 ligation by our spectroscopic work is confirmed by these as-
isolated and metal-substituted H228Y structures. It should be noted that the metal center in chain 
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B in the mutant structures shows a noticeable degree of disorder. This was the same as 
previously observed in the as-isolated and cobalt-substituted wild-type ACMSD structures 
(2HBV & 2HBX) (80).  
The most significant structural difference with respect to the WT structure is that the water 
ligand is missing from the metal center in Fe(III)-H228Y, Co(II)-substituted H228Y, and Zn(II)-
reconstituted H228G proteins. Modeling of the omit maps (Figure S2.2) show the electron 
density can only be fitted by the metal ion in these structures. However, the resolution is not 
sufficiently high to assign the solvent content in the Fe(III)-H228Y and Zn(II)-H228G data sets, 
the missing water ligand cannot be reliably concluded based on these structures. In contrast, 
Zn(II)-H228Y and Co(II)-substituted H228Y structures contain reasonable amount of water 
molecules. The water ligand is missing from the cobalt structure, whereas, the water ligand is 
still present in the Zn(II)-substituted H228Y structure but at a much longer distance from the 
metal, 2.44 Å in chain A and 2.38 Å in chain B from the zinc ion as compared to 2.05 and 2.07 Å 
in WT Zn-ACMSD structure. Our EPR, resonance Raman and optical data suggest a low 
coordination number in the Co(II)- and Fe(III)-H2228Y metal center. Taken together, it is likely 
that the water ligand is missing, or dissociated, from the metal center in Co(II)- and Fe(III)-
H228Y mutants. Moreover, the hydrogen bonding network that potentially activates the water 
ligand is significantly altered. In the WT Zn-ACMSD crystal structure the water ligand hydrogen 
bonds to both His228 and Asp294, while in the H228Y mutant the distance between Asp294 and 
the water ligand is elongated to 3.60 Å in chain A and 3.67 Å in chain B, ,compared to 2.88 and 
3.33 Å in the WT Zn-ACMSD. In the H228G structure, the metal center is still five-coordinate 
even though the water ligand is absent. Asp294 becomes a bidentate ligand to the metal ion. 
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From the H228G structure and the three H228Y structures, we conclude that His228 plays an 
important role in metal ion recruitment and maintaining the position of the water ligand. 
2.5 Discussion 
His228 is a major determinant of metal ion selectivity in PfACMSD—ACMSD was thought 
to be a cofactor-free enzyme for about 50 years until we found many divalent transition metal 
ions can effectively activate it (14). In the subsequent study, we found that the as-isolated protein 
contains only zinc ion (80). However, the molecular basis of metal selectivity in proteins is 
generally poorly understood and the preference for zinc within the active site of ACMSD has 
remained a mystery prior to this work. In the present study, a point mutation of a second 
coordination sphere His228 residue to Gly or Tyr is described to change PfACMSD’s metal ion 
selectivity from Zn to Fe ion. In general, the primary control of metal selectivity in proteins 
should be the metal-binding ligand set. A single site mutation on a non-metal ligand residue 
changes metal selectivity in a protein is a surprising result. To our knowledge, the finding 
described in this work for metal selection role of a second coordination sphere residue is only the 
second example in literature. Previously, mutation of a conserved glutamate in Escherichia coli 
manganese superoxide dismutase has been shown to change metal preference to Fe ion (179). In 
all other documented cases the residue identified for affecting metal selectivity is a metal ligand. 
The lesson learned from PfACMSD His228 is anticipated to improve our understanding of metal 
ion selectivity in proteins and expand the scope of roles histidine plays in the enzyme active site.  
The origin of blue color in H228Y—To understand the underlying reason for the loss of 
enzyme activity due to mutation of His228, a spectroscopic study was performed to interrogate 
the metal center’s chemical and electronic structure in H228Y. The optical and NBT-staining 
data suggest the ligation of Tyr228 to the Fe ion in the as-isolated Fe(III)-H228Y, and this notion 
55 
is further supported by our resonance Raman results. These data also eliminate the possibility of 
post-translational modification of Tyr228 to a DOPA. 
The role of His228 in maintaining the hydrolytic water ligand forcatalysis—His228 attracted 
our attention because it is a strictly conserved active site residue. It lies on the opposite side of 
the presumed substrate binding pocket (80,131). A previous structural study has revealed the 
conformational diversity of this active site residue (80). In the present work, His228 was mutated 
to tyrosine and glycine. In line with our expectations, neither of the protein variants had a 
measureable catalytic activity; regardless of which metal was incorporated into the active site. 
The biochemical and spectroscopic data suggest that the loss of catalytic activity is, in large part, 
due to the missing histidine that acts as an acid/base catalyst and, the loss of the water ligand. 
Thus, a dual role of His228 is revealed, i.e., it stabilizes the water ligand while plays an 
important role in metal selectivity of the enzyme. 
Tyrosinate ligation to the metal center was identified by resonance Raman spectroscopy and 
further supported by the EPR data. The UV-Vis absorption spectra of both WT and Co(II)-
substituted H228Y suggest five-coordinate metal centers. Therefore, the water ligand in the wild-
type enzyme is likely replaced by the Tyr228 residue in the mutant. In the crystal structures of 
H228Y proteins loaded with three different metal ions, Tyr228 is a metal ligand. The 
spectroscopic data and the crystallographic results are consistent to each other. 
A water ligand is observed in all published structures of ACMSD, including Co(II)- and Zn(II)-
PfACMSD, as well as Zn(II)-hACMSD proteins. Such a water ligand is also present in other 
members of the ACMSD subfamily, including 4-oxalomesaconate hydratase, and γ-resorcylate 
decarboxylase (21,80,180). The structures of Fe(III)-H228Y, Co(II)-H228Y and H228G are the 
first structures determined that do not show a water ligand, while Zn(II)-H228Y shows a weakly 
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bound water ligand with a longer distance to the metal center compared to the WT protein. 
Because of its weak binding to the Zn center, the pKa of the water ligand in Zn(II)-H228Y may 
not be decreased as effectively as in the WT proteins by coordination to the zinc ion. Cobalt and 
zinc ions are particularly strong Lewis acids and can dramatically reduce the pKa of bound water 
ligands. In a well-established example of carbonic anhydrase, the bound Zn(II) ion decreases the 
pKa of its water ligand from 15.7 to 7 (181-183). Catalysis ensues from this zinc activation of its 
bound water. His228 is strictly conserved within all known ACMSD amino acid sequences, and 
in all available structures of the enzyme this residue is in hydrogen bonding distance to the water 
ligand. The primary role of this His228 is proposed as deprotonation of the metal-bound water so 
that a hydroxide ion can be generated as an active site nucleophile at ca. pH 6 – 7, the optimum 
pH range for ACMSD. Although the hydroxide attack mechanism model shown in Scheme 2.1 
for ACMSD is distinct from other metal-dependent decarboxylases, it shares common features 
with the established mechanisms in the amidohydrolase superfamily (19).  
The results described in this work are consistent with our working model of the ACMSD 
reaction (Scheme 2.1). In the working mechanistic model shown in Scheme 2.1, the metal-bound 
water molecule is deprotonated to hydroxide anion (OH-) with the assistance of His228, which is 
acting as a general acid/base catalyst to deprotonate the zinc-bound water molecule for attack on 
the substrate. The hydroxide ion performs a nucleophilic attack on the C2=C3 double bond of 
ACMS with concomitant protonation at C3. Essentially, a water molecule is added across the 
double bond with the hydroxyl group at C2 and the new proton at C3, generating a substrate-
based tetrahedral intermediate. Collapse of the tetrahedral intermediate initiates the 
decarboxylation and produces α-aminomuconate-ε-semialdehyde and regenerate the metal 
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center. This decarboxylation model follows a hydrolytic mechanism consistent with the 
mechanistic paradigm of the amidohydrolase superfamily.  
 
Scheme 2.1. The proposed catalytic role of His228 in ACMSD reaction. 
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2.6 Supporting Information 
Figure S 2.1. Ponceau S (left) and nitroblue tetrazolium (NBT) quinone (right) staining of 
purified MADH and blue H228Y ACMSD from Pseudomonas fluorescences. Lane 1: MADH; 
lane 2: blue H228Y ACMSD; lane 3: pre-stained protein molecular weight ladder. The quinone-
based staining assay was carried out to test the potential presence of the quinonoid compounds, 
including L-3,4-dihydroxyphenylalanine (DOPA). Methylamine dehydrogenase (MADH) from 
Paracoccus denitrificans was used as a control. Reversible ponceau S staining of the 
nitrocellulose membrane reveals three bands on the MADH lane corresponding to the β-subunit, 
α−subunit, and a small amount of αβ heterodimer, while there is only one single band on the 
H228Y lane under the SDS-PAGE conditions (left panel), demonstrating that MADH and blue 
Fe-H228Y were both purified to near homogeneity. After thoroughly rinsing away the ponceau S 
red dye, the same membrane was subjected to the quinone-based NBT staining. Only the small 
β-subunit and the partially dissociated αβ fraction of MADH were visualized by the NBT 
staining, while Fe-H228Y and the large α-subunit of MADH were both unstained (right panel). 
Blue Fe-H228Y was insensitive to specific staining. Hence, the NBT staining data led us to 
eliminate the possibility of a quinonoid compound in blue Fe-H228Y. 
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Figure S 2.2. Omit maps (green) generated from the 2Fo-Fc maps (blue) after removing metal ion 
and any assigned water ligand(if any). The electron density is contoured at 1.5 σ. (A) as-isolated 
Fe(III)-H228Y (PDB entry: 4ERG), (B) Co(II)-substituted H228Y (4ERA), (C) Zn(II)-H228Y 
(4ERI), and (D) Zn(II)-substituted H228G (4EPK). 
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CHAPTER 3    THE POWER OF TWO: ARGININE 51 AND ARGININE 239* FROM A 
NEIGHBORING SUBUNIT ARE ESSENTIAL FOR CATALYSIS IN α-AMINO-β-
CARBOXYMUCONATE-ε-SEMIALDEHYDE DECARBOXYLASE 
The section of chapter 3 is a published work on ACMSD: The Power of two: arginine 51 and 
arginine 239* from a neighboring subunit are essential for catalysis in α-amino-β-
carboxymuconate-ε-semialdehyde decarboxylase. Lu Huo, Ian Davis, Lirong Chen, and Aimin 
Liu. (2013) J. Biol. Chem., 288(43), 30862-30871. This work was supported in part or whole by 
NSF grant MCB-0843537 and Georgia Research Alliance Distinguished Scholar Program (AL). 
X-ray data was collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID 
and 22-BM beamlines at the Advanced Photon Source, Argonne National Laboratory. Use of the 
Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, 
Office of Basic Energy Sciences, under Contract No. W-31-109-Eng. We thank Dr. B.-C. Wang 
and the SER-CAT staff scientists of the Section 22 of Argonne National Laboratory for 
assistance in beamline preparation and X-ray data collection. 
3.1 Abstract 
While the crystal structure of α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase 
(ACMSD) from Pseudomonas fluorescens was solved as a dimer, this enzyme is a mixture of 
monomer, dimer, and higher order structures in solution. In this work we found that the dimeric 
state, not the monomeric state, is the functionally active form. Two conserved arginine residues 
are present in the active site: Arg51 and an intruding Arg239* from the neighboring subunit. In 
this study, they were each mutated to alanine and lysine, and all four mutants were catalytically 
inactive. The mutants were also incapable of accommodating pyridine-2, 6-dicarboxylic acid, a 
competitive inhibitor of the native enzyme, suggesting that the two Arg residues are involved in 
61 
substrate binding. It was also observed that the decarboxylase activity was partially recovered in 
a heterodimer hybridization experiment when inactive R51A/K and R239A/K mutants were 
mixed together. Of the 20 crystal structures obtained from mixing inactive R51A and R239A 
homodimers which diffracted to a resolution lower than 3.00 Å, two structures are clearly 
R51A/R239A heterodimers and belong to the C2 space group. They were refined to 1.80 and 
2.00 Å resolutions, respectively. Four of the remaining crystals are apparently single mutants and 
belong to the P42212 space group. In the heterodimer structures, one active site is shown to 
contain dual mutation of Ala51 and Ala239* while the other contains the native Arg51 and 
Arg239* residues, identical to the wild-type structure. Thus, these observations provide the 
foundation for a molecular mechanism by which the oligmerization state of ACMSD could 
regulate the enzyme activity. 
3.2 Introduction 
Arginine residues perform diverse functions in proteins due to their charge distribution, 
capability of forming multiple hydrogen bonds and their long flexible side chains. One popular 
function is the formation of salt bridges in which the positively charged guanidine head pairs 
with a negatively charged carboxylate group (184,185). In enzymes, arginine residues are often 
proposed to participate in recognizing, binding and maintaining the orientation of substrates and 
reaction intermediates (186-188). Arginine is also involved in RNA recognition because its 
guanidium group is able to form five hydrogen bonds with RNA acceptor groups (189). 
Although not widespread, arginine residues have also recently been proposed to act as a general 
base in several enzymes (190-192). 
62 
Two arginine residues in α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase 
(ACMSD) caught our attention because they appear to be in an optimal position to bind the 
substrate α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) by interacting with its two 
carboxyl groups. ACMSD is a metal-dependent enzyme in the amidohydrolase superfamily 
(14,15), and its substrate, ACMS, is an unstable tryptophan catabolic intermediate in the 
kynurenine pathway (2,14,129). The conversion of ACMS to α-amino-muconate-ε-semialdehyde 
(AMS) is catalyzed by ACMSD, however ACMS spontaneously forms quinolinic acid (QA) in a 
non-enzymatic dehydration process in the absence of ACMSD (125,193) (Scheme 3.1). Thus, 
ACMSD is a key enzyme that determines the QA levels. QA is maintained only at the basal level 
for the de novo synthesis of a small fraction of NAD+ in mammals. Reduced activity of ACMSD 
leads to accumulation of QA in body fluids, a condition which is known to be related to several 
neurodegenerative diseases including Alzheimer’s disease (127), Huntington’s disease (128), 
stroke (2), and epilepsy (2,126,129). However, the instability of ACMS and the compounds with 
similar structures makes studying the mechanism of ACMSD substrate binding technically 
challenging. 
Scheme 3.1. ACMSD in metabolic pathway 
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The first crystal structure of ACMSD was solved as a homodimer from Pseudomonas 
fluorescens (80). Two strictly conserved arginine residues are present at the active site: Arg51 
and Arg239* (Figure 3.1). Arg51 is located in the mobile insertion domain, which is proposed to 
undergo conformational changes upon substrate binding because of its unique position and high 
flexibility (80). Arg239* is an intruding residue which is inserted from the sixth α-helix of the 
other subunit and it is labeled with a * hereafter to distinguish its origin from the chain of a 
neighboring subunit. Because of its high flexibility, this residue is shown to be present in 
alternative conformations in chain B of the crystal structure. 
The second ACMSD crystal structure is the human enzyme in complex with 1,3-
dihydroxyacetone-phosphate. This inactive complex was assigned as a monomer by Rizzi and 
coworkers (131). The equivalent residue of Arg51 is shown in the active site, but the counterpart 
of Arg239 is far removed from the catalytic center. The same group previously reported that 
functional human ACMSD is a monomer because gel-filtration chromatography showed the 
asisolated enzyme with a molecular mass around 50 kDa (194), which is between monomer (38 
Figure 3.1. The active site metal center of PfACMSD and the putative substrate-binding pocket 
(illustrated with an ellipse).   
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kDa) and dimer (76 kDa) mass. In fact, it is still unclear whether the catalytically active form of 
human ACMSD in solution is a monomeric or dimeric enzyme at the present time. All of the 
PfACMSD structures determined thus far, including wild type and mutants charged with 
different transition metals, are dimeric (25,80). If the monomeric form is catalytically active, 
then only one conserved arginine residue, Arg51, is present in the active site of the enzyme in 
both human ACMSD and PfACMSD structures. Arg239 of the same subunit is not located near 
the enzyme active site in the monomeric state and would therefore be less likely to be an 
essential component of catalysis. Thus, point mutation at residue 239 provides a sensible means 
for probing the effects of protein oligmerization on the catalytic activity. 
The present work represents the first attempt to investigate the molecular mechanism by which 
the oligmerization state of ACMSD could determine the enzyme activity. The quaternary state 
required for catalytic activity is reported, and the catalytic role of the two conserved arginine 
residues, Arg51 and the intruding Arg239* from the neighboring subunit, are proposed. 
Interestingly, we found that the inactive Arg51 and Arg239 mutants could form a 
crystallographically accessible, catalytically-active heterodimer through protein hybridization. 
3.3 Experimental Procedures 
Site-Directed Mutagenesis. R51A, R51K, R239A, and R239K single mutation mutants were 
constructed by using the PCR overlap extension mutagenesis technique (132) described 
previously (15) and by using the plasmid containing ACMSD from Pseudomonas fluorescens as 
a template (14). The mutants were verified by DNA sequencing to ensure that base changes were 
introduced correctly and that no random changes had occurred. After sequencing, the positive 
clone was used for protein expression in Escherichia coli BL21(DE3).  
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Protein Preparation, SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Size 
Exclusion Chromatography. Expression and purification of ACMSD proteins followed the 
protocol established previously (10,14,15,25) with a few minor changes. Rather than using pH 
8.0 buffer during affinity chromatography purification, pH 7.4 was used to increase protein 
stability of the mutants. Metal-free apo-enzyme was obtained by treating purified protein with 5 
mM EDTA for 12 h followed by running a G50 desalting column. Zn(II) and Co(II) containing 
ACMSD were reconstituted as previously described (14). Purified protein samples were mixed 
with SDS loading buffer and heated for 10 min or with no heating prior to loading to 10% SDS-
PAGE. ACMSD was loaded onto a Superdex 75 column pre-equilibrated with buffer containing 
25 mM HEPES (pH 7.0) and 5% glycerol (v/v). Protein was eluted with the same buffer. 
Enzyme Activity Assay. The substrate ACMS was generated enzymatically by catalyzing the 
dioxygenation of 3-hydroxyanthranilic acid in oxygen saturated buffer with ferrous 3-
hydroxyanthranilate 3,4-dioxygenase containing no free transient metal ion as reported 
previously (14,15,25). Briefly, the ACMSD enzyme assay mixture contained 5 – 120 μM ACMS 
and an appropriate amount of ACMSD protein in 25 mM HEPES buffer with 5% glycerol, pH 
7.0. Specific activities of ACMSD proteins were measured in triplicate at room temperature on 
an Agilent 8453 spectrophotometer by monitoring the decrease of ACMS absorbance at 360 nm 
using a molar extinction coefficient of 47,500 M-1cm-1 (195) when the substrate concentration 
was equal to or lower than 20 μM, or at 320 nm using a molar extinction coefficient of 9600 M-
1cm-1 when the substrate concentration was higher than 20 μM (15). 
      Derivation of Equations for Analysis of the Correlation of Monomer/Dimer Ratio and 
Catalytic Activity. In order to show that dimerization is required for catalytic activity, a series of 
activity assays were performed in which the stock concentration of ACMSD is varied while 
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keeping the final assay concentration constant. If the rate of dissociation of the ACMSD dimers 
is sufficiently slow on the time scale of the assay, then the measured activity should conform to 
eq 1 where kobs is the observed decarboxylation rate, kmax is the maximum rate, and %D is the 
mole ratio of dimer present in the assay.  
݇௢௕௦ ൌ ݇௠௔௫ · %ܦ     (1) 
In order to solve for the percent dimer, mass balance was invoked to define M0 as the total 
protomer concentration, M as the monomer concentration, and D as the dimer concentration. 
݂݅ ܯ଴ ൌ ܯ ൅ 2ܦ, 
ݐ݄݁݊ ܯ ൌ ܯ଴ െ 2ܦ     (2) 
The dimer percentage can then be written in terms of dimer concentration and total protomer 
concentration (a quantity which is known in an activity assay) alone. 
%ܦ݅݉݁ݎ ൌ ଶ஽
ெబ
     (2') 
The association constant for this equilibrium, can then be written in terms of dimer concentration 
and total protomer concentration by substitution of eq 2, as seen in eq 3. 
ܭ௔ ൌ
஽
ሺெబିଶ஽ሻమ
      (3) 
Distribution and collection of like terms then gives eq 4, and eq 4 can be multiplied by M0-2 to 
give eq 5. 
4ܭ௔ܦଶ െ ሺ4ܭ௔ܯ଴ ൅ 1ሻܦ െ ܭ௔ܯ଴
ଶ ൌ 0     (4) 
ܭ௔
ସ஽మ
ெబ
మ െ ቀ2ܭ௔ ൅
ଵ
ଶெబ
ቁ ଶ஽
ெబ
െ ܭ௔ ൌ 0     (5) 
The quadratic equation can now be invoked on eq 5 to solve directly for the dimer percentage 
and is shown in eq 6. Multiplying the right side of eq 6 by a disguised 1, (2M0/ 2M0), the 
expression for the dimer percentage can be simplified to eq 7. 
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     (7) 
Substitution of eq 7 back into eq 1 gives kobs as a function of kmax, Ka, and M0 (i.e., eq 8). Non-
linear least squares fitting can then be used to obtain both Ka and kmax (though both positive and 
negative square roots should be considered; only the negative roots gave convergent fits of the 
measured data). 
݇௢௕௦ ൌ ݇௠௔௫ · ൬1 ൅
ଵିඥ଼௄ೌெబାଵ
ସ௄ೌெబ
൰     (8) 
      Protein Hybridization. Arg51 and Arg239 mutants were mixed in a 1:1 ratio in 25 mM 
HEPES buffer, pH 7.0, containing 5% glycerol. The final protein concentration for each mutant 
was 12 μM. Specific activity of the mixtures was examined frequently after mixing by a 
spectrophotometric assay on an Agilent 8453 diode-array spectrophotometer as described above.  
Identification of a Competitive Inhibitor. Pyridine-2,6-dicarboxylic acid (PDC) inhibition pattern 
and constant were determined by measuring kcat and Km in the presence of varying inhibitor 
concentrations (0, 20, 40, and 80 μM). Apparent Km values for each inhibitor concentration were 
plotted as a function of inhibitor concentration and inhibition is expressed as Ki values in 
micromolar (Ki = intercept/slope). 
      Analysis of PDC Inhibitor Interaction with the Arginine Mutants. PDC in HEPES buffer 
displays UV absorbance at 270 nm with extinction coefficient of 4,100 M-1cm-1. ACMSD 
proteins (1.5 ml, 40 μM in each sample type), including wild type, R51A, R239A, H228G, and 
premixed R51A and R239A for 48 h, were incubated with one equivalent of PDC for 5 min in 
separate experiments, followed by filtration in an Amicon ultra centrifugal filter tube with 
cellulose membrane of 10,000-dalton cut-off. PDC (40 µM) with no protein was used in the 
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control experiment. Samples were centrifuged in 3,000 × g for 8 min. The flow-through solution 
containing unbound DPA was quantified by Agilent 8453 spectrophotometer. 
X-ray Data Collection and Crystallographic Refinement. Zinc-reconstituted mutant proteins 
were used for crystallization. All single crystals were obtained following the crystallization 
conditions described in the previous studies (25,80). For the heterodimer crystal, R51A and 
R239A were mixed for more than 48 h at 4 °C before being used for crystallization by hanging 
drop vapor diffusion in VDX plates (Hampton Research). Mother liquid containing 20% 
ethylene glycol was used for crystal mounting. X-ray diffraction data were collected at SER-
CAT beamline 22-ID/BM of the Advanced Photon Source (APS), Argonne National Laboratory, 
Argonne, IL. Data were processed with HKL-2000 (137). Structure solutions were obtained by 
molecular replacement with MolRep (138) from the CCP4 suite (139) with wild-type ACMSD 
(PDB code 2HBV) as the search model (80). Refinement was carried out using PHENIX 
software (196), and the model-building was carried out in COOT (141). Ala51 and Ala239 were 
modeled based on the 2Fo-Fc and Fo-Fc electron density maps. Refinement was assessed as 
complete when the Fo-Fc electron density contained only noise. 
3.4 Results 
ACMSD Does not Exist as a Single Species in Solution. As shown in Figure 3.2A, ACMSD 
presents several bands by SDS-PAGE that correspond to monomer, dimer, and higher order 
oligmerization states if the sample is not heated before loading onto the gel (Figure 3.2A lane 1). 
However, if the sample is heated before loading, the bands corresponding to the higher order 
states and most of the dimer are not observed (Figure 3.2A lane 2). The size-exclusion 
chromatography profile, on the other hand, presents two major peaks. The molecular weight of 
the protein eluted in the first peak is larger than 100 kDa, and the second peak exhibits a 
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molecular weight of ca. 51 kDa. The molecular weight of a PfACMSD monomer, however, is 38 
kDa. Also, there is no difference in the specific activity of the two fractions as they elute from 
the column. The second peak shows two major bands corresponding to ACMSD monomer and 
dimer molecular weights on SDS-PAGE when not heated before loading (Figure 3.2A lane 3). 
The band which arises from the dimer is not observed upon heating of the sample before loading 
(Figure 3.2A lane 4). Hence, we assign the second peak as a combination of ACMSD monomer 
and dimer and the first peak as a mixture of higher order complexes which are not able to be 
resolved further.  
Figure 3.2.  ACMSD is a mixture of monomer and higher oligormers in solution and is not active 
as monomer. (A) The UV absorbance at 280 nm of ACMSD as a function of the elution volume 
from size exclusion chromatography column: Superdex 75. The inset is an SDS-PAGE. Lane 1: 
As-isolated ACMSD with no heating, 2: as-isolated ACMSD heated for 10 min, M: molecular 
marker, 3: fraction 2 with no heating, 4: fraction 2 heated for 10 min. (B) The specific activity of 
ACMSD as a function of different enzyme stock concentration. 
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      In order to estimate the dimer dissociation constant, ACMSD was prepared in stock 
concentrations ranging from 0.1 to 50 μM (protomer concentration) and allowed to equilibrate at 
4 °C for 24 h. Specific activity of the different stock concentrations was determined by keeping 
the final enzyme and substrate concentrations constant. The specific activity increased with 
increasing stock concentration. Decarboxylation rates as a function of enzyme stock 
concentration were plotted in Figure 3.2B and data were fit to eq 8, which represents the 
equilibrium of ACMSD between inactive monomer and active dimer forms as described in the 
Experimental Procedures. Fitting of the data to eq 8 gives a Ka of 3.3×106 M-1, and a maximum 
specific activity of 9.4 μmol•min-1•mg-1. 
      Mutational Analysis and Catalytic Activity Rescue Through Protein Hybridization. Arg51 
andArg239 were each mutated to alanine and lysine. All of the four mutants were found to be 
completely inactive with either zinc or cobalt as the cofactor, the two metals which were 
previously found to be optimal for catalytic activity in the wild-type enzyme. Chemical rescue 
performed on R51A and R239A by guanidine derivatives was unsuccessful in restoring 
enzymatic activity. However, when the two mutants, R51A and R239A, were mixed together, 
enzyme activity was slowly restored (Figure 3.3A). Reaction rates were determined at several 
time points after mixing. Samples incubated for 1, 7, and 24 h on ice were analyzed by following 
decay of the substrate ACMS at 360 nm for 1 min. Reaction with no enzyme and the two 
inactive arginine mutants were used as negative controls. The rate of activity rescue was 
temperature dependent, and the rate of recovery was faster when the mixing reaction was carried 
out at room temperature rather than on ice. Specific activity was calculated and plotted as a 
function of incubation time as shown in Figure 3.3B and fit to a single exponential association,  
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Figure 3.3. Activity rescue by mixing R51A and R239A. (A) Catalytic activity rescue of mixed 
R51A and R239A mutants. Decay of substrate ACMS in the first 1 min was monitored by UV-
Vis at 360 nm. Autodecay of substrate (black trace), in the presence of R51A (red), and in the 
presence of R239A (blue), are three overlapped lines. R51A and R239A were pre-mixed on ice 
for 1 hour (green), 7 hour (pink), and 24 hours (tan), respectively. (B) The rescued activity 
increased as a function of incubation time of the two mutants. Data were fitted to a single 
exponential equation. The incubation and kinetic reaction are done in room temperature. (C) 
Michaelis-Menten kinetics of the 1:1 mixed R51A and R239A after 48 hours of equilibration. 
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eq 9, where A is the measured specific activity, Amax is the maximum activity, k is the 
associative rate constant, and t is time in minutes. According to the fitting, the maximum rate is 
152 ± 5 nmol•min-1•mg-1, and the rate constant is 7.2 ± 0.5 × 10-3 min-1. We also determined 
kinetic parameters for the mixed zinc-reconstituted mutants after 48h of equilibration on ice. 
Figure 3.3C shows the Michaelis-Menten plot. The Km, 9.3 ± 1 μM, of the mixed mutants is 
similar to that of the wild-type Zn-ACMSD, 9.6 μM. The kcat, 0.15 ± 0.01 s-1, of the mixed 
mutants, on the other hand, is dramatically decreased compared to the 6.5 s-1 of the WT Zn-
ACMSD (80). 
ܣ ൌ ܣ௠௔௫ · ሺ1 െ ݁ି௞௧ሻ     ሺ9ሻ 
      Structural Determination of R51A, R239A and the Hybridized Mixtures of the Two Mutants. 
All crystals of R51A and R239A ACMSD belong to the P42212 space group. They diffracted 
poorly and only at relatively low resolutions. The best structures obtained were 2.50 Å resolution 
forR51A (Protein Data Bank entry: 4IFO) and 2.40 Å for R239A (4IFR). Interestingly, crystals 
from the mixture of these two mutants were crystallized in both the P42212 and C2 space groups. 
A total of twenty data sets were collected from individual single crystals obtained from 
crystallization trays with equal molar ratio mixing of R51A and R239A mutant proteins. Among 
the twenty crystal structures that we have solved, three of them are R239A homodimer, and one 
of them is an R51A homodimer. All of these four structures are determined in the P42212 space 
group. Two single crystals were found to belong to the C2 space group, and they were refined to 
1.8 Å (Protein Data Bank entry: 4IG2) and 2.0 Å (4IFK) resolutions, respectively. The structures 
determined from these two crystals clearly differ from R51A or R239A, and they fit the proposed 
heterodimer as illustrated in Figure 3.4. Fourteen of the data sets in the P42212 space group 
cannot be assigned to any homodimer or heterodimer due to incomplete electron density which 
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might be caused by the flexibility of the arginine side chain or low arginine occupancy. The data 
collection and refinement statistics for both the homodimer single mutants and the heterodimers 
are listed in Table 3.1. 
      Both DNA sequencing and electron density map of the mutant crystal structures demonstrate 
the successful substitution of arginine residues with alanine in both R51A and R239A variants 
Figure 3.5A (top and middle panels). The alignment of R51A (4IFO) and R239A (4IFR) 
structures with the wild-type structure (2HBV) are shown in Figure 3.5B (top and middle 
panels), respectively. Both mutants exhibit homodimeric quaternary structures as previously seen 
in wild-type ACMSD. Secondary structure changes caused by mutation (colored in blue and 
cyan) can be observed in both subunits of the two structures and they are mainly observed in the 
loop regions. No significant structural deviations, however, were observed for the folding of the  
Figure 3.4. Molecular mechanism for catalytic activity rescue through protein hybridization of 
the two completely inactive mutants.  
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Table 3.1. X-ray crystallography data collection and refinement statistics. 
Data collection R51A-R239A Heterodimer #1 
R51A-R239A 
Heterodimer #2 R51A Homodimer R239A Homodimer 
Detector type MAR225 CCD MAR300 CCD MAR300 CCD MAR300 CCD 
Source APS, Sector 22-BM APS, Sector 22-ID APS, Sector 22-ID APS, Sector 22-ID 
Space group C2 C2 P42212 P42212 
Unit cell lengths 
(Å) 
a=153.10, 
b=48.52,c=109.83 
a=153.85, 
b=49.06,c=110.55 
a=b=91.21, 
c=170.47 
a=b=91.16, 
c=167.99 
Unit cell angles (°) α=γ=90, β=126.80 α=γ=90, β=127.10 α=β=γ=90 α=β=γ=90 
Wavelength (Å) 1.00 0.80 0.80 0.80 
Temperature (K) 100 100 100 100 
Resolution (Å) a 35.00-1.80 (1.86-1.80) 
35.00-2.00 
(2.03-2.00) 
35.00-2.50 
(2.54-2.50) 
35.00-2.40 
(2.44-2.40) 
Completeness (%)a 86.1(42.7) 97.6 (87.6) 99.9(100.0) 99.6(95.7) 
Rmerge (%)a, b 5.0(60.0) 10.7(47.8) 7.8(64.0) 9.9(79.3) 
I/σI a  37.2(1.5) 28.4(1.9) 34.9(2.9) 50.0(1.9) 
multiplicity a 6.8(3.7) 5.9(2.9) 15.8(11.4) 22.0(7.5) 
Refinement
Resolution (Å) 1.80 2.00 2.50 2.40 
No.reflections; 
working/test 51829/2590 42682/2143 25616/1304 28612/1452 
Rwork (%)c 23.2 20.9 19.7 21.0 
Rfree (%)d 28.2 26.3 24.4 29.5 
No. of protein 
atoms 5174 5184 5162 5144 
No. of ligand 
atoms 2 3 2 2 
No. of solvent sites 141 229 100 26 
Average B factor (Å2) 
Protein 49.0 39.7 54.0 73.5 
Zn(II) 36.9 31.3 55.2 64.8 
Mg(II) N/A 60.4 N/A N/A 
Solvent 40.8 38.7 42.5 59.1 
Ramachandran statisticse
preferred (%) 93.01 94.07 93.76 91.32 
allowed (%) 4.56 4.10 4.11 5.18 
Root mean square deviation 
Bond lengths (Å) 0.009 0.008 0.010 0.009 
Bond angles (°) 1.249 1.149 1.175 1.236 
PDB entry 4IG2 4IFK 4IFO 4IFR 
a Values in parentheses are for the highest resolution shell. 
b Rmerge = Σi |Ihkl,i - ‹Ihkl›|/Σhkl Σi Ihkl,i, where Ihkl,i is the observed intensity and ‹Ihkl› is the average intensity of multiple 
measurements. 
c Rwork = Σ||Fo|-|Fc||/Σ|Fo|, where |Fo| is the observed structure factor amplitude, and |Fc| is the calculated structure 
factor amplitude. 
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d Rfree is the R factor based on 5% of the data excluded from refinement. 
e Based on values attained from refinement validation options in COOT. 
 
overall TIM-barrel scaffold, indicating that the impact due to mutation is limited to specific 
flexible regions. We further analyzed the dimerization interface using the ACMSD wild-type and 
mutant structures at an online server: Protein Data Bank Europe Protein Interfaces, Surfaces and 
Assemblies (PDBePISA) (197). The results indicate the interface contains a total of 13 H-bonds 
and 13 salt bridges. Nevertheless, these analyses would not be sufficient to draw a definitive 
conclusion if there were no intruding residue Arg239 catalytically important which allowed us to 
generate an active heterodimer from mixing two inactive dimers. In the wild-type structure, 
Arg239 contributes two Hbonds by interacting with the main chain molecules of the neighboring 
monomers to help to stabilize the dimer. In the R239A structure, the dimerization is not 
interrupted because these two hydrogen bonds are substituted by the following two new H-
bonding interactions: Glu252 of chain A interacts with Lys189 of chain B and Arg247 of chain A 
interacts with Met191 of chain B.  
      Figure 3.5B (bottom panel) shows the superimposition of the heterodimer structure (4IFK) 
and the wild-type Zn-ACMSD structure (2HBV). The structural deviations of the mutant relative 
to the wild-type are highlighted in red. The comparison clearly shows that major changes can 
only be observed in chain B. This observation is expected because in subunit A of the 
heterodimer, Arg51 and Arg239* are both in place with electron density similar to that in the 
wild-type structure (Figure 3.5A bottom). The electron density for both arginine residues’ side 
chains in subunit B is missing, indicating that both residues 51 and 239* are alanines (Figure 
3.5A bottom). Hence, subunit A represents a complete native-like ACMSD subunit, but subunit 
B is a “double mutant” containing two alanine residues. It is noted in the structure of the native 
enzyme that Arg239* adopts two conformations because of its high flexibility (80). Likewise, 
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this residue in subunit A has alternative conformations which are only partially covered by the 
electron density map. 
Figure 3.5. Active site and overall structures of R51A, R239A, and heterodimer. (A) Electron 
density of position 51 and 239 in the R51A homodimer (top panel), R239A homodimer (middle), 
and R51A-R239A heterodimer (bottom). (B) Superimposed overall structures of WT Zn-ACMSD 
with Zn-R51A (top) and Zn-R239A (middle), and heterodimer (bottom). The well-aligned 
structural components are shown in gray color, while structural changes for R51A and R239A are 
highlighted in blue and cyan colors, respectively. 
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      Arg51 and Arg239 are Essential for Substrate Binding. Based on the current and previous 
studies, we propose that the two arginines are critical for proper substrate binding at the enzyme 
active site and for preventing its autocyclization to QA. Since the substrate, ACMS, is unstable 
and all arginine mutants are catalytically inactive, studying the postulated role of the two 
arginines in substrate binding is challenging. Therefore, an efficient competitive inhibitor needs 
to be found. Unfortunately, the inhibitors reported from previous in vivo studies, phthalate esters 
for instance (198,199), were not effective on the pure enzyme in our experiments. Acyclic 
ACMS analogue compounds tend to be unstable in solution, however, 2,6-pyridine-dicarboxylic 
acid (PDC), a cyclic compound, is structurally similar to ACMS (Figure 3.6A). Both compounds 
contain conjugate repeating single-bond double-bond structures and two carboxylate groups. The 
difference is that PDC is a stable compound due to its cyclic, aromatic structure, while ACMS 
tends to dehydratively autocyclize. Figure 3.6B shows that PDC behaves kinetically as a 
competitive inhibitor for the ACMS decarboxylation. The Ki value was determined to be 22.7 ± 
1.8 μM. This allows for use of PDC as an analog of ACMS to study substrate binding. 
      The catalytic activity-based kinetic approach, unfortunately, cannot be employed to assess 
the binding of substrate or substrate analog compounds to the inactive mutant proteins. We took 
advantage of the fact that PDC has an electronic absorption band at 270 nm (ε270 nm = 
4100 M-1cm-1, determined in 25 mM HEPES buffer, pH 7.0) and designed an experiment to test 
PDC’s binding to the wild-type and mutant proteins of ACMSD utilizing separation by 
centrifuge filters. The threshold for membranes in centrifuge filters with a 10,000 Da cut-off is 
smaller than ACMSD but much larger than PDC. If the PDC is bound to ACMSD it will not be 
able to pass the filter membrane while unbound PDC molecules can pass freely. The amount of 
PDC in the flow-through was quantitated by UV absorbance. Wild-type ACMSD was employed 
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as a positive control while the same buffer containing no protein was used as one negative 
control. A previously well-characterized mutant H228G (25), was also employed as a secondary 
positive control. His228 is a strictly conserved residue sitting in the interior side of the metal 
center which is previously shown to function as a general base to deprotonate the water ligand 
during catalysis and is not related with substrate binding. The properties and crystal structure of 
H228G have been reported previously (25). Figure 3.6C shows that WT and H228G ACMSD 
proteins exhibit similar binding of PDC. In contrast, R51A and R239A are unable to effectively 
bind PDC as exhibited by the similar absorbance of their flowthroughs to the negative control. 
This experiment suggests that the two arginine residues play an important role in binding of the 
substrate analogue, which implies that they play a role in substrate binding in the native enzyme. 
Figure 3.6. Arginine mutants cannot bind the competitive inhibitor PDC. (A) Chemical structure of 
ACMS and PDC. (B) Competitive inhibition of wild-type ACMSD by 0, 20, 40, and 80 μM of PDC. (C) 
PDC in flow through of centrifuge detected by UV-Vis spectroscopy. 
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3.5 Discussion 
It is often a challenging task to determine whether or not an experimentally determined 
structure represents the biologically-relevant assembly. It is also often difficult to pin down the 
role of a critical residue in catalysis when its mutants are completely inactive. An additional 
complexity in the present case is that the two conserved arginine residues which are being 
studied are proposed to bind the substrate, ACMS, which is unstable, so no binding constant can 
be easily measured. We have crafted a series of biochemical tests to show that P. fluorescens 
ACMSD must function as a dimer, and the two conserved arginine residues, including one 
intruded into the catalytic center from a neighboring subunit, are required for substrate binding in 
catalysis. 
The molecular mechanism by which the catalytic activity is rescued through hybridization is 
illustrated in Figure 3.4. During dimer–monomer equilibrium, three kinds of dimers form in 
solution when the two inactive homodimers of R51A and R239A are mixed: R51A homodimer, 
R239A homodimer, and R51A-R239A half-active heterodimer, in which one of the monomers 
has both Arg51 and Arg239 to constitute a complete active site identical to that of the native 
enzyme. If it is assumed that all homodimers are completely dissociated and rearranged, the 
percentage of formation of R51A homodimer and R239A homodimer will be both 1/4. 
Consequently, the rest 1/2 will be the half-active heterodimer. As a result, the maximum activity 
that can be rescued theoretically will be 25% of the wild-type ACMSD assuming there is no 
cooperative interaction and that each of the dimers has the same association constant. By 
comparing the kcat values of the equilibrated mixed mutant ACMSD with WT ACMSD, 9.2% of 
the theoretical maximum activity is recovered. The inability to recover more activity can likely 
be attributed to unequal equilibrium constants for each of the species (inactive homodimer 
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formation may be thermodynamically preferred to half-active heterodimer formation), or some 
protein dynamics and cooperativity may have been lost due to the mutations of important active 
site residues. 
To our knowledge, this X-ray crystallographic study provides the first unambiguous 
experimental evidence for the formation of hybridized active heterodimer by mixing of two 
inactive homodimers. These structures allow for a molecular level understanding of the 
correlation of enzymatic activity with the protein quaternary structure and the mechanism of 
activity rescue from two completely inactive mutants. Together with our previous work, we now 
can describe the functionally-active assembly of the enzyme and the role of the two arginines in 
a more definitive manner as discussed below. 
The homodimer structures contain a ~2,500 Å2 dimer interface area. Prior to this work, the 
question of whether dimerization is an artificial aggregation or required for enzyme activity was 
not known. We showed here two major bands corresponding to monomer and dimer on the 
polyacrylamide gel, indicating the existence of both dimer and monomer forms in aqueous 
solution. Enzyme specific activities were measured under identical assay conditions using 
protein at different stock concentrations. The finding, i.e. increasing specific activity with 
increasing protein stock concentrations, indicates that ACMSD is active when in the dimeric 
form and loses activity as it dissociates to the monomeric form. 
      Dimer formation as a mechanism for enzyme activation is common in nature. Cytochrome c 
peroxidases (200), cell death protease caspases (201,202), diaminopimelate epimerase (203), and 
histidine kinase CheA (204) are just a few examples similar to ACMSD. The reason behind this 
dimerization-induced activation is usually the generation or extension of binding faces at the 
dimer interface (205). Hence, protein activation is triggered by an increase in the local protein 
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concentration. As calculated by the dependence of specific activity on stock enzyme 
concentration, the dissociation constant of ACMSD is 0.3 μM. This is within the Kd range for 
“weak” transient complexes that show a dynamic mixture of both monomer and dimer states in 
vivo which could be tuned by physiological environmental factors such as pH and local protein 
or ligand concentrations (206). 
      The mutagenesis and reaction rescue experiments described in this study show that both 
Arg51 and Arg239 are required for enzyme activity. However, their role in catalysis was 
unknown due to the silent nature of their activity in all the point mutants, including the 
conservative Lys mutants, until the identification of an effective competitive inhibitor of the 
enzyme, PDC. By using this competitive inhibitor, the problems which arise from use of an 
unstable substrate can be mitigated. The inability of PDC to bind to the arginine mutants is 
demonstrated by the filtration experiment. With proper positive and negative controls, the 
designed experiment provides a straightforward and reliable conclusion. Hence, we propose both 
arginine residues R51 and R239* are involved in substrate binding during catalysis (Figure 3.7). 
It is noteworthy that this scenario resembles a well-documented example in a highaffinity nitrate 
transporter where two perfectly conserved arginine residues are required for substrate binding 
(207). Likewise, arginines play crucial roles in the active sites and subunit interfaces of the 
ATPase domains of AAA and AAA+ proteins (208). 
      Heterodimer-induced activity restoration has also been previously observed, although not 
structurally characterized, in histidine protein kinase CheA, a protein essential for bacterial 
chemotaxis’ stimulus-response coupling by phosphorylating another two chemotaxis proteins: 
CheY and CheB (209). CheA must be autophosphorylated at its own His48 residue before this 
phosphoryl group can be transferred to CheY and CheB (210,211). Escherichia coli expresses 
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two kinds of CheA proteins: the full length CheAL and the N terminally truncated CheAS, which 
lacks His48, the site of autophosphorylation (210). But in the presence of both CheAS and kinase 
defective CheAL mutant, CheA470GK, the mutant can still be phosphorylated. Thus, the 
autophosphorylation is accomplished within the CheAS-CheA470GK heterodimer is suggested 
even in the absence of structural proof as shown in the present study (204). 
      The results described in this work helped us further refine our working model for the 
ACMSD catalytic cycle. Previously, the roles of His228 and the metal bound water were 
proposed and demonstrated (25). The two catalytically essential arginine residues Arg51 and 
Arg239* are now added to the model (Figure 3.7). They are proposed to work as a team to 
recognize the substrate and stabilize both the substrate and possibly catalytic intermediates. 
Because the two residues at each metal center belong to two different subunits, the requirement 
of protein dimerization for enzyme activity becomes evident. 
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      Among cellular metabolic proteins, monomers are a small fraction compared to multimeric 
proteins. Homodimers and homotetramers are two major forms of oligomerized proteins (205). 
Compared to monomeric proteins, oligomerized proteins have some apparent advantages. Firstly, 
oligomerization enables higher-order protein regulation, such as allosteric and concentration 
sensing regulations. Secondly, protein oligomerization can help to increase protein stability and 
the flexibility of activity by subunitcooperation. Lastly, homo-oligomers are more economic 
because they allow for a smaller genome while still building large proteins. Hence, the 
oligmerization of ACMSD may function as a mechanism of protein concentration sensing and 
enzyme activity adjustment in vivo. 
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CHAPTER 4    HUMAN α-AMINO-β-CARBOXYMUCONATE-ε-SEMIALDEHYDE 
DECARBOXYLASE (ACMSD): A STRUCTURAL AND MECHANISTIC UNVEILING 
The section of chapter 4 is our manuscript under preparation: Human α-amino-β-
carboxymuconate-ε-semialdehyde decarboxylase (ACMSD): A structural and mechanistic 
unveiling. Lu Huo, Fange Liu, Hiroaki Iwaki, Tingfeng Li, Yoshie Hasegawa, and Aimin Liu. 
We thank Dr. Shin-Ichi Fukuoka for providing cDNA clone of human ACMSD, Dr. Lirong Chen 
for stimulating discussions in the analyses of the structural data. 
4.1 Abstract 
Human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase determines the fate of 
tryptophan metabolites in the kynurenine pathway by controlling the quinolinate levels for de 
novo NAD biosynthesis. The unstable nature of its substrate has made gaining insight into its 
reaction mechanism difficult. Our electron paramagnetic resonance (EPR) spectroscopic study 
on the catalytically active, Cu-substituted enzyme suggests that the native substrate does not 
directly ligate to the metal ion. Substrate binding did not result in a change of either the 
hyperfine structure or the super-hyperfine structure of the EPR spectrum. We also determined the 
crystal structure of the enzyme in its native state (at 1.99 Å resolution), a substrate analogue-
bound form (2.50 Å resolution), and a selected active site mutant form with one of the putative 
substrate binding residues altered (2.32 Å resolution). These structures illustrate that each 
asymmetric unit contains 3 pairs of dimers. Consistent with the EPR findings, the ligand-bound 
complex structure shows that the substrate analogue does not directly coordinate to the metal ion 
but is bound the active site and stabilized by positively charges residues through non-covalent 
interactions. 
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4.2 Introduction 
α-Amino-β-carboxymuconate-ε-semialdehyde (ACMS) is a metabolic intermediate found in 
two catabolic pathways: the kynurenine pathway (Scheme 4.1), which is responsible for 
tryptophan catabolism, and the 2-nitrobenzoic acid biodegradation pathway (14). ACMS is 
unstable and non-enzymatically dehydrates to quinolinic acid (QUIN) with a t1/2 of 33 min at 20 
°C, pH 7.0 (10). QUIN is the universal precursor for the de novo biosynthesis of NAD, providing 
the pyridine ring (193,212). In humans, QUIN levels must be tightly regulated (< 100 nM) 
because it is also an agonist of N-methyl-D-aspartate receptors, and its overproduction can cause 
overexcitement of neurons and cell death in the central nervous system (2,5,8,9,213). Elevated 
QUIN concentrations in bodily fluids have been observed in an exceptionally wide range of 
neuropsychiatric diseases including anxiety, depression, epilepsy, and neurodegenerative 
conditions such as Alzheimer’s and Huntington’s diseases (3-7,127,128). A 300-fold elevation of 
QUIN has also been detected in the brain of patients with HIV infection (214). Moreover, over 
the past two decades, an increasingly accumulating volume of evidence unanimously suggest 
that abnormal activity of the kynurenine pathway participates in the initial phases of 
neuropathological processes (7,129), the pathogenesis of AIDS-dementia complex (215,216), 
and Alzheimer’s disease (2-4,217). When QUIN was injected into healthy rats, the characteristic 
neuropathological features of Huntington’s disease started to develop (5). Thus, the connection 
between QUIN and related diseases flows both ways, i.e. in symptomatic patients QUIN levels 
are elevated, and in healthy mammals QUIN injection induces symptoms of disease. Notably, 
ACMS decarboxylase (ACMSD) directs the vast majority of metabolites to further catabolic 
steps controlled by enzymes and, by doing so, avoids the overproduction of QUIN (Scheme 4.1) 
(14,193). Thus, the decarboxylase ACMSD is of significant biomedical importance. 
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Prior to this work, the structure of human ACMSD (hACMSD) in its catalytically active 
form was unavailable. The elucidation of this structural information is crucial for the design of 
small molecule regulators and for the interpretation of biochemical and spectroscopic studies. 
We are also interested in the structural and mechanistic divergence between hACMSD from the 
tryptophan kynurenine pathway and Pseudomonas fluorescens (PfACMSD) from the 2-
nitrobenzoic acid metabolic pathway. However, hACMSD has proven to be a considerable 
challenge to express in prokaryotic systems. Although expression of hACMSD as a weakly 
active enzyme has been achieved in mammalian cell lines (13) and the eukaryote, Pichia pastoris 
(194), prior attempts to express hACMSD in bacterial systems were all unsuccessful 
(13,131,194). 
In the present work, we successfully expressed hACMSD in E. coli and obtained catalytically 
active form of the enzyme. By using substrate analogue and metal-substituted hACMSD, we 
employed a combined structural and spectroscopic approach to tackle the question of how the 
unstable substrate interacts with the enzyme’s active site. 
4.3  Experimental Procedures 
Expression of Human ACMSD. To construct an Nterminally His10-tagged hACMSD 
expression plasmid, the hACMSD cDNA (13), a generous gift from Dr. Fukuoka, was amplified 
 Scheme 4.1. ACMSD in the Kynurenine pathway 
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by the polymerase chain reaction with the forward primer 5’-
GGAATTCCATATGAAAATTGACATCCATAG-3’ and the reverse primer 5’- 
CCGCTCGAGTCATTCAAATTGTTTTCTCTC-3’ (built-in NdeI and XhoI sites are 
underlined). The PCR product was purified from a 0.8% agarose gel, digested with NdeI and 
XhoI, and ligated in the equivalent sites of pET16b (Novagen). After sequencing, the positive 
clone was used for transformation into E. coli BL21 (DE3) containing the GroEL/ES 
overexpression plasmid pGro7, pColdII-pGro7, pColdII-pG-Tf2, and pET16b-pG-Tf2, 
respectively (Takara Corp., Japan). 
      Cell Culture. Single colonies of E. coli containing the appropriate pET-hACMSD plasmid 
were used to inoculate 50 mL of M9 growth medium (1×M9 medium supplement with 1 mM 
MgSO4, 0.1 mM CaCl2, 2 μg/mL vitamin B1, 0.04% casamino acids, 0.4% D-glucose, and a 
divalent metal ion described below). To obtain hACMSD with desired metal at the active site, a 
divalent metal ion of either CoCl2, CuSO4, Fe(NH4)2(SO4)2, or ZnCl2 was added to a final 
concentration of 0.05 to 0.5 mM prior to induce expression. The cell culture medium also 
contained 100 μg/mL ampicillin, 40 μg/mL chloramphenicol and 500 μg/mL L-arabinose, the 
latter of which induces the expression of the protein chaperone GroES-GroEL. The cells were 
grown at 37 °C with shaking until the OD600 reached 0.4, at which time the temperature was 
lowered to 25 °C. hACMSD expression was induced by 0.1 mM isopropyl β 
Dthiogalactopyranoside at an OD600 of 0.6. The cultures were allowed to further grow at 25 °C 
for 16 h before being harvested by centrifugation at 8000 × g for 15 min at 4 °C. The wet cells 
were washed with 50 mM potassium phosphate buffer, pH 8.0, twice before storage at -80 °C. 
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      Protein Isolation. Human ACMSD was purified using a modified procedure described for the 
bacterial analogue (25,26). Frozen cells were resuspended in 50 mM potassium phosphate, pH 
8.0, containing 300 mM NaCl and 0.1 mM protease inhibitor phenylmethylsulfonyl fluoride. 
The cell slurry was passed through an M-110P Microfluidics cell disruptor and the debris was 
removed by centrifugation at 27,000 × g for 30 min at 4 °C. The supernatant was loaded onto a 
HiPrep immobilized metal ion affinity chromatography (Ni-NTA) 26/20 column (80 mL resin) 
for isolation of the native enzyme or FF 16/10 columns charged with either Co2+, Cu2+ or 
Zn2+ depending on the corresponding metalspecific hACMSD preparations in order to minimize 
possible metal cross-contamination in purified protein. The proteins were eluted in a two-step 
gradient with increased concentration of imidazole in the buffer. The major fractions with 
ACMSD decarboxylase activity were pooled, concentrated, and further purified on a Superdex 
75 column (26/60) using an ÄKTA FPLC protein purification system with a 25 mM HEPES 
buffer, pH 7.0, containing 5% glycerol. Protein concentrations were determined using Coomassie 
Plus protein assay reagent (Pierce). The expression level and enzyme purity were determined by 
SDS-PAGE on 12% polyacrylamide gels. 
      Metal Analysis. The metal content of ACMSD was assayed in triplicate by inductively 
coupled plasma optical emission spectrometry (ICP-OES) using a Spectro Genesis spectrometer 
(Spectro Analytical Instruments GmbH & Co. KG, Germany) as previously described (25). 
Metal ions loosely or nonspecifically bound to the enzyme were removed by an overnight 
incubation of 0.5 mM EDTA with the protein solution at 4 °C followed by desalting on a 5-mL 
HiTrap column with 10 mM Tris-HCl (pH 7.4) and buffer wash with the ICP buffer and 
ultrafiltration. 
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      EPR Spectroscopy. The interaction between ACMS and the enzyme-bound metal center was 
measured by EPR spectroscopy using Cucontaining ACMSD in the absence or presence of 3 
equivalents of ACMS in the assay buffer. The EPR samples were obtained by mixing the protein 
solution with the substrate solution at 25 °C using a rapid-freeze-quenching apparatus, Update 
Instruments, system 1000. The reaction mixture was shot directly to an EPR tube and frozen in 
liquid nitrogen. The entire mixing and freezing process was completed in less than 5 seconds. In 
a parallel EPR experiment, the response of the addition of 3 equivalents of ACMS to copper 
sulfate was determined with the same buffer system. The same X-band EPR instrumentation is 
used as those previously described (14,15). 
      Steady State Kinetics. The enzyme activity of the recombinant hACMSD was determined 
according to the procedures described in detail in earlier reports (14,15,25). Briefly, ACMS was 
generated from 3-hydroxyanthranilate by an enzymatic method (14). The ACMSD enzyme assay 
mixture contained 0 – 120 μM ACMS and an appropriate amount of ACMSD protein in 25 mM 
HEPES buffer, pH 7.0 with 5% glycerol. Specific activities were calculated from the initial 
velocities of ACMS decay monitored by the loss of absorption at 360 nm using an absorbance 
coefficient constant of 47,500 M-1cm-1 when the substrate concentration was equal to or lower 
than 20 μM, or at 320 nm using an absorbance coefficient constant of 9,600 M-1cm-1 when the 
substrate concentration was between 20 – 120 μM. In the enzyme concentration dependence 
assay, 800 μM Zn-hACMSD was diluted to 200 nM by the reaction buffer. The initial rate of the 
reaction was monitored from 1 to 240 min frequently in triplet after dilution: a saturated 
substrate concentration of 15 μM was used. The inhibition pattern of pyridine-2,6-dicarboxylic 
acid (PDC) acting on hACMSD was obtained by determining the kcat and Km in the presence of 
varying concentrations of PDC (0, 20, 40, and 80 μM) in both buffer and substrate solution. 
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Apparent Km values for each inhibitor concentration were plotted as a function of inhibitor 
concentration and inhibition is expressed as Ki values in micromolar (Ki = y-intercept/slope). 
X-ray Protein Crystallography. Catalytically active form of Zn-hACMSD was used to screen 
crystallization conditions in Art Robbins 96-well Intelli-Plates using an ARI Gryphon 
crystallization robot. The initial hit was obtained from the Index Screening Kit (Hampton 
Research). After optimization, crystals were obtained from drops assembled with 1.5 μL of 28 
mg/mL hACMSD mixed with 1.5 μL of a reservoir solution containing 0.2 M lithium sulfate 
monohydrate, 0.1 M Tris-HCl pH 6.5 - 7.5, and 20 - 25% polyethylene glycol 3,350, by hanging 
drop diffusion in VDX plates (Hampton Research). PDC-hACMSD co-crystals were obtained by 
preincubating hACMSD with 10 equivalents of PDC for 30 min prior to crystallization. Crystals 
suitable for X-ray diffraction were obtained ca. 10 days after crystal growth at 18 °C. 
Crystallization mother liquor containing 20% glycerol was used as a cryoprotectant. All crystals 
obtained under these conditions belong to the P212121 space group and data were processed with 
HKL-2000 (137). The three dimensional structures of hACMSD were solved by molecular 
replacement using our previously published Pseudomonas fluorescens (PfACMSD) structure as a 
search model (PDB code: 2HBV) using PHENIX (196). Electron density analysis and model 
building were carried out in Coot (141). The unit cell images were generated with PyMol (218) 
with the aid of the SuperSym plugin available at http://supersym.sourceforge.net. 
4.4 Results 
Overexpression of the Human Enzyme in E. coli. hACMSD expressed from the constructed 
vectors, pColdII-pGro7, pColdII-pG-Tf2, and pET16bpG-Tf2 was only found in inclusion 
bodies.Fortunately, the constructed pET16b-pGro7 plasmid expressed hACMSD as a soluble and 
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enzymatically active protein. The enzyme expressed from this system was purified to near 
homogeneity as described under “Experimental Procedures”. Five to ten mg of pure enzyme was 
obtained from each liter of cell culture when gown in the LB medium; however the yield was 
significantly reduced when a minimal medium was used. Purified hACMSD is stable at 4 °C for 
weeks and can endure freeze/thaw cycles with liquid nitrogen multiple times without a 
significant loss of activity.  
      Metal Content and Catalytic Activity. Metal analysis of hACMSD purified from cells grown 
in the LB medium contained several metals. Iron, zinc and copper were present and the total 
metal content was substoichiometric. Metal analysis of hACMSD purified from the cells cultured 
in the M9 minimal media supplemented with 100 μM of varying metal ions is presented in Table 
4.1. Activity assays demonstrated that hACMSD expressed in the presence of Zn2+ exhibited 
activity comparable to what was found for the most active forms of PfACMSD bound with a 
Zn2+ or Co2+ ion (14). Co2+-containing hACMSD, on the other hand, exhibited very little specific 
enzymatic activity relative to Co-PfACMSD. It should be noted that the contribution of Zn ion to 
the activity of Co-, Cu-, and Fe-hACMSD was subtracted based on Table 4.1 metal analysis data 
with regard to the Zn-hACMSD activity. 
Table 4.1. Percentage of metal occupation and corresponding activity of hACMSD from different 
medium cultures. 
 
LB M9 M9 + Co2+ 
M9 + 
Cu2+ 
M9 + 
Fe2+ 
M9 + 
Zn2+ 
Co 0 0 96.8 0.4 0.8 0 
Cu 2.2 2.9 0.7 47.9 3.6 9.7 
Fe 28.7 9.8 1.0 10.0 55.1 7.5 
Zn 13.8 9.8 0.8 0.6 7.7 64.4 
Specific activity      
(nmol/min/mg) 910 800 190 90 400 3540 
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Unlike PfACMSD (14), the metal ions in hACMSD could not be removed by the metal 
chelators EDTA, 1,10-phenanthroline or 8-hydroxy-quinoline-5-sulfonic acid, and the enzyme 
activity was not affected by the addition of these metal chelators. Moreover, the addition of one 
to ten equivalents of Co2+, Cu2+, Fe2+, or Zn2+ to purified hACMSD did not increase enzyme 
activity, indicating that the purified human enzyme cannot be reconstituted in vitro. Since in 
vitro metal reconstitution was not successful for the human enzyme, we attempted to add zinc 
ions to the M9 medium at various concentrations prior to induction of the cells, so that a variety 
of zinc/hACMSD ratios could be obtained. Although we had no control over the final zinc 
content in the purified protein using this method, we did successfully purify the human enzyme 
with different amounts of zinc ion. Figure 4.1 shows that the specific activity of hACMSD is 
proportional to the zinc content of the enzyme. 
 
      Kinetic Properties. Zn-hACMSD yielded steady-state kinetic parameters similar to those of 
Zn2+-containing PfACMSD (31). A kcat value of 4.8 s-1 was measured for hACMSD with 64.4% 
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Figure 4.1. The specific catalytic activity of hACMSD as a function of Zn content in the protein 
reveals that hACMSD is a zinc-dependent enzyme. 
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zinc ion occupancy. According to Figure 4.1, this value is anticipated to be 7.5 s-1 with a 
fullyloaded zinc ion. The Km (5.8 μM) and the kcat (7.5 s-1) values of hACMSD are comparable to 
the Km (9.6 μM) and the kcat (6.5 s-1) reported for Zn-PfACMSD with ca. 80% zinc occupancy 
(80). When hACMSD was diluted from 800 μM to 200 nM, it lost 90% of activity after 4 h 
(Figure 4.2). Since proteins prefer to form higher oligomer state at higher concentration, the 
hACMSD dimer will start to dissociate once its concentration drops. Loosing catalytic activity 
after dilution implies that hACMSD is unlikely to be active in the monomeric state. Similar 
observations have been reported for the bacterial ACMSD (26). 
 
      Probing the Nature of the Enzyme-Substrate Interactions. Although ACMS is an unstable 
molecule, we find that it tends to form stable complexes with various metal ions. Figure 4.3A 
shows that ACMS binds to a cupric ion in solution. The EPR signal intensity of CuSO4 solution 
is weak due to the coupling of copper ions. Addition of unstable ACMS to CuSO4 led to the 
formation of stable Cu2+-ACMS complex which gives rise to well-resolved type II copper EPR 
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Figure 4.2. The catalytic activity of hACMSD decays after dilution, indicating that hACMSD 
has better activity at higher oligomerization sate. The relative activity of concentrated and 
diluted samples was measured under the same conditions as described in the text. The 
experimental data was fitted with first exponential decay (red line). 
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spectrum (219). Since this technique is highly sensitive to the changes of the electronic/chemical 
structure of a Cu2+ ion, especially when the superhyperfine structure is resolved, we analyzed 
ACMS perturbation to the enzyme-bound copper center by EPR spectroscopy. 
      To probe whether the substrate ACMS is ligated directly to the metal, we obtained Cu-
substituted hACMSD. Since the metal ion cannot be extracted and reconstituted, we 
circumvented this problem by isolating the human enzyme from cell culture of a metal-depleted 
minimal medium supplemented with cupric ion. The Cu-substituted protein is catalytically active 
although it is a relatively poor catalyst. Its kcat value was 0.1 ± 0.02 s-1 and Km value was 3.3 ± 
0.2 μM. 
240 270 300 330 360
CuSO4 + ACMS
CuSO4
B0 (mT)
240 270 300 330 360
Cu-hACMSD + ACMS
Cu-hACMSD
B0 (mT)
320 330 340
Cu-HsACMSD + ACMS
B0 (mT)
Cu-hACMSD
Figure 4.3. Low-temperature X-band EPR spectroscopic study confirms that the substrate binds to the free
metal ion but does not directly coordinate to the catalytic metal ion in ACMSD.  (A) Free CuSO4 and
CuSO4-ACMS, (B) as-isolated Cu-hACMSD and Cu-hACMSD-ACMS, and (C) a magnified view of
superhyperfine structure of Cu-hACMSD in the absence/presence of ACMS. The spectrometer
conditions: temperature, 20 K; modulation amplitude, 0.3 mT; microwave power, 0.5 mW; time constant,
40.96 ms; and sweep time 1.79 mT/s for the field from 225 to 375 mT.
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      Both hyperfine splitting due to the nuclear spin of copper (I = 3/2) and nitrogen (I = 1)-
induced superhyperfine interactions are present in the EPR spectrum of Cu-hACMSD (Figure 
4.3B). The EPR parameters obtained from a simulation of the spectrum of wild-type Cu-
hACMSD have an A// value of 18.7 mT and a g// value of 2.218, both typical for a type II Cu2+ 
center. In the perpendicular region, a multiple-line superhyperfine structure with a splitting of 
about 1.5 mT is well resolved in the spectrum (Figure 4.3C). The superhyperfine structure 
originates from the spin-spin interaction between the nuclear spin of the nitrogen atoms (nuclear 
spin I = 1) and the electron spin of the Cu2+ ion. When 3 molar equivalents of ACMS were added 
to Cu-hACMSD, frozen in less than 5 s, and subsequently measured by EPR at 20 K, no spectral 
change was observed. In sharp contrast to the free copper ion in solution, the presence of 
ACMS is unable to induce any disturbance in the hyperfine and superhypefine structures of the 
Cu center in hACMSD. Thus, there is no direct ligation between ACMS and the Cu center. 
Crystal Structure. The structure of hACMSD was obtained from native, catalytically competent 
form of the enzyme and was refined to 1.99 Å resolution (Table 1, PDB entry: 4OFC). Each unit 
cell contains four asymmetric units in which six protomers are found as a trimer of dimers, 
Figure 4.4A. The dimer interface contains a surface area of about 2,400–2,460 Å2 and is 
primarily formed by three helical regions which are composed of residues 191 to 201, 230 to 
244, and 271 to 281 of each subunit. The central area of the dimer interface is strictly 
hydrophobic. Analysis of the dimer interface reveals a total of 24-33 direct hydrogen bonding 
interactions and 18-21 salt bridges for each dimer. The detailed interactions are listed in Table 
4.3. 
      Due to the instability of ACMS, the substratebound ACMSD structure is not yet available. 
However, pyridine-2,6-dicarboxylic acid is a heterocyclic, stable ACMS analogue that 
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competitively inhibits the bacteria ACMSD (26). We found that it is also an effective 
competitive inhibitor of hACMSD (Figure 4.5A) with a Ki value of 15.2 ± 0.5 μM. We 
successfully co-crystallized this compound with hACMSD (Table 1, PDB entry: 4IH3) and the 
overall structure is nearly identical to the ligand-free enzyme. PDC is bound at the active site and 
forms ionic interactions with Arg47 and Arg235*, where the asterisk indicates this residue is 
from a neighboring subunit (Figure 4.5B). The PDC-bound structure shows that the inhibitor is 
fairly close to the zinc ion with the C4 ca. 2.6 Å from the zinc ion. However, the closest oxygen 
is 5.6 Å away from the metal ion. Thus, the substrate analogue does not directly coordinate to the 
metal ion. 
 
Figure 4.4. The crystal structure of hACMSD is solved as a homodimer. (A) Each unit cell contains 4
asymmetric units of 3 pairs of dimers. (B) The catalytic center contains two arginine residues, Arg47
and Arg235* from a neighboring subunit. 
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Table 4.2. X-ray crystallography data collection and refinement statistics. 
a Values in parentheses are for the highest resolution shell. 
b Rmerge = Σi |Ihkl,i - ‹Ihkl›|/Σhkl Σi Ihkl,i, where Ihkl,i is the observed intensity and ‹Ihkl› is the average intensity of multiple 
measurements. 
c Rwork = Σ||Fo|-|Fc||/Σ|Fo|, where |Fo| is the observed structure factor amplitude, and |Fc| is the calculated structure 
factor amplitude. 
d Rfree is the R factor based on 5% of the data excluded from refinement. 
e Based on values attained from refinement validation options in COOT. 
Data collection hACMSD PDC-hACMSD R47A hACMSD 
Space group P212121 P212121 P212121 
Unit cell lengths (Å) a=88.704, b=101.082, c=232.820 
a=88.368, b=101.655, 
c=233.117 
a = 89.142, b=101.686, 
c = 232.613 
Unit cell angles (˚) α=γ= β=90 α=γ= β=90 α = β = γ = 90 
Wavelength (Å) 1.0 1.0 0.8 
Temperature (K) 100 100 100 
Resolution (Å)a 45.00-1.99 (2.03-1.99) 45.00-2.50 (2.50-2.54) 50.00-2.33 (2.37-2.33) 
Completeness (%)a 87.6 (81.3) 75.4 (65.7) 98.4 (82.8) 
Rmerge (%)a, b 15.3 (78.2) 9.9 (29.3) 13.2 (48.6) 
I/σI a 20.6 (2.3) 10.3 (1.5) 17.9 (2.0) 
Multiplicity a 10.1 (8.0) 9.7 (8.5) 25.3 (13.7) 
Refinement 
Resolution (Å) 1.99 2.50 2.32 
No. reflections; 
working/test 130135/6497 55192/2809 85220/4492 
Rwork (%)c 19.88 20.20 20.8 
Rfree (%)d 24.07 28.28 27.6 
No. of protein atoms 15984 15810 15774 
No. of ligand atoms 6 78 6 
No. of solvent sites 994 286 821 
Average B factor (Å2) 
Protein 29.7 33.3 30.0 
Zn(II) or PDC 26.3 39.4 23.6 
Solvent 31.3 28.4 32.2 
Ramachandran statisticse 
Preferred (%) 96.15 91.82 97.7 
Allowed (%) 2.60 5.86 2.3 
Root mean square deviation 
Bond lengths (Å) 0.008 0.029 0.015 
Bond angles (˚) 1.155 1.262 1.785 
PDB entry 4OFC 4IH3 4IGN 
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Table 4.3. Hydrogen bonds stabilizing the dimeric surface in the 2.0 Å resolution crystal 
structure of human ACMSD (4OFC.pdb) calculated from PDBePISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H-Bond # Subunit B Distance (Å) Subunit C 
1 ASP 151[ OD1] 3.01 ARG 183[ NE ] 
2 ASP 151[ OD1] 2.89 ARG 183[ NH2] 
3 ASP 151[ OD2] 2.45 LYS 186[ NZ ] 
4 ASP 151[ OD2] 3.06 ARG 183[ NE ] 
5 TYR 187[ O  ] 3.64 CYS 247[ SG ] 
6 TYR 187[ OH ] 3.12 ASN 153[ ND2] 
7 TRP 191[ O  ] 2.8 ARG 235[ NE ] 
8 TRP 191[ O  ] 3.02 ARG 235[ NH2] 
9 MET 195[ SD ] 3.29 ARG 235[ NH2] 
10 GLU 198[ OE2] 2.88 ARG 183[ NH1] 
11 GLU 198[ OE2] 2.95 ARG 183[ NH2] 
12 MET 208[ O  ] 3.52 TYR 187[ OH ] 
13 PHE 231[ O  ] 2.62 SER 273[ OG ] 
14 ASP 250[ OD2] 2.5 TYR 187[ OH ] 
15 ASP 270[ OD2] 2.64 LYS 256[ NZ ] 
16 PRO 295[ O  ] 2.94 HIS 238[ NE2] 
17 GLY 297[ O  ] 2.96 HIS 238[ NE2] 
18 ASN 153[ ND2] 3.34 TYR 187[ OH ] 
19 ARG 183[ N  ] 3.9 GLU 149[ OE1] 
20 ARG 183[ NE ] 2.99 ASP 151[ OD2] 
21 ARG 183[ NH1] 2.83 GLU 198[ OE2] 
22 ARG 183[ NH2] 3.36 GLU 198[ OE1] 
23 ARG 183[ NH2] 2.78 ASP 151[ OD1] 
24 LYS 186[ NZ ] 2.75 ASP 151[ OD2] 
25 TYR 187[ OH ] 2.67 ASP 250[ OD2] 
26 ARG 235[ NE ] 2.83 TRP 191[ O  ] 
27 ARG 235[ NH2] 2.96 TRP 191[ O  ] 
28 ARG 235[ NH2] 3.51 MET 195[ SD ] 
29 HIS 238[ NE2] 2.94 PRO 295[ O  ] 
30 HIS 238[ NE2] 3.01 GLY 297[ O  ] 
31 CYS 247[ SG ] 3.68 TYR 187[ O  ] 
32 LYS 256[ NZ ] 2.82 ASP 270[ OD1] 
33 SER 273[ OG ] 2.71 PHE 231[ O  ] 
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To further prove that the unstable substrate binds to the enzyme by the active site arginines, 
we mutated Arg47 and Arg235* to alanine. Both R47A and R235A variants showed no 
detectable catalytic activity, proving that they are important residues for catalysis. The result of 
this analysis is consistent with our structural findings shown in Figure 4.4B. While R235A 
eludes crystallization, the crystal structure of the R47A mutant was solved at 2.32 Å resolution 
(Table 4.2). Similar to the wild-type enzyme structure, six protomers in three dimers are present 
in each asymmetric unit (Figure 4.6). The same interface region is observed between the 
protomers as observed in the wild-type enzyme. The RMSD value is only 0.254 Å from 14,034 
out of 14,040 atoms for the structures of R47A and wild type. 
 
 
 
 
Figure 4.5. The crystal structure of hACMSD in complex with a substrate analogue sheds light on the
enzyme-substrate interaction mode. (A) Competitive inhibition of hACMSD by 0, 20, 40, and 80 μM
of PDC. (B) The co-crystalized structure shows that the competitive inhibitor PDC is bound by Arg47
and Arg235* near the zinc ion. 
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Figure 4.6. Crystal structure of R47A hACMSD. A symmetric unit of the structure (shown in 
color) contains three pairs of dimers. 
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4.5 Discussion 
Our work on human ACMSD solved several longstanding mysteries. The first pertains to the 
cofactor identity. Our previous work on the analogous bacterial system indicates that PfACMSD 
is a metal-dependent enzyme (14,15,80). Thus, one would expect hACMSD is a metalloprotein. 
However, all prior studies on hACMSD suggest that the catalytic activity of human enzyme is 
independent of metal ions (13,194). This is likely due to the observation that neither a metal 
chelator, nor external metal affects the activity of purified hACMSD. The first crystal structure 
of hACMSD was later determined with a zinc ion bound at the enzyme active site, but how the 
zinc ion is associated with catalytic activity was not discussed (131), leaving a questionable 
cofactor-free conclusion for hACMSD in literature. Here, by showing protein expressed in a 
minimal medium supplemented with increasing concentrations of zinc ions, giving higher 
decarboxylase activity together with the data present in Table 4.1, we found that hACMSD has 
the best affinity for zinc ion and the zinc enzyme gives rise to the highest catalytic activity. The 
catalytic efficiency of Zn-hACMSD is significantly higher than that previously reported for the 
same enzyme expressed in Pichia pastoris, which has a similar Km but a lower kcat value of   1.0 
s-1 (194). Thus, it becomes evident that the hACMSD is a zinc-dependent enzyme. 
Since chelators are demonstrably to be able to extract the metal ion from PfACMSD but not 
the human enzyme, hACMSD apparently binds its metal more tightly. The crystal structures 
solved provide a molecular understanding for this nonconformity. An aspartate and three 
histidine residues in hACMSD coordinate the zinc ion. Notably, His174 is a metal ligand in all 
six protomers of each asymmetric unit of the structure, with a bond distance of 2.2-2.3 Å. In 
contrast, the equivalent histidine in PfACMSD, His177, presents significant flexibility in the 
structure we have solved (PDB entry: 2HBV). In subunit A, His177 coordinate to the zinc ion 
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with distance of 2.2 Å. In subunit B, His177 is no longer a metal ligand and is 4.2 Å away from 
the zinc ion. Thus, His177 is a weaker ligand in PfACMSD. The observed metal affinity 
deviation therefore becomes understood. 
It is challenging to predict the cofactor dependency of a protein base on the primary structure 
if the cofactor is a single atomic metal. Although characteristic sequences can be used to identify 
some metal binding motifs, including zinc finger, calcium hand, and iron-sulfur cluster, drawing 
conclusions based solely on sequence can be misleading. For example, LigI is a member of the 
amidohydrolase superfamily, whose members were all previously demonstrated to be divalent 
metal dependent including ACMSD. Based on sequence alignment, LigI has all four conserved 
residues, three histidines and one aspartate, for metal coordination. However, later mechanistic 
and structural studies revealed that LigI is actually metal independent and the four metal ligand 
residues are with new catalytic roles (30). Sometimes, even with the assistance of biochemical 
study, prediction of metal cofactor can still be misjudged. The enzyme urinate isomerase 
catalyzes the isomerization reaction of D-glucuronate and D-fructuronate was initially thought to 
be metal independent because metal chelators do not affect the enzyme activity (212). Later on, 
an improved study suggested that uronate isomerase is actually a mononuclear zinccontaining 
enzyme (220). Hence, a combined knowledge of sequence, biochemical assay, and structure are 
needed to correctly identify a metal cofactor. In the present case, it is fortunate that hACMSD 
holds its metal tightly, so its preference for zinc ion is visible in isolated protein in our hand 
although this property also caused misjudgment in some of the earlier studies for the metal 
cofactor-dependency (13,194). 
Since its initial identification from rat liver, ACMSD has been known for 58 years (130) and 
this enzyme has arisen significant biomedical interest. Following our success in obtaining the 
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bacterial enzyme structure in 2006 (80), a structure of the enzyme in its inactive form, 
complexed with 1,3-dihydroxyacetone-phosphate (DHAP), was obtained through molecular 
replacement in 2009 by Garavaglia et al. (PDB entry 2WM1) (131). It should be noted that the 
DHAP-bound structure is monomeric with only one subunit in each asymmetry unit, whereas the 
three hACMSD structures present in this study, including a substrate-free and ligand-bound 
structure, and all of the PfACMSD structures determined thus far (25,26,80), are homodimers. 
Although all these coordinates are highly valuable data for future structure-based design of 
bioactive small molecule targeting of hACMSD, a quaternary structure variety is apparently 
present. We think that the diversity brings up the following questions: (1) is the quaternary 
structure of ACMSD linked to the catalytic activity, and (2) is a ligand-induced structural change 
a potential mechanism of catalytic activity regulation? While the latter question will be a subject 
for future study, the results presented in this work and the comparison with our previous studies 
on the bacterial enzyme shed insightful clues, as discussed below. 
      We have recently shown that PfACMSD is a mixture of monomer and dimer in solution, and 
that the former is catalytically inactive while the latter is functionally competent (26). The 
decarboxylase activity is dependent on the presence of two arginine residues (Arg51 and 
Arg239*, star indicates that Arg239 is from the neighboring subunit), which play a key role in 
substrate binding (26). Likewise, when hACMSD is in the dimeric form, the corresponding 
arginine residues (Arg47 and Arg235*) are both present in the active site in a manner resembling 
what has been described for PfACMSD (Figure 4.7). When hACMSD is in the monomeric form 
bound with the DHAP, Arg235 is 25 Å from the catalytic metal and cannot be a residue involved 
in substrate binding (131). Thus, these conserved arginine residues are effective probes for 
determining the functional assembly of ACMSD.  
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      It is evident that alteration of the decarboxylase quaternary structure, between monomer and 
homodimer, is a possible avenue to regulate the catalytic activity. 5-Carboxyl-uracil 
decarboxylase (IDCase) is a member of the ACMSD subfamily under the amidohydrolase 
superfamily and has very high sequence similarity to ACMSD (18,81). This enzyme is the most 
closely related neighbor of ACMSD in the reconstructed evolution tree. Recently, the crystal 
structures of IDCase from both Cordyceps militaris and Metarhizium anisopliae were solved as 
homodimers (221). The overall structure and the active site of IDCase mostly resemble ACMSD. 
Interestingly, in both of the substrate 5-carboxyl-uracil and inhibitor 5-nitro-uracil bound binary 
complex structures; the catalytic metal ion does not directly interact with the substrate and 
inhibitor. The two conserved arginine residues, Arg68 (equivalent to Arg47 of hACMSD) and 
Arg262* (equivalent to Arg235* of hACMSD) from the neighboring subunit play major roles in 
substrate/inhibitor binding. Specifically, Arg68 forms two hydrogen bonds with the N1 and O2 
of the substrate pyrimidine ring and Arg262* binds to the leaving carboxyl group in the substrate 
bound structure (PDB entry: 4LAM). This observation further suggests that Arg47 and Arg235* 
Figure 4.7. A side-by-side comparison of the active site architecture of (A) PfACMSD and (B) 
hACMSD shows similar substrate binding environment. 
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are responsible for substrate binding not only in ACMSD but also in proteins from the same 
subfamily. As a result, a dimeric quaternary structure is most likely required for enzyme activity 
through the ACMSD subfamily. 
Since mammals have no mechanism to store free amino acids not used for protein synthesis, 
tryptophan is primarily directed towards catabolism. During starvation, when tryptophan levels 
are low, the priority of catabolism is to preserve the kynurenine pathway intermediates for NAD 
biosynthesis and thus, the activity of ACMSD must be lessened. Using a glycolic intermediate, 
DHAP, to force ACMSD to change its structure to the catalytically inactive monomeric form is a 
possibly unprecedented metabolic interrelation between the tryptophan kynurenine catabolic 
pathway and glycolysis. 
4.6 Conclusion 
The biochemical, spectroscopic, and structural results led us to conclude that hACMSD is a 
zinc dependent dimeric enzyme that harnesses its unstable, negatively charged substrate by its 
two positive charged residues rather than by the metal ion during substrate positioning at the 
early stage of the catalytic cycle. The quaternary structure variety, previously demonstrated in 
the bacterial analogous enzyme (80) and now implicated in the human enzyme, is directly linked 
to the enzyme catalytic activity. Thus, the structural arrangement of the catalytic center offers a 
potential regulatory mechanism at a critical junction of the downstream tryptophan kynurenine 
pathway. 
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CHAPTER 5 EVIDENCE FOR A CATALYTIC ROLE OF THE WATER LIGAND IN α-
AMINO β-CARBOXYMUCONATE ε-SEMIALDEHYDE DECARBOXYLASE 
REVEALED BY KINETICS AND CRYSTAL STRUCTURES IN COMPLEX WITH 
AZIDE AND BROMIDE 
The section of chapter 5 is our manuscript under preparation: Evidence for a catalytic role of the 
water ligand in α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase revealed by kinetics 
and crystal structures in complex with azide and bromide. Lu Huo, Vesna de Serrano, Lirong 
Chen, and Aimin Liu.  
5.1 Abstract 
We found that the catalytic activity of Pseudomonas fluorescens α-amino-β-
carboxymuconate-ε-semialdehyde decarboxylase (PfACMSD) is inhibited by common anions. 
Bromide and azide were used to study the anion inhibition mechanism. Inhibition assay suggests 
a competitive inhibition by azide and a mixed-type inhibition by bromide. Co-crystallized 
structures of the enzyme with these two anions were determined at 2.15 and 2.50 Å resolutions, 
respectively, and each with two ligand molecules in the active site of the enzyme. Both of the 
azide molecules are shown to bind in the putative substrate-binding pocket, consistent with its 
competitive inhibition. In contrast, the bromide-bound ACMSD structure reveals that one 
bromide is bound at the site where azide molecules bind, and the other substitutes the metal 
bound water ligand. These results help establish that the metal-bound water ligand plays a major 
catalytic role and that the Arg51 residue is an important component in the second metal 
coordination sphere involved in substrate binding. 
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5.2 Introduction 
Metal-bound water molecules have been long thought to be critical for playing a catalytic 
role in several enzyme families, including amidohydrolase superfamily (19,81), carbonic 
anhydrase family (181), metallo β-lactamases (222), and restriction endonucleases (223). 
However, it is very difficult to experimentally prove the catalytic role of a specific water 
molecule in enzymes. Until now, the only widely accepted and well-documented example for a 
definitive catalytic role of metal-bound water is found in carbonic anhydrase, in which 
biochemical, modeling and crystal structural studies all come together to demonstrate that the 
catalytic driving force is indeed derived from the water ligand (181-183,224). In the past 50 
years, hydrolytic water as a catalytic main power in enzymes, especially in many of those zinc-
dependent hydrolytic enzymes, has increasingly been appreciated. Thus, it is imperative to 
explicitly establish a second example from an enzyme other than the members of the carbonic 
anhydrase family the catalytic role of metal bound water. It has become a textbook knowledge 
that the metal coordination significantly reduces the pKa value of water from 15.7 to nearly 
neutral, making it possible to become a hydroxide anion for subsequent nucleophilic attacks on 
the substrate. However, this type of mechanism has never been proposed for a decarboxylase 
prior to our study on an enzyme from the amidohydrolase superfamily. Here we present 
biochemical and structural evidence for a catalytic role of the water ligand in a decarboxylase. 
α-Amino-β-carboxymuconate-ε-semialdehyde (ACMSD) is an important enzyme that controls 
the biosynthesis of quinolinic acid in kyneurine pathway in mammals (125) and also directs the 
metabolic flux to energy production in 2-nitobenzoic acid degradation pathway in bacteria (12). 
ACMSD is a metal-dependent enzyme (14) belonging to the amidohydrolase superfamily (15). 
The members of this superfamily are believed to initiate catalysis by a water molecule (19,81). In 
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all but one characterized members the water is a metal ligand. The catalytic role of the water 
molecule was initially suggested by a pH-dependence study on phosphotriesterase (225) and the 
crystal structure of adenosine deaminase in complex with a transition state analogue (226), both 
of which are the well-studied members in the amidohydrolase superfamily. In a most recent 
study, the enzyme Ligl is shown to be a very unique member of the superfamily. It does not 
contain a metal ion in its active site (30). However, a water molecule is found in the active site 
where substrate binds and a nucleophilic attack of the substrate by the water molecule is still 
believed to be the critical step in catalytic cycle of Ligl. 
5.3 Results and Discussion 
We found in this work that ACMSD from Pseudomonas fluorescens is inhibited by 
ammonium sulfate during protein purification, following the procedures previously established 
for substrate generation and kinetic assays (15). We further carried out inhibition assays in the 
presence of 25 mM following salts in 25 mM HEPES buffer (pH 7.0), NH4Cl, KCl, NaCl, NaBr, 
NaI, NaNO2, NaN3, NaHCO3, CH3COONa, Na2SO4, NaH2PO4, and KH2PO4. The enzyme assay 
results showed that NaI, NaN3, NaBr, and NaNO2 had the strongest inhibition power, whereas 
CH3COONa, NaH2PO4, and KH2PO4 had no inhibition effect. NH4Cl, KCl, NaCl, NaHCO3 and 
Na2SO4 had mild inhibition effects. Furthermore, NH4Cl, KCl and NaCl had the same inhibitory 
effect while NaH2PO4 and KH2PO4 did not inhibit ACMSD, and therefore we conclude that the 
cations we have tested are not potential inhibitors for the decarboxylation activity of ACMSD. 
Hence, our subsequent study was placed on the anion inhibition mechanisms. 
Two inhibition patterns were observed among different anioins, i.e. competitive inhibition 
and a mixed-type inhibition. We focused on sodium bromide and sodium azide, the 
representatives of the two observed inhibitory patterns. Figure 5.1A shows that in the presence of 
109 
0, 1.25 mM, 2.5 mM, and 5 mM sodium azide, it inhibits the decarboxylation activity follows a 
nearly pure competitive inhibition pattern with an inhibition constant of 0.76 ± 0.23 mM. In 
contrast, in the presence of 0, 2.5, 5 mM and 7.5 mM sodium bromide, the ACMSD kcat values 
decrease, whereas the corresponding Km values increase, suggesting a mixed-type, i.e., 
competitive and noncompetitive, inhibition (Figure 5.1B) with the competitive inhibition 
constant of 1.30 ± 0.02 mM, and noncompetitive inhibition constant of 10.67 ± 2.66 mM. 
 
 
 
 
 
 
 
      The ligand-bound crystal complexes were obtained by co–crystallizing ACMSD with 25 mM 
NaN3 or NaBr. Crystals were grown by hanging drop vapor diffusion method at 18 °C. A total 
drop volume of 3 µL was set up at 1:1 protein to crystallization solution ratio and equilibrated 
against 500 μL of crystallization solution containing 0.2 M MgCl2, 0.1 M Tris, pH 8.75 and 15% 
PEG 5000. X-ray diffraction data for N3–ACMSD were collected at the SER-CAT beamline 22–
ID of the Advanced Photon Source (APS), Argonne National Laboratory, Argonne, IL. Data for 
the NbaD-Br complex were collected using a Rigaku MicroMax–007 HF copper rotating anode 
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Figure 5.1. ACMSD activity inhibition by azide and bromide salts. Lineweaver-Burk plots of 
ACMSD inhibited by azide ion competitively (A). Symbols of black, red, blue, and green 
indicate sodium azide at 0, 1.25, 2.5, and 5 mM. And bromide ion (B), the axis crossing is 
shown in the inset, indicating a mixed-type inhibition. Symbols of black, red, blue, and green 
indicate inhibitors at 0, 2.5, 5 and 7.5 mM concentrations, respectively. 
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generator operated at 40 kV and 30 mA with Saturn944+ CCD detector at the Emory University 
X–ray Crystallography Core Facility (Atlanta, GA). All data were indexed, integrated, and scaled 
using the HKL-2000 suite (137). Structure solutions were obtained by molecular replacement 
using MolRep (138) from the CCP4i program suite (139) with the published ACMSD structure 
(PDB entry 2HBV) as a search model. Structures were then refined by iterative cycles of model 
building in COOT (141) and positional and isotropic B factor refinement using Refmac5 (140) in 
the CCP4i suite of programs (139) and PHENIX software. The X–ray data collection and 
refinement statistics are summarized in Table 5.1. 
Table 5.1. Data Collection and Refinement Statistics 
Data collection ACMSD-Br- Complex ACMSD-N3- Complex 
detector type Saturn944+ CCD MAR300 CCD 
space group C2 C2 
unit cell lengths  (Å) a=152.89, b=48.40, c=109.93 a=152.19, b=44.77, c=110.21 
unit cell  (°) α=γ=90, β=126.74 α=γ=90, β=127.76 
temperature (K) 100 100 
wavelength (Å) 1.54 1.00 
Resolution (Å) a 35.00-2.15(2.19-2.15) 50.00-2.50(2.54-2.50) 
Completeness (%) a 95.3(92.9) 94.8(62.8) 
Rmerge (%) a, b 12.7(67.3) 7.0(28.7) 
I/σI a 21.9(2.5) 21.2(2.9) 
multiplicity a 7.1(7.0) 3.4(1.7) 
Refinement
resolution (Å) 2.15 2.50 
no. reflections; working/test 32085/2216 19234/1923 
Rwork (%) c 22.6 19.8 
Rfree (%) d 30.9 27.9 
no. of protein atoms 5298 5190 
no. of ligand atoms 4 8 
no. of solvent sites 99 60 
Average B factor (Å 2) 
protein 50.3 50.7 
Zn(II) 45.0 43.0 
Br- or N3-       56.1 47.4 
solvent 41.3       35.8 
Ramachandran statistics e 
preferred (%) 88.6 91.6 
allowed (%) 10.5 6.7 
Root mean square deviation 
bond lengths (Å) 0.014 0.009 
bond angles (°) 1.668 1.250 
a Values in parentheses are for the highest resolution shell. 
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b Rmerge = Σi |Ihkl,i - ‹Ihkl›|/Σhkl Σi Ihkl,i, where Ihkl,i is the observed intensity and ‹Ihkl› is the average intensity 
of multiple measurements. 
c Rwork = Σ||Fo|-|Fc||/Σ|Fo|, where |Fo| is the observed structure factor amplitude, and |Fc| is the calculated structure 
factor amplitude. 
d Rfree is the R factor based on 5% of the data excluded from refinement. 
e Based on values attained from refinement validation options in COOT. 
 
      The overall structures of ACMSD bound anions remain unchanged except some loop 
movements compared to the ligand-free ACMSD structure (PDB code: 2HBV). Amino acids 
arrangement in the active site, including metal ligands and second sphere residues, are not 
interrupted, with the exception of Arg51, which moved away 1.1 Å from its original position for 
accommodating azide ions and 0.9 Å for accommodating bromide ions. In the N3–bound 
ACMSD structure, extra electron density in the substrate binding pocket of chain A revealed the 
presence of two azide molecules (Figure 5.2A). The two azide molecules are in close proximity 
to each other (2.8 Å), and both of them are at a distance of forming weak interaction with Arg51 
residue (3.3 and 3.4 Å). The position of metal bound water is not disrupted by the azide anions 
compared to the ligand-free ACMSD structure. The water ligand interacts with one of the azide 
molecules that is localized just 2.6 Å away from the water ligand (Figure 5.2B).  The substrate 
ACMS is an unstable molecule, autocyclizing to quinolinic acid, and its binding site in ACMSD 
has not been previously established. Azide inhibits ACMSD following a pure competitive 
pattern, and accordingly we believe that the binding pocket for azide anions represents the 
putative substrate binding site. Binding at this pocket is favored partly because that the positively 
charged Arg 51 provides strong ionic interactions with the compounds with negative charges 
including ACMS, which possess two carboxylate groups. The maximum rate was also slowed 
down when higher concentration sodium azide was involved (above 5 mM in this work). It may 
due to hydrogen bonding interaction between the metal bound water and one of the azide ions is 
becoming stronger when higher concentration sodium azide salt is used (Figure 5.2B).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      In ord
scattering
crystals t
0.9202 Å
the Br bin
phases fr
correspon
electron d
the fifth l
A 
Figure
ACM
(A) Th
compl
repres
repres
sticks 
electro
σ. (B)
active
is intr
er to localli
 of this atom
hat belong t
, it still has 
ding site, a
om the final
ding to wav
ensity in ch
igand which
 5.2. Crysta
SD inclomp
e structure 
ex with azid
ents zinc me
ents water m
represent az
n densities 
 The H-bond
 site. * indic
uded from c
zed bromide
, and for th
o the C2 spa
scattering si
nomalous di
 refined mod
elength–dep
ain A (Figu
 was previo
l structure o
lex with azid
of PfACMS
e ions. Gold
tal, blue sph
olecule, an
ide ions. Th
are countere
 network ar
ates the resi
hain B. 
 
 atom in the
at purpose w
ce group. Ev
gnal of 1.4 e
fference Fo
el of Br¯ d
endent Bijv
re 5.3A). On
usly served 
B
f 
e ions. 
D in 
en sphere 
ere 
d red 
e 2Fo-Fc 
d at 1.0 
ound the 
due R247 
 structure, w
e collected
en though B
lectrons at 
urier electro
erivatized st
oet differen
e of the bro
by a water m
e took adv
 360 degree
r atom has 
1.54 Å. Hen
n density m
ructure and 
ces. Two Br
mide ions is
olecule in 
antage of an
s of diffracti
an absorptio
ce, in order 
aps were cal
coefficients 
 atoms were
 ligated to th
the wild typ
omalous 
on data from
n edge at 
to help iden
culated with
| F + | – | F ¯
 placed into
e metal Zn 
e structure. T
112 
 the 
tify 
 
 |, 
 the 
as 
he 
other bro
(Figure 5
 
 
 
 
 
 
 
Figure 5.
complex 
PfACMS
sphere re
represent
densities 
network 
 
      Sodiu
competit
substrate
nearby P
noncomp
thus repla
serves as
anhydras
 
A 
mide ion wa
.3B). No oth
3. Crystal st
with bromid
D in comple
presents zin
 bromide ion
are countere
around the a
m bromide 
ive portion i
 binding poc
he50 and Va
etitive porti
cing the me
 a major cat
e (224,227)
s found at t
er positivel
ructure of A
e ions. (A) 
x with brom
c metal, pur
s. The 2Fo-
d at 2.0 σ. (
ctive site. 
inhibits the 
s attributed 
ket. Its ioni
l82 make it 
on is very p
tal bound w
alytic drivin
. 
 
he salt bridg
y charged re
CMSD in 
The structur
ide ions. G
ple spheres 
Fc electron 
B) The H-b
decarboxyla
to the bindin
c interaction
compete wi
ossibly caus
ater. This is
g force, alre
e distance to
sidues can b
e of  
olden  
 
 
ond  
tion activity
g of one of 
 with Arg51
th substrate 
ed by the lig
 likely due t
ady shown i
B 
 the conserv
e found wit
 of ACMSD
the bromide
 and hydrop
to bind to th
ation of bro
o the loose o
n the mecha
ed R51 res
hin 4 Å to th
 in a mixed
 ions in the 
hobic intera
e active site
mide ion to 
f the water 
nism of hum
idue (4.0 Å)
is bromide 
 pattern. The
putative 
ction with 
. The 
the zinc me
ligand that 
an carbonic
113 
 
ion.  
 
tal, 
 
114 
CHAPTER 6 CAPTURE OF TETRAHEDRAL THIOHEMIACETAL AND THIOACYL 
INTERMEDIATES IN AN AMINOMUCONATE SEMIALDEHYDE 
DEHYDROGENASE 
The section of chapter 6 is our manuscript under preparation: Capture of tetrahedral 
thiohemiacetal and thioacyl intermediates in an aminomuconate semialdehyde dehydrogenase. 
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Department of Energy and NIH grant P41GM103473 (A.B. & A.M.O.). We thank Dr. Siming 
Wang for assistance of Mass spec analysis. X-ray data was collected at the Southeast Regional 
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6.1 Abstract 
Aldehydes are ubiquitous intermediates in metabolic pathways, and their innate reactivity can 
often make them quite unstable. There are several aldehydic intermediates in the metabolic 
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pathway for tryptophan degradation which can decay into neuroactive compounds that have been 
associated with numerous neurological diseases. An enzyme of this pathway, 2-aminomuconate-
6-semialdehyde dehydrogenase, which is responsible for ‘disarming’ the final aldehydic 
intermediate, has yet to be studied at the molecular level. Its activity steers the vast majority of 
metabolic flux to further catabolism and prevents overproduction of a metabolic dead-end, 
picolinic acid. Here we show crystal structures of a bacterial analogue enzyme in five 
catalytically relevant forms: resting state, one binary and two ternary complexes, and a thioacyl 
intermediate. We also report the structures of a tetrahedral thiohemiacetal intermediate and a 
thioacyl intermediate from an active site mutant. These intermediates were characterized by 
single-crystal, solution electronic absorption spectroscopy, and the mutant intermediate was 
confirmed by mass spectrometry. The crystal structures also reveal that the substrate must 
undergo an E/Z isomerization prior to oxidation. This study provides an in-depth mechanistic 
understanding of this dehydrogenase. 
6.2 Introduction 
The dominant route of tryptophan catabolism, the kynurenine pathway, has recently garnered 
increased attention given its apparent association with numerous inflammatory and neurological 
conditions, e.g. gastrointestinal disorders, depression, Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease, and AIDS dementia complex (127,128,228-231). Though the precise 
mechanism by which the kynurenine pathway influences these diseases has not yet been fully 
elucidated, it has been determined that several metabolites of this pathway are neuroactive. 
Notably, the concentration of quinolinic acid, a non-enzymatically derived decay product of an 
intermediate of the kynurenine pathway used for NAD+ biosynthesis, is elevated over 20-fold in 
patients’ cerebrospinal fluid with AIDS dementia complex, aseptic meningitis, opportunistic 
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infections, or neoplasms (232), and more than 300-fold in the brain of HIV-infected patients 
(214). This NAD+ precursor has also been shown to be an agonist of N-methyl-D-aspartate 
receptors, and an increase of its concentration may lead to over-excitation and death of neuronal 
cells (2,129). 
The apparent medical potential of the kynurenine pathway warrants detailed study and 
characterization of its component enzymes and their regulation. One enzyme in particular, 2-
aminomuconate-6-semialdehyde dehydrogenase (AMSDH), is responsible for oxidizing the 
unstable metabolic intermediate 2-aminomuconate-6-semialdehyde (2-AMS) to 2-
aminomuconate (2-AM). Based on sequence alignment, AMSDH is a member of the 
hydroxymuconic semialdehyde dehydrogenase (HMSDH) family under the aldehyde 
dehydrogenase (ALDH) superfamily (86). Aldehyde dehydrogenases are prevalent in both 
prokaryotic and eukaryotic organisms and are responsible for oxidizing aldehydes to their 
corresponding carboxylic acids. They use NAD(P)+ as a hydride acceptor to harvest energy from 
the primary substrate and generate NAD(P)H, which provides the major reducing power to 
maintain cellular redox balance (233,234). In addition to being commonly occurring metabolic 
intermediates, aldehydes are reactive electrophiles, making many of them toxic. Enzymes of the 
ALDH superfamily are typically promiscuous with regards to their substrates, however in recent 
years, this superfamily has had several new members identified with greater substrate fidelity, 
especially when the substrate is identified as a semialdehyde (235). 
The putative native substrate of AMSDH, 2-AMS, is a proposed metabolic intermediate in 
both the 2-nitrobenzoic acid degradation pathway of Pseudomonas fluorescens KU-7 (11) and 
the kynurenine pathway for L-tryptophan catabolism in mammals (2,14,129). In the presence of 
NAD+ and AMSDH, 2-AMS is oxidized to 2-AM (Fig. 6.1A), however it can also spontaneously 
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decay to picolinic acid and water with a half-life of 35 s at neutral pH (10). Due to its instability, 
2-AMS has not yet been isolated, leaving its identity as the substrate of AMSDH an inference 
based on decay products and further metabolic reactions. There are several reasons for the poor 
understanding of this pathway: it is complex with many branches, some of the intermediates are 
unstable and difficult to characterize, and several enzymes of the pathway, including AMSDH, 
are not well understood.  Hence, the structure of AMSDH will help to address questions such as 
what contributes to substrate specificity for the semialdehyde dehydrogenase, how 2-AMS is 
bound and activated during catalysis, and to help identify its counterpart in the human genome.  
Figure 6.1. Activity of AMSDH. (A) Reaction scheme showing the enzymatic generation of 2-
AMS. (B) Representative assay showing the ACMSD catalyzed consumption of ACMS. (C) 
Coupled-enzyme assay in which AMSDH oxidizes 2-AMS to 2-AM. (D) Reaction scheme 
showing 2-HMS oxidation by AMSDH. (E) Representative assay showing the activity of 
AMSDH on 2-HMS. The inset is a Michaelis-Menten plot. 
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6.3 Methods 
Expression and Purification of PfAMSDH and PfACMSD. To construct a His10-tagged 
AMSDH expression plasmid, nbaE gene from P. fluorescens (accession: AB088043.2) encoding 
AMSDH was amplified by the polymerase chain reaction (PCR) using genomic DNA of P. 
fluorescens strain KU-7 as a template and primers 5’- 
GGAATTCCATATGAATACCTTACCAAGTCAAG-3’ and 5’- 
CCCTCGAGTTAAATTTTTATGCAGATGTTGG-3’ (built-in NdeI and XhoI sites are 
underlined). The PCR product was purified from a 0.8% agarose gel, digested with NdeI and 
XhoI, and ligated in the equivalent sites of pET-16b (Novagen). Ligation product was 
transformed to Escherichia coli BL21(DE3) for protein expression. A single colony was 
introduced to 10 mL of autoclaved LB medium containing 100 µg/mL ampicillin and cultured at 
37 °C. When cells reached ca. 0.6 OD at 600 nm, 1.5 mL of cells were diluted into 500 mL 
autoclaved LB medium containing ampicillin. The cells were cultured in 37 °C until the optical 
density reached ca. 0.8 at 600 nm. Isopropyl β-D-1-thiogalactopyranoside was then added to a 
final concentration of 0.6 mM, and the temperature was lowered to 28 °C for 12 hours to induce 
AMSDH expression before the cells were harvested by centrifugation at 8,000 g. The harvested 
cells were then resuspended in 50 mM potassium phosphate buffer, pH 8.0, containing 300 mM 
NaCl and 5% glycerol. The cell slurry was passed through an M-110P Microfluidics cell 
disruptor and the debris was removed by centrifugation at 27,000 g for 30 min at 4°C. The 
supernatant containing AMSDH was purified using a Ni-NTA affinity column on an ÄKTA 
FPLC system (GE Healthcare). The major fraction with AMSDH activity was eluted by 
increased imidazole concentration. Purified protein was concentrated and desalted on a pre-
packed HiTrap desalting column (GE Healthcare) using buffer containing 50 mM HEPES (pH 
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7.5), 150 mM NaCl, and 1 mM DTT. Expression, purification and protein re-constitution of 
ACMSD were performed as described previously (26). 
Site-directed Mutagenesis. C302S, E268A, R120A, and R464A single mutation variants were 
constructed by the PCR overlap extension mutagenesis technique (132). Plasmid containing 
AMSDH from P. fluorescens was used as a template. The forward primers used in the site-
directed mutagenesis are 5'-CAACTCGGGGCAGGTCagcCTGTGTTCCGAACG-3' for C302S, 
5'-GAAAGAAGTGTCTTTCgcgTTGGGGGGCAAGAACG-3' for E268A, 5'-
GGACCCTCGATATTCCTgcgGCCATTGCCAACTTTC-3' for R120A, and 5'-
GAACACCTGGTACTTGgcgGATCTGCGTACGCC-3' for R464A. The insert of each mutant 
was verified by DNA sequencing and the positive clone was transformed to E. coli BL21(DE3). 
The expression and purification of the mutants are the same as wild-type AMSDH. 
Preparation of ACMS and 2-HMS. ACMS was generated by catalyzing the insertion of 
molecular oxygen to 3-hydroxyanthranilic acid by purified, Fe2+ reconstituted 3-
hydroxyanthranilate 3,4-dioxygenase as described previously (14,26). 2-HMS is generated non-
enzymatically from ACMS following a previously established method (236). The pH of 
solutions containing ACMS was adjusted to ~2 by the addition of hydrochloric acid. 2-HMS 
formation was monitored on an Agilent 8453 diode-array spectrophotometer at 315 nm. The 
solutions were then neutralized with sodium hydroxide once the absorbance at 315 nm stopped 
increasing. 2-HMS at neutral pH has a maximum UV absorbance at 375 nm (236). 
Enzyme Activity Assay Using 2-HMS as Substrate. Steady-state kinetics analyses were 
carried out at room temperature on an Agilent 8453 diode-array spectrophotometer. Reaction 
buffer contains 25 mM HEPES and 1 mM NAD+, pH 7.5. Consumption of the substrate 2-HMS 
by 200 nM AMSDH was detected by monitoring the decrease of its absorbance at 375 nm with a 
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molar extinction coefficient of 43,000 M-1cm-1 for 15 s with a 0.5 s integration time. For mutants, 
700 nM protein and a wavelength of 420 nm, ε420 11,180 M-1cm-1, was used. UV absorbance at 
375 nm decreased and blue shifted to 295 nm, the maximum UV absorbance for the product, 2-
hydroxymuconic acid. This is consistent with previously reported data in which the ending 
compound was purified and verified as the correct product (236). The pre-steady state spectra 
were obtained by using Applied Photophysics Stopped-Flow Spectrometer SX20 (UK) with the 
mixing unit hosted inside an anaerobic chamber made by Coy Laboratory Products (MI, USA). 
Pre-steady state activity used the same reaction buffer but with 23 μM AMSDH or E268A and 
25 μM 2-HMS and were carried out at 10 °C. The change in absorbance was monitored for 1.0 s. 
Crystallization, Data Collection, and Refinement. Purified AMSDH samples at a final 
concentration of 10 mg/mL containing no NAD+ or 10 equivalents of NAD+ were used to set up 
sitting-drop vapor diffusion crystal screening trays in Art Robbins 96-well Intelli-Plates using an 
ARI Gryphon crystallization robot. The initial crystallization conditions were obtained from 
PEG-Ion 1/2 (Hampton Research) screening kits at room temperature. The screened conditions 
were optimized by increasing protein concentration to 40 mg/mL and lowering crystallization 
temperature to 18 °C. NAD+-bound AMSDH crystals were obtained from drops assembled with 
1.5 μL of protein (pre-incubated for 10 minutes with 10 equivalents of NAD+) mixed with 1.5 μL 
of a reservoir solution containing 20% polyethylene glycol 3350 and 0.2 M sodium phosphate 
dibasic monohydrate, pH 9.1, by hanging drop diffusion in VDX plates (Hampton Research). 
Pyramid shaped crystals which diffract up to ~1.9 Å appeared overnight. The reservoir solution 
for crystallizing the cofactor-free AMSDH crystals contains 12% polyethylene glycol 3350, 
0.1M sodium formate, pH 7.0. Crystals belonging to the same space group formed within 2-3 
days with an irregular plate shape and diffracted up to ~2.2 Å. NAD+-AMSDH crystals were 
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used for substrate-soaking experiments. Crystals were transferred to mother liquor solution 
containing ~1 mM 2-HMS and incubated for 10 – 180 minutes before flash-cooling in liquid 
nitrogen. Soaking 2-AMS as substrate is more complicated because of its instability.  
Crystallization solution containing ~1.5 mM ACMS were used for soaking. After transferring 
several crystals to the soaking solution (8 μL), 2 μL of 1 mM purified ACMSD was included to 
catalyze the conversion of ACMS to 2-AMS. Crystals were flash-frozen after a 5 min-
incubation. Crystallization solution containing 20% glycerol or ethylene glycol was used as 
cryoprotectant. X-ray diffraction data were collected on SER-CAT beamline 22-ID or 22-BM of 
the Advanced Photon Source, Argonne National Laboratory.  
Ligand Refinement and Molecular Modeling. The first AMSDH structure, the cofactor NAD+ 
bound structure, was solved by the molecular replacement method with the Advanced Molecular 
Replacement coupled with Auto Model Building programs from the PHENIX software using 5-
carboxymethyl-2-hydroxymuconate semialdehyde dehydrogenase (PDB: 2D4E) as a search 
model, which shares 39% of amino acids sequence identity with P. fluorescens AMSDH. The 
ligand-free, mutant and ternary complex structures were solved by molecular replacement using 
the refined NAD+-AMSDH as the search model. Refinement was conducted using PHENIX 
software (196). The program Coot was used for electron density map analysis and model 
building (141). NAD+/NADH, substrates 2-AMS and 2-HMS, and Cys-substrate covalent adduct 
intermediate were well-defined and added to the model based on the 2Fo - Fc and Fo - Fc electron 
density maps. Refinement was assessed as complete when the Fo - Fc electron density contained 
only noise. The structural figures were generated using PyMOL software 
(http://www.pymol.org/).  
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Single-Crystal Spectroscopy. Electronic absorption spectra from single crystals held at 100 K 
were collected at beamline X26-C of the National Synchrotron Light Source (NSLS) (237). The 
electronic absorption data were typically obtained between 200 – 1000 nm with a Hamamatsu 
(Bridgewater, N.J.) L10290 high power UV-Vis light source. The lamp was connected to one of 
several 3-meter long solarization-resistant optical fibers with an internal diameter of 115, 230, 
400, or 600 µm (Ocean Optics, Dunedin, FL). The other end was connected to a 40 mm 
diameter, 35 mm working distance 4x, Schwardchild design reflective microscope objective 
(Optique Peter, Lentilly France). The spectroscopy spot size is a convolution of the optical fiber 
diameter and the magnification of the objective, which in this case produced 28, 50, 100, or 150 
µm diameter spots, respectively. Photons that passed through the crystal were collected with a 
second, aligned objective that was connected to a similar optical fiber or one with a slightly 
larger internal diameter. The spectrum was then recorded with either an Ocean Optics USB4000 
or QE65000 spectrometer. Anisotropic spectra and an image of the crystal/loop were collected as 
a function of rotation angle in five-degree increments. These were analyzed by XREC (238) to 
determine the flat face and optimum orientation. 
Mass Spectrometry. To prepare samples for ESI mass spectrometry (MS), as-isolated E268A 
AMSDH was buffer-exchanged to 10 mM Tris (pH 8.0) by running through a desalting column 
(GE Healthcare). Intermediate bound E268A was obtained by mixing E268A with 3 eq. of 2-
HMS. Excess 2-HMS was removed by desalting chromatography using the same buffer. 
Desalted proteins were concentrated to a final concentration of 20 µM. Freshly prepared samples 
were rinsed by acetonitrile and 0.1% formic acid (1:1 ratio) before injection. MS experiments 
were conducted using a Waters (Milford, MA) Micromass Q-TOF micro (ESI-Q-TOF) 
instrument operating in positive mode. The capillary voltage was set to 3500 V, the sample cone 
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voltage to 35 V, and the extraction cone voltage to 2 V. The source block temperature and the 
desolvation temperature were set to 100 and 120 °C, respectively. The samples were introduced 
into the ion source by direct injection at a flow rate of 5 µL/min. The raw data containing 
multiple positively charged protein peaks were deconvoluted and smoothed using MassLynx 4.1. 
6.4 Results 
Catalytic activity of wild-type AMSDH. Due to the unstable nature of its substrate, 2-AMS, 
activity of AMSDH was detected using a coupled enzyme assay that employed its upstream 
partner, α-amino β-carboxymuconate ε-semialdehyde decarboxylase (ACMSD), to generate 2-
AMS in situ. ACMSD transforms α-amino β-carboxymuconate ε-semialdehyde  (ACMS) (λmax at 
360 nm) to 2-AMS (λmax at 380 nm) (10,14). As seen in Figure 6.1B, in an assay which uses only 
ACMSD, the absorbance peak of its substrate, ACMS, red-shifts to 380 nm as 2-AMS is formed. 
The absorbance at 380 nm then quickly decays as 2-AMS decays to picolinic acid, which has no 
absorbance features above 200 nm. In a coupled-enzyme assay, ACMSD, AMSDH, and NAD+ 
are included in the reaction system. As shown in Figure 6.1C, ACMS is still consumed, however 
there is no red shift observed because 2-AMS is enzymatically converted to 2-AM (λmax at 325 
nm) rather than accumulating and decaying. The production of 2-AM requires that an equimolar 
amount of NAD+ be reduced to NADH (λmax at 339 nm). A stable alternative substrate, 2-
hydroxymuconate-6-semialdehyde (2-HMS), was used to pursue kinetic parameters (Figure 
6.1D), when using saturating NAD+ concentrations (≥ 1 mM), the kcat and Km of AMSDH for 2-
HMS were 1.30 ± 0.01 s-1 and 10.4 ± 0.2 μM, respectively (Figure 6.1E). 
Crystal structures of AMSDH. Five crystal structures of wild-type AMSDH, including the 
ligand-free (2.20 Å resolution), NAD+-bound binary complex (2.00 Å), ternary complex with 
NAD+ and substrate 2-AMS (2.00 Å) or 2-HMS (2.20 Å), and a thioacyl intermediate (1.95 Å), 
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have been solved by molecular replacement. All five structures belong to space group P212121. 
Data collection and refinement statistics are listed in Table 6.1. The complete AMSDH model 
includes four polypeptides per asymmetric unit describing one homo-tetramer (Figure 6.2A).  
Each monomer of AMSDH contains three domains: a subunit interaction domain, a catalytic 
domain, and an NAD+ binding domain (Figure 6.2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
      Each polypeptide contains 500 amino acids, but the first 16 - 17 amino acids are not included 
in our model due to missing electron density even though full-length AMSDH was used for 
crystallization. It is most likely that these N-terminal residues belong to a random coil as in most 
Figure 6.2. Overall crystal structure of AMSDH.  (A) View of the tetramer. (B) Structure of one 
AMSDH subunit with NAD+ and substrate 2-AMS. (C) Topology diagram showing the AMSDH 
secondary structure. 
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other ALDH structures. The first 135 residues comprise a cap which surrounds the cofactor 
binding domain. This cap region starts with two β-hairpin motifs (residues 22 - 50) and is 
followed by four α-helixes (residues 51 - 134). The sequence then extends to the subunit 
interaction domain with two beta strands (residues 138 -158). The central strand of the cofactor 
binding domain starts at residue 161 and stops at residue 266 and resembles a distorted 
Rossmann fold. The catalytic domain (residues 267 - 476) is based on a topologically related βαβ 
polypeptide fold and contains a thiol, Cys302, in the catalytic center. The sequence ends with a 
C-terminal helix and a beta strand (residue 477 - 500), which is part of the oligomerization 
domain. The active site is located in the region between the NAD+ binding domain and the 
catalytic domain with entrances for NAD+ and substrate on two separate sides.  
      In the structure of the co-crystallized binary complex, an NAD+ molecule is present in an 
extended, anti-conformation in the N-terminal, co-substrate binding domain of each monomer 
(Figure 6.3A). The electron density map of NAD+ is well defined, and the interactions between 
the protein and NAD+ are equivalent in all four subunits as shown in Figure 6.3E. The NAD+-
bound AMSDH structure is similar to the ligand-free structure with an aligned RMSD of 0.239 
Å. Residues which belong to the NAD+ binding pocket are also well aligned with the exception 
of Cys302, Arg108, and Leu116 (Figure 6.4).  Upon binding NAD+, the thiol moiety of Cys302 
rotates so that the sulfur is 2.3 Å closer to the substrate binding pocket and away from the 
nicotinamide head of NAD+. 
      The adenine ribose ring and the two phosphate groups are the main components that stabilize 
the NAD+ position by interacting with protein residues which all belong to the surrounding 
loops, except Thr250, which belongs to the 8th α-helix. The nicotinamide half of NAD+ has less 
interaction with local residues. Two oxygen atoms (O2 and O3) of the ribose ring form H-bonds 
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with OE2 and OE3 of Glu404, respectively. On the other ribose ring, the O3 atom forms an H-
bond with the Nz of Lys192 while its O2 atom forms H-bonds with both Lys192 (Nz) and 
Glu195 (OE1). The O1 belonging to the phosphate group nearer the nicotinamide is H-bonded to 
NE1 of Trp168. The anionic O2 of the other phosphate group forms H-bonds with both Thr250 
(OG1) and Glu247 (N) (Figure 6.3E). 
Figure 6.3. Crystal structures of wild-type AMSDH and single-crystal electronic absorption 
spectrum of a catalytic intermediate. Active site structure of AMSDH-NAD+ complex (A), 
ternary complex of AMSDH-NAD+-2-AMS (B), ternary complex of AMSDH-NAD+-2-HMS 
(C), and thioacyl intermediate (D). (E) 2D-interaction diagram for NAD+ binding. (F) Close-up 
of the thioacyl intermediate in D. (G) Single-crystal electronic absorption spectrum of D. 
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      Crystal structures of enzyme substrate ternary complexes. Structures of AMSDH in ternary 
complex with co-substrate NAD+ and its primary substrates, 2-AMS or 2-HMS, were obtained 
by soaking co-crystallized AMSDH-NAD+ crystals with substrate for 5 and 10 min for 2-AMS 
and 2-HMS, respectively. Extra density which fits with the corresponding substrate molecule 
was observed in the active site of each subunit. The co-substrate NAD+ in the ternary complex 
structures is bound in the same manner as in the binary complex. Binding of the primary 
substrates introduced minimal change to the protein structure; the RMSD for the superimposed 
structures of substrate-free with 2-AMS- and 2-HMS-bound ternary complex structures are 0.170 
and 0.276 Å, respectively. These two primary substrates bind to AMSDH in an identical fashion, 
with two arginine residues, Arg120 and Arg464, playing important roles in stabilizing the 
substrate by forming four H-bonds with one of the carboxyl oxygens and the 2-amino or hydroxy 
group of 2-AMS (Figure 6.3B) or 2-HMS (Figure 6.3C), respectively. Mutation of Arg120 to 
alanine causes a moderate decrease of the kcat to 0.7 ± 0.2 s-1 from 1.30 ± 0.01 s-1 and a dramatic 
increase of the Km with a lower bound of 446.3 ± 195.9 µM (an accurate determination of the Km 
Figure 6.4. Local changes at the active site of AMSDH induced by NAD+ binding. 
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is hindered by insufficient 2-HMS concentrations) compared to 10.4 ± 0.2 μM in the wild-type 
(Figure 6.5, top). Mutation of Arg464 to alanine decreased the kcat to ~ 0.3 s-1, and not only 
increased the Km to ~ 170 µM, but also leads to a substrate inhibition effect with a Ki of ~ 6 µM 
(Figure 6.5, bottom). This substrate inhibition effect is likely caused by unproductive binding of 
a second substrate molecule in the space created by the deletion of arginine.  
 
      Catalytic intermediates trapped after ternary complex formation. Enzyme-NAD+ binary 
complex crystals were soaked in mother liquor containing 2-HMS for a range of time points 
from 5 minutes to more than 3 hours before flash-cooling in liquid nitrogen. In a crystal which 
Figure 6.5. Kinetic assays of R120A and R464A with 2-HMS. Top, activity of R120A fit 
with the Michaelis-Menten. Bottom, activity of R464A fit with the Michaelis-Menten 
equation with substrate inhibition. 
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was soaked for 40 min, an intermediate was trapped and refined to the resolution of 1.95 Å 
(Figure 6.3D). Crystals soaked for longer time points gave a similar intermediate with poorer 
resolution. In this structure, 2-HMS has isomerized from the (2E, 4E)-2-hydroxymuconate-6-
semialdehyde of the substrate-bound ternary structure to a (2Z, 4E) conformation and interacts 
with Arg120 and Arg464 with both of its carboxyl oxygens rather than one carboxyl oxygen and 
the 2-hydroxy oxygen as shown in the 2-HMS ternary complex structure. Fitting this density 
with the 2E, 4E conformation resulted in unsatisfactory 2Fo - Fc and Fo - Fc density maps as 
shown in Figure 6.6A. Likewise, attempting to fit the 2Z, 4E isomer to the ternary complex 
structure did not produce satisfactory results (Figure 6.6B). Upon E to Z isomerization, the 
carbon chain of the substrate extends, and the distance between its 6th carbon and Cys302’s 
sulfur is now at 1.8 Å, which is within covalent bond distance for a carbon-sulfur bond. Also, the 
continuous electron density between Cys302-SG and 2-HMS-C6 indicates the presence of a 
covalent bond (Figure 6.3F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Alternate fitting of substrate-bound ternary complex and thioacyl intermediate. 
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       Another feature of this intermediate is that the nicotinamide ring of NAD+ has moved 4.6 Å 
away from the active site and adopted a bent conformation (Figure 6.3D) compared to the 
position in the binary or ternary complex structures (Figure 6.3A, B, and C), indicating that it has 
been reduced to NADH. Thus, this intermediate is assigned as a thioacyl enzyme-substrate 
adduct. The single crystal electronic absorption spectrum of the sample has an absorbance 
maximum at 394 nm (Figure 6.3G). The same absorbance band was observed in crystals soaked 
with 2-HMS from 30 min to 2 h (Figure 6.7A). However, this long-lived intermediate in the 
crystal was not observed in solution with millisecond to second time resolution in stopped-flow 
experiments (Figure 6.8A). Thus, it is either present in an earlier time domain (sub-
Figure 6.7. Single-crystal electronic absorption spectra of wtAMSDH and E268A AMSDH co-
crystallized with NAD+ and soaked with 2-HMS before flash-freezing.  
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milliseconds), or alternatively, it may not accumulate in solution because NADH can readily 
dissociate in solution, whereas it may be trapped in the active site when in the crystalline state.  
 
 
Figure 6.8. Time-resolved, stopped-flow UV-Vis spectra of the reactions catalyzed by 
wtAMSDH and E268A for 1 s. 
 
      Another notable change in the intermediate structure is the movement of the side chain of 
Glu268, which rotates 73° towards the active site. In order to probe the function of Glu268, we 
constructed an alanine mutant and found that it exhibited no activity in steady-state kinetic 
assays. Interestingly, E268A exhibits completely different pre-steady state activity than the wild-
type enzyme. As shown in Figure 6.8B, a peak at 422 nm was formed concomitant with decay of 
the 2-HMS peak within the one second of reaction. This new species is generated 
stoichiometrically upon titration of 2-HMS with E268A (Figure 6.9D). The moiety which gives 
rise to this new absorbance band is stable for minutes at room temperature and cannot be 
separated from the protein by membrane filtration-based methods (26), suggesting that it is 
covalently bound to the protein.  The formation of an enzyme-substrate adduct in the E268A 
mutant was investigated by mass spectrometry. For as-isolated E268A, the resultant multiply 
charged states (Figure 6.10) were deconvoluted to obtain a molecular weight (MW) of 56,252 Da 
(Figure 6.11, top). This value is in good agreement with the predicted MW of E268A AMSDH 
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plus an N-terminal His-tag and linking residues, 56,251 Da. The second largest peak in the 
deconvoluted spectrum has a MW 177 Da greater than that of the most abundant signal. This is 
likely due to post translational modification of the His-tag; α-N-Gluconoylation of His-tags has 
been observed in E. coli expressed proteins which cause 178 Da extra mass (239). The mutant 
protein was then treated with the alternate substrate, 2-HMS, and the mass spectrum shows a 
new major peak at 56,390 Da (Figure 6.11, bottom), 138 Da heavier than the as-isolated mutant. 
Similarly, the second most abundant peak corresponds to a His-tag modified mutant plus 139 Da. 
In this spectrum, the peaks arising from the as-isolated mutant are substantially reduced, 
indicating that 2-HMS, 141 Da, has formed a covalent adduct with the E268A mutant enzyme. 
Figure 6.9. Crystal structures of the E268A mutant and its solution and UV-vis spectra. Structure
of the active site of (A) E268A-NAD+ binary complex, (B) thiohemiacetal intermediate, (C) 
thioacyl intermediate. (D) Solution UV-vis spectra of a titration of 2-HMS with E268A. (E) 
Single-crystal UV-vis spectrum of the intermediate in B (top panel) and C (bottom panel). 
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Figure 6.10. Raw ESI mass spectra of as-isolated E268A AMSDH (top) and E268A treated with 
2-HMS (bottom). Narrow range scans corresponding to the proteins are shown in the insets. 
 
 
 
Figure 6.11. Deconvoluted positive-mode electrospray ionization (ESI) mass spectra of as-
isolated E268A (top) and 2-HMS treated E268A (bottom). 
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      We determined the crystal structure of E268A and refined it to 2.00 Å resolution. The overall 
structure aligns very well with the wild-type binary complex structure with a RMSD of 0.139 Å. 
The active site of E268A also resembles the native AMSDH structure (Figure 6.12). The nature 
of the absorbing species was further investigated by soaking co-crystallized E268A-NAD+ 
crystals in mother liquor containing 2-HMS. By doing so, two temporally, structurally, and 
spectroscopically distinct intermediates were identified.  
Figure 6.12. Superimposition of E268A (pink) active site with wtAMSDH (light blue). 
 
      When E268A-NAD+ crystals are soaked with 2-HMS for 40 min or less, their single crystal 
electronic absorption spectra show an absorbance maximum at 422 nm (Figure 6.7B), as was 
observed in the solution-state titration and the stopped-flow assays. An individual electronic 
absorption spectrum for an E268A-NAD+ crystal soaked with 2-HMS for 15 min can be found in 
Figure 6.9E. The structure of E268A-NAD+ soaked with 2-HMS for 30 minutes before flash-
cooling was solved and refined to 2.15 Å resolution. In this structure, a continuous electron 
density between Cys302-SG and 2-HMS-C6 is observed, similar to the thioacyl intermediate 
observed in the wild-type enzyme. However, in contrast to the thioacyl intermediate, the density 
135 
around C6 is not flat, indicating an sp3- rather than sp2-hybridized carbon (Figure 6.13A). More 
importantly, the C6 of 2-HMS and the C4N of NAD+ are very close (2.4 - 2.8 Å), making it 
unlikely that the hydride has been transferred from the substrate. Taken together, these data 
allow us to assign this intermediate to a thiohemiacetal enzyme adduct (Figure 6.9B). A similar 
intermediate has only been trapped once previously in a crystal which contains no co-substrate 
(116). Hence, this is the first time for this intermediate to be trapped in the presence of NAD+. 
 
Figure 6.13. Crystal structures of two distinct catalytic intermediates. Electron density map of 
(A) the thiohemiacetal intermediate and (B) the thioacyl intermediate. 
 
If the E268A-NAD+ crystals are soaked with 2-HMS for longer than 1 hour, their single-
crystal UV-Vis spectra begin to resemble that of the wild-type thioacyl intermediate with a 
corresponding absorbance maximum at 394 nm (Figure 6.7B), as seen in wild-type thioacyl 
intermediate crystals. An individual electronic absorption spectrum for an E268A-NAD+ crystal 
soaked with 2-HMS for 120 min can be found in Figure 6.9E, bottom.  The structure of an 
E268A-NAD+ crystal soaked with 2-HMS for 180 minutes was solved and refined to 2.20 Å. 
The structure of this intermediate is also similar to the wild-type thioacyl enzyme adduct with 
NADH, rather than NAD+ found at the active site. The distance between the C4N of NADH and 
C6 of 2-HMS is longer than 6.1 Å (Figure 6.9C). The electron density around C6 is flatter 
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(Figure 6.13B) compared with the thiohemiacetal intermediate and similar to the thioacyl 
intermediate trapped in the wild-type AMSDH structure (Figure 6.3F). Based on the similarities 
in their absorbance and structures, we conclude that this latter intermediate is equivalent to the 
wild-type thioacyl intermediate. It is also worth noting that the strictly conserved asparagine 169 
is seen to stabilize both the thiohemiacetal and thioacyl intermediates.  
6.5 Discussion 
The substrate of AMSDH, 2-AMS, is an unstable aldehyde which can decay to picolinic acid 
and water, presumably through an electrocyclization reaction as its upstream intermediate does 
(193). So, to assay enzymatic activity, the upstream enzyme was utilized in the reaction mixture 
to generate substrate, and it was shown that AMSDH is catalytically active. Unfortunately, no 
kinetic parameters can be reliably determined because the concentration of 2-AMS is not well-
defined in the coupled-enzyme assay. To circumvent this issue, a previously-identified, stable 
alternative substrate, 2-HMS (236,240), in which a hydroxyl group replaces the amino group in 
2-AMS to prevent cyclization, was used to characterize the activity of AMSDH and to examine 
the activity of the mutants.  
Substrate bound ternary complex structures were obtained by soaking co-crystallized protein 
and NAD+ with 2-AMS or 2-HMS. 2-AMS is an unstable compound which decays with a t1/2 of 
about 9 s at pH 7.4 and 37 °C or 35 s at pH 7.0 and 20 °C. Notably, this is its first reported 
structure. It appears to be stabilized in the enzyme active site by interactions with Arg120 and 
Arg464 so that the electrocyclization reaction cannot occur. Both arginine residues are close to 
the protein surface and in good positions to serve as gatekeepers, bringing the substrate into the 
active site. As a residue residing on a loop, Arg464 should be relatively flexible. The electron 
density for the side chain of Arg120 is partially missing in the binary complex structure but very 
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well resolved in both ternary complex structures. This observation indicates that the presence of 
substrate can stabilize what may be a flexible residue. It becomes evident from the coordinates 
that Arg120 and Arg464 play an important role in substrate recognition, stabilization, and 
possibly product release. Two arginine residues are rarely observed in such close proximity, 
stabilizing one end of the same molecule with multiple H-bonds. With the exception of the H-
bonds provided by Arg120 and 464, the substrate-binding pocket is mostly composed of 
hydrophobic residues (Figure 6.14 B). Based on sequence alignment (Figure 6.14A), these two 
arginine residues are strictly conserved throughout the HMSDH family but are not found in other 
members of the ALDH superfamily. We propose that these dual arginines combined with the 
size restrictions provided by the hydrophobic pocket endow this enzyme with its specificity 
towards small α-substituted carboxylic acids with an aldehyde moiety, such as 2-AMS and 2-
HMS.  
 
Figure 6.14. Identification of substrate binding residues for the hydroxymuconic semialdehyde 
dehydrogenase (HMSDH) family. (A) Sequence alignment of several enzymes from the 
HMSDH family. (B) Substrate binding pocked of 2-AMS, left, and 2-HMS, right, ternary 
complex crystal structures. 
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      Two strictly conserved catalytic residues, Cys302 and Glu268, are present at the interior of 
the substrate-binding pocket. General features regarding these residues in the ALDH superfamily 
are (1) that the cysteine serves as a catalytic nucleophile which is anticipated to form a covalent-
adduct intermediate with the substrate by a nucleophilic addition during catalysis (113,115,241), 
and (2) that the glutamate serves as a base to activate water for hydrolysis of the thioacyl-enzyme 
adduct (108,117,119,242). In the ternary complex structures, Cys302 is located at an ideal 
position to initiate catalysis. It is proposed to attack the aldehydic carbon (C6) of the substrate. In 
the two ternary complex structures, the distance between the sulfur of Cys302 and the C6 of 
substrate is ca. 3.3 Å. Cys302 and the aldehydic carbon form covalent bond in both thioacyl and 
thiohemiacetal intermediates. Mutation of Cys302 to serine led to completely inactive enzyme, 
further confirming its catalytic significance.  
      Examining the wild-type AMSDH structures shows that in the NAD+-bound binary complex, 
Glu268 adopts a ‘passive’ conformation, pointing away from the substrate binding pocket, and 
forms H-bonds with both NE of Trp177 (3.2 Å distance) and the backbone oxygen of Phe470 
(3.6 Å) to leave space for the reduction of NAD+. Its electron density is very well resolved and 
the side chain B-factor is close to average: 28.2 Å2/28.5 Å2. The thiol moiety of Cys302 is 7.14 
Å from Glu268 and is unlikely to form interactions. Interestingly, in both substrate bound 
structures, Glu268 becomes more flexible and exhibits much weaker electron density and 
increased side chain B-factors compared to average protein B-factors: 37.8 Å2/28.5 Å2 and 66.37 
Å2/39.7 Å2. In the thioacyl intermediate structure, the electron density of Glu268 becomes very 
well defined again, but its side chain rotates 73° towards the bound substrate and seems to be in 
an ‘active’ position to abstract a proton from a deacylating water (Figure 6.3D). At this point in 
the reaction cycle, the NADH molecule needs to leave the active site to make room for the 
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catalytic water molecule. Movement of the nicotinamide ring of NAD+ coupled with the rotation 
of an active site glutamate has previously been observed in other aldehyde dehydrogenases 
during catalysis (108,117,119). 
      Mutation of Glu268 to alanine led to the accumulation of the thiohemiacetal intermediate in 
both solution and crystal structure. The strictly conserved glutamate residue in the active site of 
ALDH enzymes has been proposed to play up to three possible roles during catalysis. It is 
strictly required to activate the deacylating water which allows for product release, it is in a 
‘passive’ conformation during NAD(P)+ reduction, and in some cases, it may serve to activate 
cysteine for nucleophilic attack (120). Based on these roles, mutation to alanine would be 
expected to decrease the rate of hydrolysis of the thioacyl adduct, have no effect on the rate of 
reduction of NADH, and possibly decrease the rate of nucleophilic attack by cysteine. Based on 
these understandings, deletion of the active site glutamate should cause an accumulation of the 
thioacyl intermediate. However, in this work the E268A mutant is shown to accumulate the 
preceding thiohemiacetal intermediate both in crystal and in solution. This finding suggests an 
additional catalytic role for this residue:  rotation of Glu268 towards the active site facilitates the 
hydride transfer from the tetrahedral thiohemiacetal adduct to NAD+. The rapid formation of the 
intermediate in solution indicates that Glu268 of AMSDH does not play a role in activating 
cysteine. However, it does appear necessary to complete hydride transfer from the substrate to 
NAD+, and its removal turns the native substrate into a suicide inhibitor. 
      Based on previous studies of the ALDH mechanism and the eight high-resolution crystal 
structures solved, we propose a catalytic mechanism for AMSDH. As shown in Figure 6.15, 
NAD+ binds to the enzyme, 1, to form an NAD+-bound AMSDH complex, 2. The substrate, 2-
AMS, is then recognized by Arg120 and Arg464 through multiple hydrogen-bonding 
140 
interactions, 3. At this point, it is not yet clear whether the E/Z isomerization of the 2,3 double 
bond takes place before, during, or after the nucleophilic attack by Cys302 on the aldehydic 
carbon, which produces the tetrahedral thiohemiacetal intermediate, 4. The isomerization drives 
a rotation of the substrate at the C1 end so that only the carboxylate group interacts with the two 
arginine residues. Next, NAD+ is reduced to NADH by abstraction of a hydride from 4, forming 
a thioacyl intermediate, 5. Upon reduction, the nicotinamide portion of NADH moves away from 
the substrate as Glu268 rotates into position to activate a water molecule to perform a 
nucleophilic attack on the same carbon that was previously attacked by Cys302, forming a 
second tetrahedral intermediate, 6. Finally, the second tetrahedral intermediate collapses, 
breaking the C-S bond and releasing the final products, 2-AM and NADH. In the present work, 
species 1 – 5 are spectroscopically and structurally characterized while intermediate 6 was not 
seen to accumulate. 
 
Figure 6.15. Proposed catalytic mechanism for the oxidation of 2-AMS by AMSDH. 
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      In this work, five catalytically relevant structures of the wild-type AMSDH and three mutant 
structures yield a comprehensive understanding of the protein’s overall structure, co-substrate 
binding mode, and elucidate the primary reason for substrate specificity among the HMSDH 
family of the ALDH superfamily. The structural and spectroscopic snapshots capture the crystal 
structure of a highly unstable kynurenine metabolite, 2-AMS, and two catalytic intermediates, 
including stabilizing a tetrahedral intermediate in a mutant protein, which was further verified by 
mass spectrometry. Another interesting finding revealed through solving the ternary complex and 
intermediate crystal structures is that an E to Z isomerization of the substrate occurs in this 
dehydrogenase before hydride transfer. This is the first piece of structural evidence illustrating an 
aldehyde dehydrogenase which proceeds via an E/Z isomerization on its substrate during 
catalysis. 
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Table 6.1. X-ray crystallography data collection and refinement statistics. 
Data 
collection 
Apo-
AMSDH 
NAD-
AMSDH 
NAD- 
2-AMS-
AMSDH 
NAD- 
2-HMS-
AMSDH 
WT- 
Thioacyl  
E268A-
AMSDH 
E268A-
Hemiacetal  
E268A- 
Thioacyl  
detector type MAR300 CCD 
MAR225 
CCD 
MAR300 
CCD 
MAR300 
CCD 
MAR225 
CCD 
MAR225 
CCD 
MAR225 
CCD 
MAR225 
CCD 
source APS  22-ID 
APS 
 22-BM 
APS 
22-ID 
APS 
22-ID 
APS 
 22-BM 
APS 
22-BM 
APS 
 22-BM 
APS, 
Sector 22-
BM 
space group P222121 P222121 P222121 P222121 P222121 P222121 P222121 P222121 
unit cell 
lengths (Å) 
 
a=88.27 
b=141.89 
c=172.92 
 
 
a=88.58 
b=142.00 
c=174.38 
 
a=88.40 
b=142.12 
c=174.41 
a=88.57 
b=142.72 
c=175.01 
a=88.36 
b=141.75 
c=174.37 
a=88.53 
b=141.98 
c=173.80 
a=88.57 
b=141.56 
c=174.63 
a=88.33 
b=141.35 
c=173.53 
unit cell 
angles (˚) α=β=γ=90 α=β=γ=90 α=β=γ=90 α=β=γ=90 α=β=γ=90 α=β=γ=90 α=β=γ=90 α=β=γ=90 
wavelength 
(Å) 0.8 1.0 0.8 0.8 1.0 1.0 1.0 1.0 
temperature 
(K) 100 100 100 100 100 100 100 100 
resolution 
(Å) a 
45.00-
2.20 
(2.24-
2.20) 
35.00-
2.00 
(2.07-
2.00) 
35.00-
1.98 
(2.03-
1.98) 
45.00-
2.15 
(2.19-
2.15) 
45.00- 
1.95 
(1.98-
1.95) 
50.00-
2.00 
(2.03-
2.00) 
 
50.00- 
2.15  
(2.15- 
2.19) 
 
50.00-
2.20 
(2.24-
2.20) 
completenes
s (%)a 
99.8 
(99.4) 
99.8 
(98.9) 
95.2 
(99.7) 
99.9 
(100.0) 
94.9 
(88.8) 
97.2 
(97.4) 
99.9  
(100) 
99.6 
(99.2) 
Rmerge (%)a, b 
8.0  
(53.5) 
11.2  
(8.9) 
10.7 
(78.3) 
12.2 
(84.1) 
10.4 
(84.3) 
10.8 
(74.5) 
14.8  
(58.7) 
9.9  
(71.7) 
I/σI a 45.2  (4.4) 
27.3  
(2.3) 22.7 (2.2) 27.1 (2.7) 28.4 (2.2) 13.3 (3.2) 17.7 (3.9) 36.9 (3.7) 
multiplicity a 14.0 (11.6) 
13.7 
(9.1) 9.8(7.8) 12.5(10.3) 10.5(6.4) 11.9(10.5) 8.8(7.6) 11.4(10.3) 
Refinement 
resolution 
(Å) 2.20 2.00 2.00 2.15 1.95 2.00 2.15 2.20 
no. 
reflections; 
working/test 
109619/ 
5469 
149298/ 
7485 
140017/ 
7401 
114123/ 
6029 
145080/ 
7649 
144988/ 
7303 
119216/ 
5973 
110312/ 
5518 
Rwork (%)c 18.6 17.2 16.2 18.0 17.6 19.5 19.2 18.4 
Rfree (%)d 23.9 21.8 20.8 23.7 21.6 23.7 23.5 22.7 
no. of 
protein 
atoms 
14651 14684 14684 14684 14684 14668 14668 14668 
no. of ligand 
atoms 23 188 220 220 220 204 220 220 
no. of 
solvent sites 702 1682 1397 802 1702 1188 1136 882 
Average B-factor (Å2) 
protein 41.1 28.5 28.5 39.7 27.9 31.7 29.2 36.2 
NAD+ N/A 28.8 40.1 56.7 37.5 37.0 41.4 56.4 
NA+ 35.3 N/A 32.3 41.6 30.7 34.0 43.6 43.9 
EG/GOL/A
MS/HMS 38.4 42.7 32.4 45.6 23.0 42.1 25.1 28.1 
solvent 42.7 37.3 37.5 43.3 35.4 37.4 34.9 39.2 
PDB code 4I26 4I1W 4I25 4I2R 4NPI 4OE2 4OU2 4OUB 
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a Values in parentheses are for the highest resolution shell. 
b Rmerge = Σi |Ihkl,i - ‹Ihkl›|/Σhkl Σi Ihkl,i, where Ihkl,i is the observed intensity and ‹Ihkl› is the average intensity of 
multiple measurements. 
c Rwork = Σ||Fo|-|Fc||/Σ|Fo|, where |Fo| is the observed structure factor amplitude, and |Fc| is the calculated structure 
factor amplitude. 
d Rfree is the R factor based on 5% of the data excluded from refinement. 
e Based on values attained from refinement validation options in COOT. 
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CHAPTER 7 SUMMARY 
      Work in this dissertation focuses on two enzymes in the kynurenine pathway and 2-NBA 
biodegradation pathway: ACMSD and AMSDH. Substrates for both of the enzymes are unstable 
metabolic intermediates and spontaneously decay to QUIN and PIC, respectively. Structure and 
mechanistic studies on these two enzymes may shed light on the mechanism for regulation of 
side product formation in both pathways.  
      ACMSD is the first transition metal dependent, oxygen independent decarboxylase. The 
unique cofactor dependency requires a novel catalytic mechanism. Hence, a new working model 
has been proposed for ACMSD based on the findings described in the earlier chapters, in which 
a metal bound water ligand activated by His228 residue acts as a nucleophile to initiate the 
reaction. Investigation of the His228 residue reveals two roles: tuning metal selectivity and 
interacting with the metal bound water molecule. Anion inhibition experiments further 
demonstrated that replacing of the metal bound water ligand by bromide leads to the loss of 
enzyme activity. These results are consistent with the proposed ACMSD mechanism.  
      Since the substrate for ACMSD, ACMS, is an unstable aldehyde compound, the question of 
how ACMS is stabilized during catalysis is worth study. In the crystal structure of homodimer 
PfACMSD, we found two conserved arginine residues in the active site are in good position to 
bind ACMS by forming hydrogen bonding interactions with its carboxyl groups. Interestingly, 
one of the arginines is inserted from the neighboring subunit. Mutation of either of the arginine 
residues leads to the loss of enzyme activity. Simply mixing the two inactive arginine mutants 
can partially rescue ACMSD activity by forming hybridized heterodimers, indicating the dimeric 
state is the active form of ACMSD. A membrane based experiment demonstrated that these two 
arginine residues are involved in substrate binding. In the crystal structures of hACMSD we 
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solved later, two arginine residues are also observed in the active site. Both of the arginines form 
hydrogen bonds with a competitive inhibitor in the co-crystallized structure. Hence, ACMSD 
harnesses its unstable substrate by stabilizing it through two active site arginine residues, one of 
which is contributed by a neighboring subunit, and thus, the dimeric state is required for enzyme 
activity. The dimer dissociation constant calculated based on our experiments is in the range for 
“weak” transient complexes that show a dynamic mixture of both monomer and dimer states in 
vivo. Hence, ACMSD activity could be tuned by local protein concentration and physiological 
environmental factors such as pH and local protein or ligand concentrations in vivo.  
      Unlike ACMSD, AMSDH has not been studied at molecular level before our work. We have 
cloned and expressed PfAMSDH in E.coli and isolated it as soluble and active enzyme. We have 
crystallized PfACMSD in both its apo form and co-substrate NAD+ bound binary complex form. 
Substrates 2-AMS and 2-HMS bound ternary complex structures are also obtained by substrate 
soaking and reveal two arginine residues that play a major role in substrate binding. Mutagenesis 
and sequence alignment further indicate that these two arginine residues are responsible for 
substrate selectivity in the whole HMSDH family. We have also trapped a covalent bound 
thioacyl intermediate in WT-AMSDH, in which the substrate molecule tautomerized to a 
different conformation, suggesting an innate isomerase activity of AMSDH. Mutation of a 
conserved active site glutamate leads to the accumulation of a new intermediate. Crystal 
structure of this intermediate reveals a thiohemiacetal tetrahedral covalent adduct, which is then 
further verified by single crystal spectroscopy and MS spectrometry. Hence, it becomes clear 
that this glutamate residue facilitates hydride transfer during catalysis. Based on the crystal 
structures we have solved and intermediates we have trapped, a better understanding of AMSDH 
is achieved and a working model for its mechanism of action is proposed.   
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